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 Adenylyl cyclase isoforms are distinctly modulated by G protein subunits 
and are therefore hypothesized to be uniquely regulated by proteins that 
influence G protein signaling.  Activator of G protein signaling 3 (AGS3) is a G 
protein modulator that binds Gαi subunits in the GDP-bound state, implicating 
AGS3 as an important regulator of Gi-coupled receptor signaling.  We studied the 
ability of AGS3 to modulate recombinant adenylyl cyclase (AC) type 1 and 2 
signaling in HEK293 cells following both acute and persistent activation of the D2L 
dopamine receptor (D2LDR).  AGS3 expression modestly enhanced the potency 
of acute quinpirole-induced D2LDR modulation of AC1 or AC2 activity.  AGS3 
also promoted desensitization of D2LDR-mediated inhibition of AC1, whereas 
desensitization of D2LDR-mediated AC2 activation was significantly attenuated.  
Additionally, AGS3 reduced D2LDR-mediated heterologous sensitization of AC1 
and AC2.  Our results suggest that AGS3 alters G protein signaling in a complex 
fashion that is effector-specific and dependent on the duration of receptor 
activation.  The present work also addressed the role of Gβγ subunits in the 




components that contribute to the development of heterologous sensitization are 
largely unknown, but G protein subunits are strongly implicated in this adaptive 
process.  We utilized Gβγ subunit sequestering proteins, small molecule and 
peptide Gβγ signaling inhibitors, and pharmacological Gβγ effector and kinase 
inhibitors to study the role of Gβγ subunit signaling pathways in the development 
of AC2 sensitization in HEK293 cells.  Our results suggest that Gβγ subunit 
signaling is necessary for D2LDR-mediated sensitization of AC2.  The multitude 
and diversity of Gβγ signaling pathways that may underlie AC sensitization 
prompted us to develop a high-throughput cAMP assay platform to facilitate 
future unbiased approaches for the study of AC sensitization, such as siRNA 
library screening.  As an intermediate step to the development of such assays, 
we addressed the lack of potent and selective small molecule modulators of AC.  
Identification of chemical probes for AC2 is particularly important because there 
are no published genetic deletion studies and few small molecule modulators.  
Therefore, we developed and executed an intact-cell small molecule screening 
approach and subsequent validation paradigm for the discovery of AC2 inhibitors.  
The NIH clinical collections I and II were screened for inhibitors of AC2 activity, 
using PMA-stimulated cAMP accumulation as a functional readout.  Active 
compounds were subsequently confirmed and validated as direct AC2 inhibitors 
using orthogonal and counter screening assays. The screening effort identified 
SKF-83566 as a selective AC2 inhibitor with superior pharmacological properties 





inhibitors.  The utility of SKF-83566 as a small molecule probe to study the 






CHAPTER 1. INTRODUCTION 
1.1 The foundation of second messenger signaling: A historical perspective 
 Cyclic AMP (cAMP) is the prototypical second messenger signaling 
molecule and the impact of cAMP signaling research is highlighted by the fact 
that four Nobel prizes have been awarded for the study of cAMP signaling 
components (Sutherland in 1971, Krebs and Fischer in 1992, Gilman and 
Rodbell in 1994, and Lefkowitz and Kobilka in 2012). The identification of cAMP 
was first reported in the late 1950s by Earl Sutherland and colleagues while 
studying the relationship of the hormones epinephrine and glucagon to the 
activation of liver phosphorylase (Rall et al., 1957; Sutherland and Rall, 1958).  
Specifically, hormone treatment resulted in activation of liver phsophorylase and 
a heat-stable molecule was isolated from the particulate fraction of the tissue 
homogenate following fractionation (Sutherland and Rall, 1958).  Remarkably, 
the heat-stable factor was able to activate liver phosphorylase in the supernatant 
fraction, while hormone treatment had no effect on the liver phosphorylase in the 
supernatant fraction (Rall et al., 1957; Sutherland and Rall, 1958; Sutherland and 
Rall, 1960).  Ultimately, the heat-stable factor was found to be cAMP and the 
enzyme that synthesizes cAMP was termed the adenylyl cyclase (AC) enzyme 




considered a second messenger because their results suggested that the 
hormone-mediated activation of liver phosphorylase occurs in two distinct steps 
(Rall et al., 1957).  For example, the first messenger (hormone) was unable to 
activate liver phosphorylase on its own, but stimulated AC to produce cAMP 
(second messenger), which was capable of activating liver phosphorylase in the 
supernatant fraction (Sutherland and Rall, 1960).  It was subsequently realized 
that a variety of hormones and catecholamines were able to stimulate cAMP 
responses in multiple tissue types (and elicit specific physiological responses), 
suggesting a common mechanism of signal relay (Robison et al., 1968; 
Sutherland and Rall, 1960).  Nonetheless, until the early 1970s, it was unclear if 
adenylyl cyclases were responsible for both hormone-binding and cAMP 
synthesis or if intermediates between hormone and adenylyl cyclase existed 
(Robison et al., 1968).  The requirement of GTP for hormonal activation of AC 
was the first explicit suggestion that intermediate signal transducers were 
involved in hormone-mediated AC activity (Rodbell et al., 1971a; Rodbell et al., 
1971b).  It was further observed that a stimulatory regulator (the guanine 
nucleotide-binding protein, Gs) was necessary for significant adenylyl cyclase 
activity under physiological conditions and that binding of GTP to the G protein 
promoted its association with the catalytic moieties (Pfeuffer, 1979; Ross and 
Gilman, 1977).  It was also demonstrated that agonist binding of receptor 
increased the receptor size as measured by gel exclusion chromatography, but 
was not due to interaction of the AC catalytic moieties, as they eluted 




demonstrated that agonist-activated receptor coupled with G protein (Limbird et 
al., 1980), leading to the conclusion that the G protein is a communicator 
between the agonist-activated receptor and the AC enzyme (Figure 1.1).  These 
studies intimately link receptor and G proteins to AC/cAMP-mediated 
physiological responses and form the backbone of the signaling pathway 












1.2 Adenylyl cyclase topology and catalytic mechanism 
 Early studies of cAMP suggested that the enzyme that catalyzes the 
formation of cAMP is membrane-bound (Sutherland and Rall, 1958).  The 
topology of AC, however, was not realized until over three decades later, upon 
the cloning of the first AC isoform (Krupinski et al., 1989).  Specifically, 
hydropathy analysis of the primary sequence suggested that the enzyme could 
be conceptually divided into two large sets of alternating hydrophobic and 
hydrophilic domains, where each of the hydrophobic domains consisted of six 
transmembrane spans and each of the hydrophilic domains was homologous to 
the cytoplasmic domain of guanylyl cyclase (Krupinski et al., 1989).  The cloning 
of eight additional transmembrane AC isoforms suggested similar overall 
topology.  The proposed structure of AC is thought to have a short, variable 
cytoplasmic N-terminus that is followed sequentially by the first six-
transmembrane cassette (M1), the first large cytoplasmic domain (C1a and C1b), 
the second six-transmembrane cassette (M2), and finally another large 
cytoplasmic domain (C2a and C2b) (Figure 1.2) (Sunahara et al., 1996).  The 
most conserved stretches of primary sequences reside in the N-terminal 
segments the large cytoplasmic domains, specifically in C1a and C2a, whereas 
the sequences are most divergent in the N-terminus and C1b and C2b domains 











 A complete understanding of the structure of AC has remained elusive, as 
a crystal structure of an entire AC enzyme remains to be reported.  However, 
much of what we know about the structure and function of AC stems from 
biochemical studies of the C1a and C2a cytoplasmic domains.  For example, 
these regions can be expressed independently of other domains and possess 
catalytic activity (Dessauer and Gilman, 1996; Whisnant et al., 1996; Yan et al., 
1996) and such biochemical studies of the catalytic domains provided the basis 
for the crystal structures of AC.  Specifically, high resolution crystal structures of 
a C2 domain homodimer from AC2 (Zhang et al., 1997) and an AC5-C1a/AC2-
C2a heterodimer (Tesmer et al., 1997) have been described.  The crystal 
structures of the two cytoplasmic domains suggest that they interact to form a 
“pseudosymmetrical” structure that makes up the catalytic core of AC (Tesmer et 
al., 1997; Zhang et al., 1997).  The interface of the C1a and C2a domains is 
expected to have conformational flexibility that allows for the relative orientation 
of the domains to change, while remaining associated (Tesmer et al., 1997).  For 
example, the catalytic core is thought to exist in at least two states: an open state 
that is thought to be unable to accommodate ATP, and a closed state where 
domains collapse around ATP to form the active site (Tesmer et al., 1997).  The 
mechanism of catalysis of ATP to cAMP is thought to be a two-metal-ion 
catalysis mechanism (similar to that utilized by Pol I DNA polymerases) where 
two metal ions coordinate with ATP in the active site to stabilize a pentavalent 
transition state, facilitating the conversion of ATP to cAMP (Tesmer et al., 1999).  




Gαs and the small molecule AC activator, forskolin, (see below for discussion of 
AC modulation by forskolin) act allosterically to influence the orientation of the 
C1a/C2a interface, thus priming the active site for catalysis (Tesmer et al., 1999).  
In contrast, the Gαi subunit of the inhibitory G protein (Gi) is thought to 
allosterically influence the relative orientation of the C1a/C2a interface in an 
opposite manner, thereby inhibiting the collapse of catalytic residues around ATP 
(Dessauer et al., 1998; Tesmer and Sprang, 1998).  The crystal structures of the 
AC catalytic domains, together with biochemical studies have provided a great 
deal of insight into the mechanism of AC modulation by forskolin, Gαs, and Gαi 
subunits.  However, the nine membrane-bound ACs are distinctly modulated by 
many signaling molecules (including Gαi/o subunits, Gβγ protein subunits, Ca2+, 
and protein kinases) that are downstream components of G protein coupled-
receptor signaling (Hanoune and Defer, 2001).  Each of these signaling 
molecules may affect catalysis by allosterically modulating the C1a/C2a interface, 
but the precise molecular details that contribute to the differential modulation of 
AC isoforms are currently not well understood (Tesmer and Sprang, 1998). 
 
 
1.3 Overview of cAMP signaling: Adenylyl cyclase as a signal integrator within 
the cascades that link extracellular stimuli and the resulting cellular 
responses 
 The early studies of hormone-stimulated AC signaling identified the 




extracellular ligands can modulate cellular responses via cAMP second 
messenger signaling (i.e., receptor-binding of ligand stimulates G protein 
activation, resulting in AC activation and cAMP formation).  These studies 
defined ACs as effectors of G protein-coupled receptor signaling.  The decades 
following these seminal studies have provided a great deal of research that has 
built upon the backbone of G protein-mediated signal transduction to reveal a 
high level of complexity and specificity.  ACs serve as general signal integrators, 
receiving input that is transduced from a variety of ligands that modulate diverse 
types of G protein-coupled receptors, thus providing cAMP as an intermediate 
signal between extracellular stimuli and cellular response.   
 The cellular levels of cAMP are directly modulated by two families of 
enzymes: adenylyl cyclases, that synthesize cAMP from ATP as described above 
(Hanoune and Defer, 2001), and phosphodiesterases (PDEs) that degrade cAMP 
(Bender and Beavo, 2006).  PDE activity was described soon after the discovery 
of cAMP and AC activity (Butcher and Sutherland, 1962) and it is currently known 
that PDEs are phosphohydrolase enzymes that regulate the cellular levels of 
cyclic second messengers by catalyzing the hydrolysis of the 3’ cyclic phosphate 
bonds of cyclic adenosine- and guanosine-3’,5’-monophosphate (cAMP and 
cGMP) (Bender and Beavo, 2006).  PDEs have been classified into 11 different 
families based on amino acid sequence homology and can be further grouped 
into three categories based on their substrate specificity (i.e., cAMP-specific, 
cGMP-specific, or dual specificity for cAMP and cGMP).  There are 21 different 




splicing of mRNA, yielding the possibility of >100 PDE protein products (Bender 
and Beavo, 2006).  The many forms of PDE dynamically modulate the balance of 
cellular cAMP and have been linked to specific physiological processes (Bender 
and Beavo, 2006). 
 The ACs functionally integrate signals that are transduced from a variety 
of diverse extracellular stimuli into a single second messenger molecule, cAMP.  
Downstream of cAMP, the canonical signaling pathway proceeds by direct 
activation of cAMP-dependent kinase, also known as protein kinase A (PKA).  As 
cAMP is the prototypical second messenger, PKA is the prototypical protein 
kinase and was identified in 1968 (Walsh et al., 1968).  The PKA holoenzyme is 
formed by two regulatory subunits and two catalytic subunits from a selection of 
four regulatory subunit isoforms (RIα, RIβ, RIIα, and RIIβ) that are functionally 
non-redundant and three catalytic subunit isoforms (Cα, Cβ, and Cγ) (Taylor et 
al., 2012).  Upon binding of two cAMP molecules to each regulatory subunit 
within a holoenzyme, the catalytic subunits dissociate and phosphorylate specific 
targets on serine and threonine residues that are found within a (RRX-S/T-X) 
PKA consensus motif (Kemp et al., 1977; Taylor et al., 2012; Ubersax and Ferrell, 
2007).  PKA signaling specificity is achieved by the complement of regulatory 
and catalytic subunit isoforms and PKA substrates that are expressed within a 
particular cell (Taylor et al., 2012).  The signaling is further fine-tuned by the 
directed subcellular localization of PKA by direct binding to A-kinase anchoring 




macromolecular complexes that form PKA signaling hubs within specific cellular 
locations that contribute to diverse biological processes (Taylor et al., 2012).   
 PKA was initially thought to be the sole downstream effector of cAMP and 
remains a prevalent effector signaling system, but it has also become apparent 
that cAMP modulates additional downstream targets.  For example, cyclic 
nucleotides directly modulate channels that conduct cations into the cytoplasm.  
Two structurally-related families of cyclic nucleotide modulated cation channels 
have been identified that differ in their mode of activation (Craven and Zagotta, 
2006).  Specifically, the cyclic nucleotide gated (CNG) cation channels are 
opened upon direct binding of cAMP or cGMP (Kaupp and Seifert, 2002).  The 
CNG channels have been detected in several tissue types and are highly 
expressed in retinal photoreceptors and olfactory neurons, where they are known 
to be key mediators of visual and olfactory signal transduction (Kaupp and Seifert, 
2002).  The other family of cyclic nucleotide-modulated cation channels are the 
hyperpolarization-activated cyclic nucleotide-modulated (HCN) channels and are 
mainly modulated by voltage (the channels open to cations upon 
hyperpolarization, but close due to depolarization), but the probability of channel 
opening is increased upon cyclic nucleotide binding (Craven and Zagotta, 2006).  
HCN channels are expressed in brain and heart tissue and are thought to 
underlie the cation current following hyperpolarization in excitable cells such as 
neurons and cardiac pacemaker cells (Biel, 2009).  
 In 1998, it was discovered that cAMP activates a family of guanine 




cAMP (Epacs) (de Rooij et al., 1998; Kawasaki et al., 1998).  Two Epac isoforms 
have been characterized, Epac1 and Epac2, and it is thought that Epacs catalyze 
the exchange of GDP for GTP on the ras-like GTPases Rap1 and Rap2 upon 
binding cAMP (Gloerich and Bos, 2010).  Interestingly, Rap-independent Epac 
signaling has more recently been observed through a variety of additional 
signaling molecules including ras, phospholipase C, protein kinase D, and 
ERK1/2 (Billington and Hall, 2012).  The expanding signaling functions of Epac 
proteins have gained attention for their contribution to cAMP signaling in the 
heart, brain, pancreas, vasculature, and lungs (Schmidt et al., 2013). 
 In summary, ACs are central mediators of the signal relay that is initiated 
by extracellular stimuli and results in a cellular response (Figure 1.3).  Signaling 
input from a large number of G protein-coupled receptors is integrated by ACs 
and is further relayed in the form of cAMP.  Cyclic AMP proceeds to modulate 
downstream effector proteins that include PKA, Epacs, and CNG/HCN channels 
that influence specific cellular responses that ultimately modulate diverse 
physiological processes including metabolism (Robison et al., 1968), cell growth 
and differentiation (Boynton and Whitfield, 1983; Friedman, 1976), learning and 
memory (Kandel, 2001), cardiac contractility (Drummond and Severson, 1979; 
Sobel and Mayer, 1973), and immune responses (Mosenden and Tasken, 2011; 
Peters-Golden, 2009; Serezani et al., 2008).  The complete molecular details that 
contribute to the signaling specificity that allows for such diverse responses 




proteins that are expressed within a given cell and the molecular organization of 











1.4 Adenylyl cyclase signaling properties: Contributions to cAMP signaling 
specificity 
 The specificity of cAMP signaling is tightly regulated, in part, by the 
repertoire and interplay of signaling molecules present within a given cell.  
Though ACs are only one part of the cAMP signaling pathway, a major 
contributing factor to this specificity is that nine membrane-bound mammalian AC 
isoforms have been identified, each with distinct patterns of regulation by G 
protein subunits, protein kinases, and Ca2+ (Hanoune and Defer, 2001; Patel et 
al., 2001).  The modulation of cAMP signaling at the level of AC is considered in 
detail below. 
 
1.4.1 G protein-coupled receptor signaling 
1.4.1.1 G protein activation cycle 
 The G protein-coupled receptor family is a large (~1000 genes in the 
human genome) (Fredriksson et al., 2003) and versatile receptor family whose 
members contribute to nearly all physiological processes (Lefkowitz, 2004).  G 
protein-coupled receptors bind extracellular ligands that induce conformational 
changes in the receptor that facilitate the activation of associated G protein 
heterotrimers by exchange of GDP for GTP on the G protein α subunit (Gilman, 
1987).  Upon activation, the G protein heterotrimer undergoes a conformational 
change that allows Gα and Gβγ subunits to dissociate/rearrange into an 




al., 1994; Lambright et al., 1994; Taussig et al., 1994).  The G protein signaling 
cycle terminates upon hydrolysis of GTP to GDP on the Gα subunit, resulting in 
the inactivating reassociation/rearrangement of Gα and Gβγ (Figure 1.4) 










1.4.1.2 Effector modulation 
 Four families of Gα, five Gβ subunit isoforms, and twelve Gγ subunit 
isoforms have been identified (Hurowitz et al., 2000; Khan et al., 2013).  Early 
studies implicated Gα subunits in effector modulation and it is known that the 
specific type of Gα subunit can contribute to the direct or indirect modulation of 
AC (Figure 1.5).  For example, members of the Gαs family (the GNAS gene is 
thought to give rise to several gene products) (Bastepe, 2007) are thought to 
directly bind to AC in the C2a region (Tesmer et al., 1997; Yan et al., 1997) and 
stimulate AC activity (Iyengar, 1993).  The inhibitory Gα subunits are comprised 
of Gαi1, 2, and 3, Gαo, and Gαz and directly inhibit AC activity by interacting with the 
C1a domain (Dessauer et al., 1998), presumably preventing the “closed state” of 





   
  




The identification of Gα12 and Gα13 was first reported in 1991 (Strathmann and 
Simon, 1991) and Gα12/13 modulation of Rho guanine nucleotide exchange 
factor proteins (RhoGEFs) has been widely observed (Siehler, 2009).  However, 
Gα12/13 has also recently been implicated in the direct and selective modulation 
of AC7 (Jiang et al., 2008; Jiang et al., 2013b).  In contrast to Gαs, Gαi, and 
Gα12/13 (that directly modulate AC activity), Gαq/11 is thought to indirectly 
modulate AC activity.  For example, Gαq/11 activates phospholipase C, which 
catalyzes the conversion of PIP2 into IP3 (binds to IP3 receptors on the ER, 
causing Ca2+ release) and diacylglycerol (stimulates protein kinase C) (Hepler et 
al., 1993; Smrcka et al., 1991; Sternweis and Smrcka, 1992).  Ca2+ and protein 
kinase C (PKC) uniquely modulate ACs in isoform-dependent manners (see 
regulatory properties). 
 Gβγ subunits were originally thought to be necessary for the inactivation of 
Gα subunits (Northup et al., 1983) and reassociation/rearrangement of the G 
protein heterotrimer, thus allowing receptor coupling and subsequent activation.  
However, the Gβγ subunits have since gained appreciation for direct modulation 
of a large number of effectors including ACs, phospholipase Cβ, Kir3 potassium 
channels, and voltage-gated Ca2+ channels and are being increasingly 
recognized for their contribution to diverse signaling pathways that are related to 
the different effectors that they modulate (for reviews, see (Khan et al., 2013; 
Smrcka, 2008)).  Furthermore, genetic knockdown of individual Gβ and Gγ 




to diverse biological functions including nociception, angiogenesis during 
embryonic development, and seizure susceptibility (Khan et al., 2013).  
1.4.1.3 Modulation of G protein cycle by accessory proteins 
 In addition to G protein-coupled receptor modulation, the G protein 
activation cycle is sensitive to accessory proteins that include regulators of G 
protein signaling (RGS) and activator of G protein signaling (AGS) proteins 
(Blumer et al., 2007; Neubig and Siderovski, 2002).  There are 20 distinct genes 
that have been identified for RGS family members (some with splice variants) 
that are categorized into four subfamilies (R4/B, RZ/A, R7/C, and R12/D) 
(Abramow-Newerly et al., 2006).  All members of the RGS protein family have a 
conserved ~120 residue region that is known as the RGS domain and this region 
binds directly to GTP-bound Gα subunits to accelerate the rate of GTP hydrolysis, 
thereby terminating the G protein cycle (Abramow-Newerly et al., 2006; Neubig 
and Siderovski, 2002).  The AGS proteins are a diverse family of 10 proteins 
(AGS1-10) that were identified in a functional yeast-based screen for receptor-
independent signaling (Blumer et al., 2007).  AGS proteins are divided into three 
groups based on their activity in the yeast-based screen and biochemical studies 
(Blumer et al., 2007).  The Group I AGS protein (AGS1) displays guanine-
nucleotide exchange activity similar to that of a G protein-coupled receptor.  The 
remaining AGS proteins function independent of guanine-nucleotide exchange 
and are subdivided based on their interaction partners.  Specifically, Group II 




proteins (AGS2, 7, 8, and 10) interact with Gβγ subunits.  The RGS and AGS 
proteins influence G protein signaling and effector activation in diverse ways, 
including modulation of the rate of GTP hydrolysis and the availability and/or 
stability of Gα or Gβγ subunits (Blumer et al., 2007; Neubig and Siderovski, 2002; 
Sato et al., 2006). 
 
1.4.2 Regulatory properties of adenylyl cyclase isoforms 
 The common regulatory property of all AC isoforms is that they are 
activated by the stimulatory G protein α subunit (Gαs), but otherwise display 
unique regulatory profiles that are modulated by multiple arms of the G protein-
coupled receptor pathways.  The AC isoforms are categorized into four 
subgroups based on their sequence similarities and specific regulatory properties 
(Hanoune and Defer, 2001; Patel et al., 2001).    
 
1.4.2.1 Group I ACs 
 Group I ACs (AC1, AC3, and AC8) are collectively considered the 
Ca2+/calmodulin-stimulated ACs.  Ca2+-bound calmodulin stimulates AC1 and 
AC8 via direct interactions (Cali et al., 1996; Choi et al., 1992a) within the C1b 
and C2 domains of AC1 and the N-terminus and C2 domains of AC8 (Gu et al., 
2000; Simpson et al., 2006).  In contrast to AC1 and AC8, AC3 appears to be 
conditionally activated by calmodulin, as it is dependent on activated Gαs or 




suggest that these ACs are physiologically modulated by Ca2+ via a phenomenon 
known as capacitative calcium entry (CCE) (Willoughby and Cooper, 2007).  
CCE was first proposed in 1986 and is characterized by Ca2+ entering the cell 
through store-operated calcium channels in the plasma membrane in response to 
depletion of intracellular Ca2+ that is stored in the endoplasmic reticulum (Putney, 
1986).  It is thought that the proximity of ACs to the store-operated calcium 
channels contributes to the modulation of these ACs by local pools of Ca2+ 
(Willoughby and Cooper, 2007).  Interestingly, AC1 appears to be more sensitive 
to Ca2+ stimulation than AC8, as Ca2+ more potently stimulates AC1 (Masada et 
al., 2009).  Furthermore , the modulation of AC1 and AC8 by Ca2+ appears to be 
influenced by coincident signaling of Gαs because the convergent stimulation of 
AC1 by Gαs and Ca2+ influx is synergestic, but merely additive for AC8 (Cumbay 
and Watts, 2001; Nielsen et al., 1996).  Though AC1 is relatively more sensitive 
to Ca2+ and Gαs signaling than AC8, studies suggest that AC1 is also more 
sensitive than AC8 to inhibition by Gαi in response to Gi-coupled receptor 
activation (Cumbay and Watts, 2001; Nielsen et al., 1996; Taussig et al., 1993a).  
Direct inhibition by Gβγ subunits is a common property of each of the group I 
ACs (Diel et al., 2008; Diel et al., 2006; Steiner et al., 2006; Tang and Gilman, 
1991).  Specifically, Gβγ subunits modulate AC1 signaling with a pattern that 
includes attenuation of AC stimulation in response to Gαs-mediated activation, 
whereas the inhibition observed by Gαi is enhanced (Tang and Gilman, 1991; 




 The group I ACs are also notably regulated by protein kinases.  For 
example, though Ca2+-bound calmodulin is known to stimulate group I ACs, AC1 
and AC3 are inhibited directly by calmodulin-dependent kinase (CaMK) 
phosphorylation.  Specifically, AC1 is inhibited by CaMKIV (Wayman et al., 1996) 
and AC3 is inhibited by CaMKII (Wei et al., 1996), offering distinct modes of 
feedback inhibition through calmodulin, whereas AC8 does not appear to be 
sensitive to either CaMKII or CaMKIV phosphorylation (Wayman et al., 1996).  It 
is also suggested that AC8 is insensitive to PKC modulation, whereas AC1 and 
AC3 are stimulated by phorbol ester treatment (Jacobowitz et al., 1993). 
 
1.4.2.2 Group II ACs 
 Group II ACs (AC2, AC4, and AC7) are collectively insensitive to Ca2+ 
(submicromolar concentrations) and widely believed to be insensitive to Gαi/o 
modulation (Tang and Gilman, 1991; Taussig et al., 1993b; Taussig et al., 1994).  
As with all AC isoforms, each of the group II ACs are activated by Gαs 
stimulation.  However, the group II ACs display unique profiles of modulation in 
response to PKC activation.  AC2 is stimulated by PKC activation and has been 
the most extensively studied group II AC isoform with regard to PKC activation.  
For example, PKC-mediated stimulation of AC2 has been demonstrated both in 
vitro and in intact cell systems and has been observed in response to phorbol 
ester treatment (Jacobowitz and Iyengar, 1994; Shen et al., 2012; Yoshimura 




activation (in response to Gq-coupled receptor activation and by constitutively 
active Gq (Q209L)) (Cumbay and Watts, 2005).  A comprehensive study of every 
PKC isoform has not been reported, but PKCα and PKCδ have both been 
implicated in the activation of AC2 (Nguyen and Watts, 2006; Zimmermann and 
Taussig, 1996).  Further solidifying the direct modulation of AC2 by PKC 
phosphorylation, a recent study mapped the phorbol ester- and muscarinic 
receptor-mediated PKC phosphorylation in HEK293 cells to S490 and S543 in 
the C1b domain (Shen et al., 2012).  Similar to AC2, AC7 is stimulated by PKC 
activation in response to phorbol ester treatment (Hellevuo et al., 1995; Watson 
et al., 1994).  Phorbol ester treatment also potentiates Gs-coupled receptor-
mediated AC7 activity (Haslauer et al., 1998) and PKCδ is thought to mediate 
this potentiation response (Nelson et al., 2003).  In contrast to AC2 and AC7, 
AC4 does not appear to be activated by PKC as tested in response to phorbol 
ester treatment and reconstituted PKCα (Jacobowitz et al., 1993; Zimmermann 
and Taussig, 1996).  Further, Gαs stimulation and Gβγ-mediated potentiation of 
AC4 activity can be inhibited by PKCα activation (Zimmermann and Taussig, 
1996).  
 In addition to PKC modulation of group II ACs, Gβγ subunits are thought 
to modulate the AC activity of all members of group II (AC2, AC4, and AC7) (Gao 
and Gilman, 1991; Tang and Gilman, 1991; Yoshimura et al., 1996).  
Interestingly, the Gβγ-mediated stimulation of group II ACs is thought to be 
conditional, as it is dependent on additional modes of AC stimulation (including 




1993b; Taussig et al., 1994).  These modulatory properties of group II ACs are 
well-established and have been demonstrated in vitro and in intact cell assays in 
response to Gi/o-coupled receptor activation. (Federman et al., 1992; Tang and 
Gilman, 1991; Tsu and Wong, 1996; Zimmermann and Taussig, 1996).  Studies 
with AC2 are consistent with a direct modulation of AC2 activity, as multiple Gβγ 
interaction sites have been characterized within the C1a, C1b, and C2 domains 
of AC2 (See Figure 1.6) (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006; 
Weitmann et al., 2001).  Though Gβγ subunits in response to Gi-coupled 
receptor activation provide enhancement of AC2 activity, recent evidence 
suggests that Gβγ subunits from Gq-coupled receptor activation provide modest 
inhibition of AC2 activity (Shen et al., 2012), suggesting bi-directional modulation 
of AC2 by Gβγ subunits that is dependent on the Gα subunit that defines the 











 Novel regulation of AC7 by Gα12/13 has also been reported.  Initially, a 
synergistic cAMP response to isoproterenol and sphingosine-1-phosphate in 
RAW 264.7 macrophages was found to be mediated by the G13 pathway (Jiang 
et al., 2007).  Subsequent research identified AC7 as the specific AC mediator of 
the synergistic response (i.e., AC2 did not mediate the synergistic response) and 
it was also shown to be dependent on Gα12/13 subunits (Jiang et al., 2008).  
Furthermore, the generation of a series of AC7/AC2 chimeras identified the C1a 
and C1b domains of AC7 to be important for the synergistic response (Jiang et 
al., 2013b). 
 
1.4.2.3 Group III ACs 
 The group III ACs (AC5 and AC6) are known as the Ca2+-inhibited group 
of ACs, as they are inhibited by submicromolar concentrations of free Ca2+.  
Analogous to the modulation observed for group I ACs, it is hypothesized that 
CCE is the mechanism by which AC5 and AC6 are physiologically modulated by 
free Ca2+, including in response to Gq-mediated receptor activation (Fagan et al., 
2000; Willoughby and Cooper, 2007).  In contrast to the inhibition of group III 
ACs by Ca2+, Gq-coupled receptor activation in cardiac fibroblasts and gastric 
smooth muscle (tissues that express both AC5 and AC6) provides enhanced 
downstream AC signaling (Beazely and Watts, 2006; Meszaros et al., 2000; 
Ostrom et al., 2003).  However, Gq-mediated signaling observed in stably 




but not AC5, suggesting a possibility for selective modulation of AC6 (Beazely et 
al., 2005). 
 AC5 and AC6 are robustly stimulated by Gαs subunits and inhibited by 
Gαi subunits (Chen-Goodspeed et al., 2005).  Though in vitro studies suggest 
that group III ACs are insensitive to Gαo (Taussig et al., 1993a; Taussig et al., 
1994), a number of intact cell and studies of cAMP signaling in tissues that 
express Group III ACs and Gαo suggest that receptor-mediated Gαo signaling 
can modulate AC5 and AC6 activity (for review, see (Beazely and Watts, 2006)).  
Some evidence exists for the modulation of group III ACs by Gβγ subunits.  For 
example, overexpression studies in cells suggest that Gβγ expression inhibits 
AC5 and AC6 (Bayewitch et al., 1998).  However, a more recent study suggests 
that Gβγ subunits bind directly to the N-terminus of AC5 and AC6 as part of a 
GαsGβγ heterotrimer and enhance Gαs-stimulated activity (Gao et al., 2007; 
Sadana et al., 2009).  The differences in the reports of Gβγ modulation of AC5 
and AC6 may be attributed to differences in the experimental methodology. 
 Protein kinases are also thought to modulate AC5 and AC6 activity.  For 
example, PKA phosphorylation of AC5 and AC6 has been observed and provides 
feedback inhibition for these isoforms (Bauman et al., 2006; Beazely et al., 2005; 
Iwami et al., 1995).  Furthermore, PKA-mediated inhibition of AC6 occurs via a 
single phosphorylation site in the C1 domain (S674) (Chen et al., 1997), and the 
corresponding residue in AC5 also mediates PKA-dependent inhibition (Bauman 




 The effects of PKC activity on the modulation of group III ACs appear to 
be complex.  AC5 activity is thought to be enhanced by PKC activity, as both in 
vitro and cell-based assays demonstrate stimulation of AC5 (Kawabe et al., 1996; 
Kawabe et al., 1994).  The effects of PKC activity on AC6, however, are difficult 
to interpret because a range of modulation has been observed.  For example, 
early studies of phorbol ester treatment on recombinant AC6 transiently 
expressed in HEK293 cells suggest only modest (Jacobowitz et al., 1993) or no 
significant stimulation of cAMP accumulation (Yoshimura and Cooper, 1993).  
However, PKC has been demonstrated to inhibit AC6 activity in in vitro 
membrane experiments (Lai et al., 1999; Lin et al., 2002).  In contrast, phorbol 
ester treatment potentiated forskolin- and Gαs-mediated cAMP in HEK293 cells 
stably expressing AC6 (Beazely et al., 2005).  Furthermore, phorbol ester 
treatment similarly potentiated drug-stimulated cAMP in two cell models thought 
to abundantly express AC6 (Chinese hamster ovary cells and Cath.a 
differentiated cells) (Beazely et al., 2005; Johnston et al., 2002; Varga et al., 
1998).  The contrasting observations surrounding PKC modulation of AC6 may 
reflect differential modulation by PKC isoforms and/or differences in the specific 
experimental approaches that were utilized. 
 
1.4.2.4 Group IV AC 
 AC9 is the lone member of group IV and is most recognized for its relative 




single residue in the C2 domain (Y1021) because mutation of this residue to 
leucine functionally restored sensitivity to forskolin (Yan et al., 1998).  Early 
studies suggest that AC9 is stimulated by Gαs (a property common to every AC 
isoform) (Hacker et al., 1998), but distinctly inhibited by Ca2+/calcineurin 
(Paterson et al., 1995).  Gi/o-coupled receptor activation inhibits Gαs-stimulated 
AC9 activity in a pertussis-toxin dependent manner, suggesting that AC9 is also 
sensitive to inhibition by Gαi subunits (Cumbay and Watts, 2004).  However, Gβγ 
subunits may also contribute to AC9 inhibition because potentiation of Gαs-
stimulated cAMP activity in cells stably expressing AC9 was observed upon 
sequestration of Gβγ subunits (via Gαt expression) (Cumbay and Watts, 2005).  
In addition to G protein modulation, AC9 appears to be susceptible to modulation 
by protein kinases.  For example, phorbol ester treatment inhibits Gαs-stimulated 
AC9 activity in a PKC isoform-dependent manner, as the PKC inhibitor 
bisindolylmaleimide I was able to block phorbol ester-mediated inhibition, but 
Gö6976 (a PKCα and –β selective inhibitor) had no effect (Cumbay and Watts, 
2004).  Interestingly, studies of Gq-mediated AC9 modulation identified a 
Ca2+/calmodulin/CaMKII-mediated potentiation of Gαs-stimulated AC9 activity 
that is PKC-independent (Cumbay and Watts, 2005).  These studies suggest that 






1.4.3 Adenylyl cyclase localization: Tissue distribution, compartmentalization, 
and signalosomes 
 The specificity of AC signaling can be further attributed to the tissue-
specificity and subcellular localization of AC isoforms and by their protein-protein 
interactions within these locations.  The AC isoforms are thought to display 
unique tissue distribution profiles.  It is notable that most AC expression studies 
are inferred from mRNA measurements, as relatively low AC expression and the 
lack of specific antibodies have hindered the study of AC isoform protein 
expression (Hanoune and Defer, 2001).  Table 1.1 summarizes the unique tissue 
expression of AC isoforms.  These expression patterns, together with the AC 
isoform-dependent regulatory properties discussed above, suggest that the 
concurrent expression of AC isoforms and other signaling molecules contribute to 





Table 1.1 Adenylyl cyclase tissue distribution 
 
AC isoform Tissue Distribution 
AC1 Brain, adrenal gland 
AC2 Brain, skeletal muscle, lung, heart 
AC3 Brain, olfactory epithelium 
AC4 Brain, heart, kidney, liver, lung 
AC5 Brain, heart, kidney, liver, lung 
AC6 Widespread 
AC7 Brain, platelets, widespread 
AC8 Brain, lung 







 AC isoforms are also thought to selectively reside in specific membrane 
microdomains (Ostrom et al., 2012; Ostrom and Insel, 2004).  The segregation of 
AC isoforms into membrane microdomains such as lipid rafts may contribute to 
specificity observed for cAMP signaling.  Lipid rafts are sphingolipid and 
cholesterol rich portions of the plasma membrane (Simons and Ikonen, 1997) 
and it is thought that AC isoforms differentially localize to either lipid raft or non-
lipid raft domains of the membrane (Willoughby and Cooper, 2007).  Specifically, 
the Ca2+-modulated ACs (AC1, AC3, AC5, AC6, and AC8) are thought to reside 
in lipid rafts, whereas the Ca2+-insensitive ACs (AC2, AC4, AC7, and AC9) 
localize to non-lipid raft domains (Ostrom and Insel, 2004; Willoughby and 
Cooper, 2007).  Furthermore, many signaling molecules that are associated with 
AC signaling including receptors, G proteins, and other effectors also reside with 
ACs in specific membrane microdomains (Allen et al., 2007; Patel et al., 2008).   
A relevant example of AC signaling specificity imparted by lipid raft organization 
has been observed in human bronchial smooth muscle cells.  It has been 
demonstrated that β adrenergic receptor-mediated signaling specifically activates 
AC6, whereas EP2 prostanoid receptor activation specifically modulates 
AC2/AC4 signaling in this cell type (Bogard et al., 2012; Bogard et al., 2011).  
Though all ACs are sensitive to stimulation by Gαs (Iyengar, 1993), and both β 
adrenergic receptors and EP2 prostanoid receptors are Gs-coupled receptors, 
AC-isoform-specific signaling was observed.  It is particularly notable that the 
selective signaling is consistent with the membrane microdomain organization of 




adrenergic receptors are in lipid rafts, whereas AC2/AC4 and EP2 prostanoid 
receptors are in non-raft membrane domains) (Bogard et al., 2011).  Similar 
specific receptor-AC signaling has also been observed according to localization 
in membrane microdomains of other tissues including aortic smooth muscle cells 
and cardiac myocytes (Ostrom et al., 2001; Ostrom et al., 2002; Ostrom et al., 
2000). Thus, it is apparent that organization of signaling molecules into 
membrane microdomains contributes to signaling efficiency and specificity by 
concentrating specific receptor-AC groups in close proximity.   
 Lipid raft structures also appear to be important for CCE-modulation of 
ACs (Willoughby and Cooper, 2007).  Disruption of lipid rafts by sequestration of 
cholesterol is known to disrupt the CCE modulation of AC6 (Fagan et al., 2000) 
and AC8 (Smith et al., 2002).  It is also thought that CCE machinery is localized 
to lipid rafts, suggesting that CCE-modulated AC signaling is dependent on 
membrane organization by lipid rafts (Martin et al., 2009; Pani et al., 2008).  It is 
clear that AC signaling modulation (and specificity) is influenced by the 
localization of ACs and additional signaling molecules that modulate AC function 
within specific membrane microdomains.   
 Cyclic AMP signaling specificity is also controlled by compartmentalization 
of AC-containing multi-protein signalosomes (Dessauer, 2009).  For example, the 
AKAP family of proteins contributes to the signaling specificity that is observed 
with cAMP signaling by enabling close proximity of signaling components via 
signalosomes (Taylor et al., 2012; Welch et al., 2010).  Over 50 AKAPs have 




interaction motif, but are otherwise divergent (Welch et al., 2010).  AKAPs are 
localized to various subcellular areas and function to anchor PKA to specific 
substrates (Dessauer, 2009).  Interestingly, several of the AKAPs that localize to 
the plasma membrane selectively associate with AC isoforms (Dessauer, 2009).  
In some cases, AKAPs are thought to be components of a feedback loop for ACs 
that are directly modulated by PKA.  For example, AKAP79/150 directly interacts 
with AC5/AC6 and also scaffolds PKA (Bauman et al., 2006).  Expression of 
AKAP79/150 functionally contributes to the modulation of AC5 by promoting 
accelerated decay of Gs-coupled receptor-mediated cAMP responses via PKA 
phosphorylation (Bauman et al., 2006).  These observations suggest that 
AKAP79/150 is part of a negative feedback loop to attenuate AC5/AC6 activation 
(consistent with Group III ACs being inhibited by PKA phosphorylation).  Similar 
observations were also reported for PKA-dependent modulation of AC5 signaling 
that is mediated by mAKAPβ in cardiac myocytes (Kapiloff et al., 2009).   
 In addition to PKA scaffolding, perhaps signaling efficiency is also attained 
by additional scaffolding functions of AKAPs.  It is known that AKAPs interact 
with both upstream modulators and downstream effectors of AC (protein kinases, 
G protein-coupled receptors, PDEs, and Epacs) (Bauman et al., 2007; Dodge-
Kafka and Kapiloff, 2006; Dodge-Kafka et al., 2005).  This is especially 
interesting in light of AKAP-mediated AC modulation that is thought to be 
independent of PKA function.  For example, the AKAP Yotiao directly interacts 
with AC2 and functionally inhibits AC2-mediated cAMP signaling (Piggott et al., 




Yotiao modulation of AC2 is unclear, but possibilities include anchoring of PDEs 
in proximity of AC2 or by direct allosteric modulation (Dessauer, 2009).  Together, 
these studies suggest that AKAPs are diverse modulators of AC signaling, but an 
appreciation of the underlying mechanisms of AKAP-mediated AC modulation 
requires further study.  A growing number of AC-interacting proteins that 
modulate cAMP signaling (Sadana and Dessauer, 2009; Wang et al., 2009) 
support the hypothesis that signalosome-mediated AC modulation is an 
important contributor to cAMP signaling specificity and may even be crucial 
components of the mechanisms that control cAMP-mediated signaling diversity. 
 
 
1.5 Heterologous sensitization of adenylyl cyclase 
 Acute activation of Gi/o-coupled receptors generally leads to attenuation 
of cAMP accumulation by inhibition of AC, but prolonged stimulation of Gi/o-
coupled receptors results in heightened sensitivity to subsequent stimulatory 
input to AC (Watts and Neve, 2005).  This phenomenon, known as heterologous 
sensitization of AC (also known as superactivation, cAMP overshoot, and 
supersensitization), was first observed in Dr. Marshall Nirenberg’s laboratory in 
1975 and was hypothesized to be a molecular form of adaptation that contributes 
to opiate dependence and tolerance (Sharma et al., 1975).  Since the 
observation of δ opioid receptor-mediated AC sensitization in Nirenberg’s lab, 




including D2 dopamine, 5HT1A serotonin, µ opioid, and CB1 cannabinoid 
receptors have also been found to mediate sensitization, suggestive of a 
signaling adaptation that is common for nearly all Gi/o-coupled receptors (Watts 
and Neve, 2005).  Despite the prevalence of AC sensitization and the study of 
this adaptive response since 1975, an understanding of the signaling steps that 
link the initial Gi/o signaling event to the enhancement of AC responsiveness 
remains elusive. 
 That sensitization occurs following prolonged Gi/o-coupled receptor 
activation and is inhibited by pertussis toxin suggests that G protein subunits 
from Gi/o heterotrimers are central to the development of sensitization (Watts, 
2002).  Subsequent studies utilized pertussis-toxin insensitive Gα subunits as 
tools to investigate the specific roles of individual Gαi/o subunit isoforms in 
heterologous sensitization of AC.  Pertussis toxin-insensitive Gαo (but not 
pertussis toxin-insensitive Gαi1, 2, or 3) was capable of supporting D2 dopamine 
receptor-induced AC sensitization, but with a reduced response as compared to 
that observed in the absence of pertussis toxin treatment in NS20Y cells stably 
expressing the D2 dopamine receptor (Watts et al., 1998).  Consistent with these 
observations, pertussis toxin-insensitive Gαi1, 2, or 3 subunits are also unable to 
support sensitization in response to μ or κ opioid receptor-activation (Tso and 
Wong, 2000; Tso and Wong, 2001).  In contrast, another study reported that 
individual pertussis toxin-insensitive Gαi1,2,3, and Gαo subunits are able to 
support μ opioid receptor-mediated sensitization of AC (but with a reduced level 




sensitization observed in these cell types is dependent on the expression levels 
of the pertussis toxin-insensitive G protein subunits (Clark and Traynor, 2006).  
Furthermore, pertussis toxin-insensitive Gαi1 partially recovers δ opioid receptor-
induced sensitization (but pertussis toxin-insensitive Gαi3 and Gαi2/z have no 
effect) (Tso and Wong, 2000; Tso and Wong, 2001).  The attenuated 
sensitization responses that are mediated by individual pertussis toxin-insensitive 
Gαi/o subunits suggest the possibility that multiple Gαi/o subunit isoforms 
simultaneously contribute to the development of the full sensitization response. 
 Pertussis toxin treatment also inhibits the rearrangement/release of Gβγ 
subunits, thus implicating Gβγ subunit signaling in the development of 
heterologous sensitization of AC.  The most direct evidence for Gβγ subunits in 
sensitization has been obtained with the Gβγ subunit-sequestering proteins Gαt 
and the C-terminus of G protein-coupled receptor kinase 2 (GRK2-ct or βARK-ct).  
Multiple studies demonstrate a consensus that expression of Gβγ subunit 
sequestering tools provides inhibition of heterologous sensitization of AC in 
response to persistent activation of several G protein-coupled receptors 
(AvidorReiss et al., 1996; Nguyen and Watts, 2005; Rhee et al., 2000; Rubenzik 
et al., 2001; Thomas and Hoffman, 1996).  Given that Gβγ subunits differentially 
influence the direction of AC modulation in an AC isoform-dependent manner 
(see AC isoform regulatory properties), it is unlikely that the development of 
heterologous sensitization is modulated by direct interactions of Gβγ with AC 
isoforms.  Thus, it is intriguing that Gβγ subunits are becoming more recognized 




suggesting that Gβγ subunits are components of complex signaling pathways 
that may lead to the development of AC sensitization.   
 Protein kinases modulate the activity of AC isoforms (see the regulatory 
properties of AC section).  It is therefore possible that prolonged Gi/o-coupled 
receptor activation leads to the downstream modulation of protein kinases that 
are able to enhance the activity of ACs, resulting in sensitization of AC.  
Consistent with this hypothesis is that Gαi and Gβγ signaling are known to 
modulate protein kinases that include PKC, PKA, and Raf-1 (Watts and Neve, 
2005).  For example, PKC enhances the activity of several AC isoforms (i.e., AC1, 
AC2, AC5, AC6, and AC7) and heterologous sensitization has been observed in 
cells that express AC2 and AC5, suggesting a role for PKC in the development of 
AC sensitization.  Furthermore, enhanced PKC-mediated phosphorylation of ACs 
(group II ACs) was observed in ileum longitudinal muscle myenteric plexus 
preparations obtained from chronic morphine-treated guinea pigs (Chakrabarti et 
al., 1998).   
 Several studies also implicate Raf-1 kinase in heterologous sensitization.  
For example, pharmacological inhibition of Raf-1 kinase in Chinese hamster 
ovary (CHO) cells decreased cAMP signaling, suggesting that Raf-1 can 
stimulate AC6 activity (endogenously expressed) (Tan et al., 2001; Varga et al., 
2003; Varga et al., 1998).  Consistent with this observation, studies also suggest 
that Raf-1 kinase inhibition attenuates sensitization of AC in CHO cells (Beazely 
et al., 2005; Varga et al., 2002; Varga et al., 2003).  Furthermore, studies 




receptor tyrosine kinases (Beazely et al., 2005; Chen et al., 1995b; Tan et al., 
2001; Varga et al., 2003). 
 Protein kinase A may also have a role in heterologous sensitization of ACs.  
For example, it is known that PKA phosphorylation inhibits AC5 and AC6 activity, 
suggesting that inhibitory modulation of PKA may enhance the catalytic activity of 
these isoforms.  Consistent with this hypothesis, activators of PKA attenuated 
sensitization, whereas inhibitors of PKA induced sensitization in a cell line that 
endogenously expresses AC6 (Johnston et al., 2002).  Additional studies also 
support a role for PKA in sensitization via the use of a PKA-deficient cell line 
(Thomas and Hoffman, 1989) and activators of PKA in DDT1-MF2 cells (Port et 
al., 1992).  Contrary to these studies, several approaches also suggest that PKA 
is not essential for heterologous sensitization of AC (Avidorreiss et al., 1995; 
Watts and Neve, 1996; Watts et al., 1999).  These differences may be reflective 
of the complement of ACs and other signaling molecules that are present in each 
given system and demonstrate the complexity associated with differential 
modulation of AC isoforms by protein kinases. 
 
 
1.6 Adenylyl cyclase isoforms in physiology and disease 
 AC isoforms are implicated in a variety of physiological processes and 
disease states in both the central nervous system and the periphery.  Much of 




biological processes is from knockout and transgenic animal studies and is 
summarized below. 
 
1.6.1 Adenylyl cyclase function in peripheral tissues  
 Knockout and transgenic overexpression models implicate both AC5 and 
AC6 in cardiac function and heart failure.  Specifically, AC5 deletion impairs 
sympathetic, parasympathetic, and Ca2+-mediated regulation of left ventricular 
function (Okumura et al., 2003a; Tang et al., 2006).  However, cardiac-directed 
overexpression of AC5 enhances heart rate and fractional shortening, but does 
not differ from wild type mice in response to β adrenergic receptor stimulation 
(Tepe et al., 1999).  Interestingly, deletion of AC6 has no significant effect on the 
basal left ventricular function, but disrupts cAMP signaling and Ca2+ handling and 
reveals a role for AC6 in β adrenergic receptor-mediated left ventricular function 
(Tang et al., 2008).  Deletion of AC5 is protective against increased apoptosis 
and reduces the left ventricular ejection fraction associated with heart failure in 
response to pressure overload induced by thoracic aortic banding (Okumura et 
al., 2003b).  Targeted overexpression of either AC5 or AC6 displays protective 
effects in cardiac function in response to Gq-expression induced cardiomyopathy 
(Roth et al., 1999; Tepe and Liggett, 1999), but only AC6 overexpression 
reduces hypertrophy and enhances survival (Roth et al., 2002).  Interestingly, 
subsequent studies further suggest beneficial effects of AC6 expression for 




these effects are independent of the cAMP-generating catalytic function of AC6 
(Gao and Hammond, 2011; Gao et al., 2011).  Further stratifying the biological 
functions of AC5 and AC6, AC5-/- mice show protective effects against age-
induced cardiomyopathy and display increased life-span associated with 
additional protective effects against age-related oxidative stress, apoptosis, and 
loss of bone quality (Yan et al., 2007).  In summary, AC5 and AC6 demonstrate 
overlapping, but distinct functions in cardiac function and models of heart failure 
and AC5 is implicated in pathophysiological processes associated with aging.   
 Immune responses also appear to be mediated by at least one AC isoform.  
For example, AC7 has recently been implicated in distinct types of immune 
responses.  Specifically, mice with AC7-deficient immune systems are sensitive 
to endotoxic shock (via lipopolysaccharide (LPS) injection) as measured by 
survival following a semi-lethal dose of LPS (Duan et al., 2010).  Biochemical 
analysis revealed blunted cAMP responses and enhanced pro-inflammatory 
cytokine production in macrophages from the AC7-deficient mice, suggesting that 
AC7-mediated cAMP signaling may underlie immune responses to bacterial 
infection (Duan et al., 2010).  The AC7-deficient mice also display an overall 
reduction of cAMP signaling in T and B cells, and altered antibody responses 
(Duan et al., 2010).  Interestingly, it has also been recently proposed that certain 
pathogens may evade host immune responses by enhancing AC7-mediated 
signaling in macrophages, thereby deceiving the system into reduced pro-
inflammatory cytokine responses (Jiang et al., 2013a).  These data suggest that 




and is potentially modulated by pathogens to evade host immune responses 
(Duan et al., 2010; Jiang et al., 2013a). 
 
1.6.2 Adenylyl cyclase function in the central nervous system 
 Several AC isoforms are implicated in distinct types of pain and analgesia.  
AC5 is thought to mediate both acute and chronic pain responses.  Specifically, 
AC5-/- mice display reduced behavioral responses to acute pain elicited by 
thermal and mechanical stimuli, inflammatory stimuli, and visceral nociceptive 
stimuli (both inflammatory and non-inflammatory) (Kim et al., 2007).  Furthermore, 
AC5-/- mice show attenuated mechanical and thermal allodynia in two separate 
neuropathic pain models (the L5 spinal nerve ligation model and a tail nerve 
injury model) (Kim et al., 2007).  Interestingly, the Ca2+/calmodulin-stimulated 
ACs, AC1 and AC8 are also implicated in chronic pain, but not acute pain 
responses.  AC1-/-, AC8-/-, and AC1-/-/AC8-/- mice are not different than wild type 
mice in acute pain response to noxious thermal, mechanical, and inflammatory 
stimuli (Vadakkan et al., 2006; Wei et al., 2002).  However, AC1-/- and AC1-/-
/AC8-/- mice display reduced responses to chronic inflammatory stimuli (injection 
of formalin and complete Freund’s adjuvant injection) (Vadakkan et al., 2006; 
Wei et al., 2002).  Furthermore, AC1-/-/AC8-/- mice show attenuated behavioral 
responses to nerve injury (Wei et al., 2002). 
 Multiple AC isoforms have also been distinctly associated with morphine 




AC5-/- mice lost morphine-induced analgesia (latency for response to acute 
thermal stimuli), locomotor activity, reward, dependence, and behavioral signs of 
withdrawal (Kim et al., 2006).  On the other hand, mice with genetic deletion of 
Ca2+/calmodulin-stimulated ACs (AC1 and AC8) retain short-term morphine-
induced analgesia, but display reduced tolerance and withdrawal-associated 
behaviors (Li et al., 2006; Zachariou et al., 2008).  Interestingly, transgenic mice 
overexpressing AC7 in the CNS demonstrate enhanced sensitivity to the acute 
analgesic effects of morphine (measured by paw-lick latency in the hot plate test) 
and show more rapid tolerance to morphine treatment, but no difference in 
withdrawal-associated behaviors as compared to wild type animals (Yoshimura 
et al., 2000).  
 The Ca2+/calmodulin-stimulated ACs are implicated in important CNS-
related biological processes that are associated with aging.  For example, the 
Ca2+/calmodulin-stimulated ACs are thought to have redundant roles in long term 
memory, as AC1-/-/AC8-/- mice are deficient in late phase long-term potentiation 
and long term memory, but genetic deletion of AC1 or AC8 individually has no 
effect on these measures (Wong et al., 1999).  The Ca2+/calmodulin-stimulated 
ACs are also implicated in neurodegenerative processes including excitotoxicity.  
Excitotoxicity is neuronal damage/death that results from overstimulation of 
NMDA receptors by glutamate.  The excessive stimulation of NMDA receptors 
results in a Ca2+ overload in neurons, resulting in cell death.  It is thought that 
excitotoxicity contributes to the acceleration of neurodegenerative processes.  




AC1-/- mice are resistant to glutamate- and NMDA-induced excitotoxicity and 
AC1-/- mice have attenuated neuronal cell death in response to intracortical 
injection of NMDA (Wang et al., 2007a).  Ca2+-stimulated ACs are further 
implicated in neurodegeneration in neonatal mice.  Specifically, ethanol, the 
GABAa receptor modulator phenobarbital, and the NMDA receptor antagonist 
MK801 each enhance neurodegeneration in neonatal AC1-/-/AC8-/- mice.  
Furthermore, AC1-/- or AC8-/- mice display similar neurodegenerative effects 
(Maas et al., 2005).  In summary, several AC isoforms contribute to biological 
processes in the central nervous system including pain, analgesia, learning and 
memory, and neurodegeneration. 
 
 
1.7 Small molecule modulation of adenylyl cyclase 
 It is clear that AC isoforms are implicated in several disease states and it 
is hypothesized that AC isoform-selective small molecules could be utilized 
together with knockout and transgenic animal models to investigate the 
physiological roles of AC isoforms and validate their therapeutic potential (Pavan 
et al., 2009; Pierre et al., 2009).  However, small molecule AC modulators are 
generally non-selective and/or display low potency for AC modulation (Seifert et 
al., 2012).  The current collection of AC modulators is discussed below.  
 Forskolin (Figure 1.7) is a labdane diterpene that was isolated from the 




adenylyl cyclase activity in several tissues including the cerebral cortex, striatum, 
heart, and liver (Seamon et al., 1981).  Subsequent studies with recombinant 
adenylyl cyclases suggest that forskolin directly binds AC and is capable of 
stimulating all AC isoforms with the exception of AC9 (Sadana and Dessauer, 
2009; Tesmer et al., 1997).  Though forskolin has been used extensively as a 
research tool for the study of ACs and cAMP signaling (Insel and Ostrom, 2003), 
several properties of forskolin are suboptimal.  For example, forskolin is not 
water-soluble, modulates AC isoforms in a non-selective fashion, and is known to 
modulate other enzymes including glucose transporters (Laurenza et al., 1989).  
To improve upon these shortcomings, much effort has been directed toward the 
synthesis and pharmacological characterization of forskolin analogs.  For 
example, NKH477 was identified as a water-soluble forskolin analog that has 
enhanced potency for AC5 as compared to AC3 and AC2 (Toya et al., 1998).  
More recent studies identified forskolin derivatives that display a range of 
modulatory properties, including inactivity, partial activation, enhanced efficacy 
for AC isoforms, and inhibition of AC isoforms (Onda et al., 2001; Pinto et al., 
2008).  Notably, BODIPY-conjugated forskolin displays potent inhibition of AC2, 
while partially activating AC1 and AC5 (Pinto et al., 2008).  Additional chemical 
modification of forskolin may yield derivatives with novel modulatory properties or 
more favorable AC isoform-selectivity profiles, but studies to date have only 










 Early approaches to the development of adenylyl cyclase inhibitors 
focused on compounds that are nucleotides that contain an adenine (or purine) 
ring, known as the “p-site” inhibitors (Dessauer et al., 1999).  The p-site inhibitors 
are generally non-selective for inhibition of adenylyl cyclase isoforms (Johnson et 
al., 1997) and bind to the active site in the presence of pyrophosphate (Tesmer 
et al., 2000), but non-competitively with respect to ATP (Dessauer and Gilman, 
1997; Tesmer et al., 2000).  It is clear that the nucleotide phosphate groups 
confer potency for inhibition of ACs, as adenine nucleoside 3’-polyphosphate 
ligands are among the most potent p-site inhibitors (Johnson et al., 1997).  
However, the polyphosphate groups are expected to be poorly membrane-
permeable. Though p-site ligands are generally non-selective, ribose-modified p-
site ligands such as SQ22,536 and 9-CP-Ade display some degree of AC isoform 
selectivity in vitro (i.e., both compounds have similar potency values for inhibition 
of AC1, AC6, and AC8, but little or no activity for inhibition of AC2), but are 
relatively less potent than the adenine 3’-polyphosphate p-site ligands (Johnson 
et al., 1997).  The p-site inhibitors identified to date appear to have a trade-off 
between potency and AC isoform selectivity.  Furthermore, p-site inhibitors may 
have off-target effects such as inhibition of DNA replication or purine metabolism 
due to their adenine rings (Seifert et al., 2012).  
 Given concerns about an intact adenine ring facilitating off-target effects, a 
virtual screen was conducted for compounds that retained the pharmacophore of 
a ribose-substituted p-site inhibitor for AC, but without an adenine ring (Onda et 




(Onda et al., 2001).  Though NKY80 displays selectivity for AC5 over AC2 and 
AC3, and binds non-competitively with ATP and forskolin, the compound 
generally lacks potency for inhibition of AC (Onda et al., 2001).   
 An additional strategy for the development of more potent and/or selective 
inhibitors of AC involved the fusion of a metal-coordinating hydroxamic acid 
moiety to an adenine ring to exploit the requirement of metal ions for AC catalytic 
activity (Levy et al., 2003; Levy et al., 2002a; Levy et al., 2002b; Tesmer et al., 
1999).  In in vitro Sf9 cell membrane assays, PMC-6 emerged as a selective AC5 
inhibitor (over AC2 and AC3), and the most potent among the PMC class of 
inhibitors (Iwatsubo et al., 2004).  Furthermore, PMC-6 has activity for inhibition 
of isoproterenol-stimulated cAMP in intact cardiac myocytes, where it also 
displays efficacy for inhibition of apoptosis (Iwatsubo et al., 2004), suggesting 
possible therapeutic utility. 
 More recent studies have identified NB001 as a potent inhibitor of AC type 
1 in intact cell assays (Wang et al., 2011).  Interestingly, in agreement with AC1 
knockout mouse studies, inhibition of AC1 activity with NB001 has analgesic 
effects in animal models of neuropathic and inflammatory pain (Vadakkan et al., 
2006; Wang et al., 2011).  These studies suggest that targeting AC1 has 
analgesic utility, but the activity of NB001 in in vitro AC assays and an 
understanding of the structure-activity relationship surrounding NB001 remain to 
be reported. 
 2’(3’)-O-N-Methylanthraniloyl (MANT)-substituted fluorescent nucleotides 




Seifert, 2003).  Subsequent crystallography studies with MANT-GTP suggest that 
the MANT moiety binds in a hydrophobic patch at the C1/C2 interface and 
prevents a necessary rotation that is required for AC catalytic activity (Mou et al., 
2005; Wang et al., 2007b).  Furthermore, a series AC isoform-selectivity and 
structure-activity relationship studies  on the MANT class of compounds revealed 
a general preference for inhibition of AC5 and AC6 over other AC isoforms and 
that the catalytic site can accommodate nucleotides including adenine, guanine, 
hypoxanthine, and uracil (Gille et al., 2004; Goettle et al., 2009; Huebner et al., 
2011; Mou et al., 2006; Pinto et al., 2011; Suryanarayana et al., 2009).  
Consistent with the latter observation, MANT-ITP was identified as the most 
potent AC inhibitor from this class of compounds.  Though the MANT nucleotides 
are generally more potent than the p-site inhibitors for inhibition of AC in vitro, 
these compounds are also limited by poor membrane-permeability (Seifert et al., 
2012).  Thus, these studies are most useful for the structural information that 
they provide surrounding the binding of ligands in the catalytic site of ACs.     
 Efforts to develop potent and AC isoform-selective small molecule 
modulators have only modestly contributed to the current understanding of AC 
targeting and several limitations surrounding specificity, AC isoform-selectivity, 
and cell permeability remain.  Furthermore, the current repertoire of AC 
modulators has not been comprehensively studied with respect to each of the 
nine membrane-bound AC isoforms in both in vitro and intact cell models, making 
it difficult to fully assess the isoform-selectivity of these compounds (Seifert et al., 




AC that are potent and isoform-selective is expected to facilitate the in vivo study 
of individual AC isoforms and allow for the full evaluation of AC isoforms as 
potential therapeutic targets. 
 
 
1.8 Scope of the work 
 The goal of the work reported here is to investigate the modulation of 
adenylyl cyclase type 2 signaling within the context of the following three specific 
aims: 
1.) To test the hypothesis that AGS3 expression influences D2L dopamine 
receptor-mediated cAMP signaling mediated via AC1 and AC2.  This specific 
aim was designed to investigate the effects of expression of the G protein 
regulator, AGS3, on recombinant AC1 and AC2 in response to both acute and 
persistent activation of the D2L dopamine receptor in HEK293 cells.  The 
differential modulation of AC1 and AC2 by G protein subunits offers unique 
properties to study the effects of AGS3 expression on G protein-coupled receptor 
signaling. 
2.)  To test the hypothesis that D2L dopamine receptor-mediated 
heterologous sensitization of AC2 is Gβγ subunit-dependent.  The 
mechanism of D2L dopamine receptor-induced heterologous sensitization of AC2 




signaling to D2L dopamine receptor-mediated sensitization of AC2 in HEK293 
cells.   
3.)  To develop and implement a high-throughput screening paradigm for 
the discovery of small molecule modulators of AC2.   Specific aim 3 
encompassed the development of a cell-based high-throughput screening 
paradigm for the measurement of cellular cAMP.  The assay platform was then 
utilized to conduct an intact-cell small molecule screen for direct AC2 inhibitors in 
HEK293 cells.  The work in this aim was designed as an intermediate step in the 




CHAPTER 2. DIFFERENTIAL EFFECTS OF AGS3 EXPRESSION ON D2L 
DOPAMINE RECEPTOR-MEDIATED ADENYLYL CYCLASE SIGNALING 
2.1 Introduction 
 G protein-coupled receptors bind ligands that induce conformational 
changes in the receptor and facilitate the activation of G protein heterotrimers by 
exchange of GDP for GTP on the G protein α subunit (Gilman, 1987).  Upon 
activation, the G protein heterotrimer undergoes a conformational change that 
allows Gα and Gβγ subunits to regulate effector proteins such as adenylyl 
cyclases (ACs) (Coleman et al., 1994; Lambright et al., 1994; Taussig et al., 
1993a).  The G protein signaling cycle ends by hydrolysis of GTP to GDP on the 
Gα subunit (Coleman et al., 1994; Mixon et al., 1995).  In addition to G protein-
coupled receptor modulation, the G protein activation cycle is sensitive to 
accessory proteins such as regulators of G protein signaling (RGS) or activator of 
G protein signaling (AGS) proteins (Blumer et al., 2007; Neubig and Siderovski, 
2002; Sato et al., 2004).  These proteins influence G protein signaling and 
effector activation by modulating the rate of GTP hydrolysis and the availability 
and/or stability of Gα or Gβγ subunits (Blumer et al., 2007; Neubig and 




 The activator of G protein signaling 3 (AGS3) is a G protein regulator that 
has been linked to adaptive behaviors involved with drugs of abuse (Bowers et 
al., 2008; Bowers et al., 2004; Yao et al., 2005).  AGS3 was identified as a 
receptor-independent G protein activator and is thought to bind Gαi subunits in 
the GDP-bound state, thereby preventing re-association of Gα and Gβγ subunits 
(De Vries et al., 2000; Peterson et al., 2000; Takesono et al., 1999).  The precise 
molecular actions of AGS3 have yet to be fully described, however it is 
hypothesized that AGS3 expression may specifically adjust the landscape of 
effector activation by modulating Gα and Gβγ subunit signaling.  Previous studies 
examining the actions of AGS3 on G protein-coupled receptor signaling in cell-
based assays suggest that the effects of AGS3-like molecules are dependent on 
the duration of receptor activation.  For example, an AGS3 consensus peptide 
was shown to have no effect on the ability of D2DRs to modulate G protein-
regulated inwardly rectifying potassium (GIRK) channels acutely, but promoted 
functional desensitization of this response following repeated receptor activation 
(Webb et al., 2005).  Furthermore, the actions of AGS3 on α2 adrenergic 
receptor regulation of cAMP signaling were explored in CHO cells, which 
predominantly express AC6 (Varga et al., 1998).  The acute effects on α2 
adrenergic receptor-mediated AC signaling were not altered, but sensitization of 
AC in response to persistent α2 receptor activation was attenuated by AGS3 
expression (Sato et al., 2004).  More recent studies in nucleus 




expression of AGS3 enhances the activity of AC5 and AC7 in a protein kinase-
dependent manner (Fan et al., 2009).  
 The observations described above suggest a complex mode of AGS3 
modulation of receptor-mediated AC signaling.  The complexity is further 
exacerbated by the expression and signaling of multiple AC isoforms that display 
unique patterns of Gα and Gβγ regulation (Sunahara et al., 1996; Watts and 
Neve, 2005).  The present study was designed to examine the effects of AGS3 
on G protein-coupled receptor modulation of two recombinant ACs, AC1 and 
AC2.  AC1 is a member of the Ca2+-stimulated group of ACs and can be 
activated by the Ca2+ ionophore, A23187, and inhibited by both Gαi and Gβγ 
subunits (Choi et al., 1992a; Cumbay and Watts, 2001; Taussig et al., 1993b).  
AC2 is a member of a group of ACs that are conditionally activated by Gβγ 
subunits (Federman et al., 1992; Taussig et al., 1993b).  AC2 is also robustly 
activated by protein kinase C (PKC) phosphorylation in response to phorbol ester 
stimulation (e.g. PMA) (Shen et al., 2012; Yoshimura and Cooper, 1993).  The 
distinct regulatory properties of AC1 and AC2 provide important tools to 
selectively study the effects of AGS3 expression on G protein-coupled receptor 
signaling. 
 It is widely accepted that alterations in cAMP signaling pathways and 
enhanced activation of dopamine systems in the brain play central roles in the 
molecular adaptations associated with drug addiction (Carlezon et al., 2005; 
McClung and Nestler, 2003; Nestler, 2001).  The dopaminergic signaling and 




adenylyl cyclases via G protein activation.  There are two families of dopamine 
receptors, D1-like (D1 and D5) that couple to Gαs, and D2-like (D2, D3, and D4) 
that couple to Gαi/o (Missale et al., 1998).  We chose to study D2LDR signaling 
based on the overlapping tissue distribution of the D2LDR with AC1 and AC2 in 
the brain, and its well-characterized roles in AC signaling and drug abuse, where 
AGS3 has also been implicated (Maldonado et al., 1997; Phillips et al., 1998; 
Ralph et al., 1999; Visel et al., 2006; Weiner et al., 1991).  HEK293 cells 
expressing the D2LDR together with either AC1 or AC2 were used to explore 
cAMP signaling in the absence or presence of AGS3.  Our studies revealed that 
AGS3 expression had modest, but significant potentiating effects on acute D2LDR 
modulation of AC1 or AC2 activity.  In contrast, AGS3 displayed differential 
effects on AC regulation following persistent D2LDR activation.  These findings, 
along with those reported in the literature, suggest that AGS3 modulates AC 




2.2 Materials and methods 
2.2.1 Materials 
 [3H]-cAMP (33 Ci/mmol) was purchased from PerkinElmer Life and 
Analytical Sciences (Boston, MA).  Spiperone, (±)-quinpirole, A23187, 3-isobutyl-




and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO).  
Phorbol 12-myristate 13-acetate (PMA) was purchased from Tocris Bioscience 
(Ellisville, MO).  Lipofectamine 2000 and Zeocin were purchased from Invitrogen 
(Carlsbad, CA).  FetalClone I (FCI) serum, bovine calf serum (BCS), and Earle’s 
balanced salt solution (EBSS) were purchased from Hyclone (Logan, UT).  
Hygromycin B was purchased from Calbiochem (La Jolla, CA). 
 
2.2.2 Cell culture and stable cell line generation 
 HEK293 cells stably expressing AC1 or AC2 were grown in DMEM 
supplemented with 5% FCI, 5% BCS, 1 unit/ml penicillin, 1 μg/ml streptomycin, 
2.5 ng/ml amphotericin B, and either 100 μg/ml Hygromycin B (HEK-AC1) or 300 
μg/ml G418 (HEK-AC2) and were maintained in a humidified incubator at 37°C 
with 5% CO2.  Cell lines were transfected with the dual expression vector 
pBudCE4 with the gene for the human D2LDR driven by the CMV promoter and 
either rat AGS3-Venus (long splice variant), AGS3-Q/A-Venus, or no gene 
behind the EF-1α promoter.  Several studies have utilized AGS3 fused with a 
fluorescent protein at the c-terminus (An et al., 2008; Oner et al., 2010; Oner et 
al., 2013; Vural et al., 2010) and these studies suggest that the AGS3-fluorescent 
fusion proteins retain similar cellular localization (An et al., 2008; Blumer et al., 
2002; Pizzinat et al., 2001; Vural et al., 2010) and interaction with Gαi subunits 
(De Vries et al., 2000; Oner et al., 2010; Oner et al., 2013; Peterson et al., 2000) 




Lipofectamine 2000 according to the manufacturer’s protocol.  Clones were 
isolated by selection with Zeocin (200 μg/ml) and characterized for specific AC 
function by cAMP accumulation assays, D2LDR expression by radioligand binding, 
and AGS3 expression by fluorescence microscopy. 
 
2.2.3 Cyclic AMP accumulation assay 
 Cells were grown to confluency in 48-well plates and cAMP assays were 
performed on ice in assay buffer (EBSS containing 15 mM Na+-HEPES, 2% BCS, 
and 0.02% ascorbic acid).  For acute cAMP accumulation experiments, cells 
were stimulated at 37°C for 15 minutes in the presence of 500 μM IBMX.  The 
stimulation buffer was decanted and cells were lysed with ice-cold 3% 
trichloroacetic acid.  The plate was stored at 4°C for at least 1 h before cAMP 
quantification.  For persistent receptor activation experiments, cells were grown 
to confluency in 48-well plates and pretreated in assay buffer with either vehicle 
or 1 μM (±)-quinpirole for 2 h at 37°C and 5% CO2.  Cells were washed with 
assay buffer three times (3 minutes each), and subsequently stimulated as 
described for acute cAMP accumulation assays.  For desensitization assays, 
pretreatments were carried out as described above, followed by re-activation of 
the receptor as described for acute cAMP accumulation experiments.  For 
heterologous sensitization experiments, subsequent stimulation was achieved by 




presence of 500 μM IBMX and 1 μM spiperone to block residual agonist binding 
from the pretreatment. 
 
2.2.4 Cyclic AMP quantification 
 Cyclic AMP was quantified using a competitive binding assay (Przybyla 
and Watts, 2010).  Duplicate samples of lysate from the cAMP accumulation 
assay were added to reaction tubes, followed sequentially by [3H]-cAMP (~1 nM 
final concentration), and cAMP-binding protein (~100 μg of crude bovine adrenal 
extract) in 500 μL of cAMP binding buffer (100 mM Tris-HCl, 100 mM NaCl, 3 
mM EDTA, pH 7.4).  The assay was carried out at 4°C for 2 hr and harvested by 
filtration through Millipore FB 96-well filter plates, and radioactivity was quantified 
on a TopCount NXT scintillation counter (Perkin Elmer).  Cyclic AMP 
concentrations were estimated from a standard curve ranging from 300 pmol to 3 
nmol cAMP. 
 
2.2.5 Data analysis 
 GraphPad Prism software was used to generate all dose-response curves 
(GraphPad Software, San Diego, CA).  All logIC50/logEC50, and maximal 
activation/inhibition values were calculated in GraphPad Prism using a non-linear 






2.3 Results and discussion 
 AGS3 interacts with the GDP-bound state of Gαi subunits, and it has been 
suggested that this interaction prevents the re-association of Gαi and Gβγ 
subunits (De Vries et al., 2000; Peterson et al., 2000).  The interaction between 
AGS3 and Gαi-GDP may cause altered G protein signaling through effectors 
regulated by Gαi and Gβγ subunits.  AC isoforms display differential patterns of 
regulation by G protein subunits (Sunahara et al., 1996; Watts and Neve, 2005).  
Given that AGS3 may alter signaling by Gαi and/or Gβγ subunits, and AC 
isoforms are differentially regulated by G protein subunits, we were interested in 
studying the effects of AGS3 expression on the regulation of AC isoforms 
following acute and persistent activation of D2LDRs. 
 
2.3.1 Characterization of HEK293 stable cell lines 
 To study the effects of AGS3 on D2LDR-mediated signaling through AC 
isoforms, several HEK293 cell lines were generated and characterized (HEK-
AC1-D2L, HEK-AC1-D2L-AGS3-Venus, HEK-AC2-D2L, HEK-AC2-D2L-AGS3-
Venus, and HEK-AC2-D2L-AGS3-Q/A-Venus).  The function of the stably 
expressed AC isoforms was characterized by the cAMP responses to 
pharmacological conditions for the selective activation of either AC1 (10 μM 






Figure 2.1 Selective activation of recombinant AC1 by the calcium ionophore, 
A23187 and recombinant AC2 by the phorbol ester, PMA.  A. Cell lines 
expressing recombinant AC1 or B. recombinant AC2 were incubated under the 
indicated conditions and cAMP accumulation was measured using a Cisbio 
homogenous time-resolved fluorescent (HTRF) cAMP assay kit according to the 
manufacturer’s protocol.  Data represent the mean ± S.E.M. of three 
experiments.  ** p < 0.01, compared to the basal condition within each cell line 




  As expected, treatment with the Ca2+ ionophore, A23187 significantly stimulated 
cAMP accumulation in cell lines expressing AC1, but had no effect in cell lines 
expressing AC2.  On the other hand, phorbol ester treatment selectively 
enhanced the cAMP activity in cells expressing AC2, but had no effect in cells 
expressing AC1.  These results suggest that the stable cell lines expressing AC1 
or AC2 can be selectively activated by A23187 or PMA, respectively.  The cell 
lines were further  
characterized for the expression levels of the D2LDR, as quantified by [3H]-
methylspiperone saturation binding (Table 2.1).  Each of the stable cell lines had 
similar Bmax and Kd values, suggesting that the D2LDR expression levels were 
similar.  AGS3-Venus expression was confirmed by fluorescence microscopy 
(Figure 2.2) and spectroscopy (Table 2.2).  Together, these data suggest that cell 
lines that were generated are suitable for studies of the effects of AGS3 





Table 2.1  D2LDR expression levels in cellular models used for functional studies.  
[3H]-Methylspiperone saturation binding assays and analysis was performed (as 
described in Przybyla and Watts, 2010) to measure the D2LDR expression level 









HEK-AC1-D2L 2.5±0.10 0.10±0.02 
HEK-AC1-D2L-AGS3-Venus 4.0±0.27 0.11±0.02 
HEK-AC2-D2L 9.1±2.5 0.11±0.01 
HEK-AC2-D2L-AGS3-Venus 15±3.0 0.17±0.04 








Figure 2.2 AGS3-Venus expression by confocal microscopy.  Representative 
fields were imaged for cell lines expressing AGS3 fused to the Venus fluorescent 
protein at 20X magnification using a Nikon A1 confocal system when excited with 





Table 2.2 The Venus fluorescence intensity (Ex: 485/20 nm and Em: 530/30) of 
cell suspensions was measured in 384-well format using a Biotek Synergy 4 
plate reader.  The fluorescence intensity values of HEK-AC1-D2L and HEK-AC2-
















2.3.2 Modulation of acute D2LDR-mediated AC1 and AC2 signaling by AGS3 
expression  
 Our initial studies used HEK293 cells stably expressing AC1 or AC2 and 
the D2LDR.  Recombinant AC1 can be selectively activated in HEK293 cells by 
Ca2+ using the calcium ionophore, A23187 or by capacitative calcium entry (Choi 
et al., 1992a; Cooper et al., 1994).  To observe acute Gαi regulation, AC1 activity 
was selectively increased using A23187, and inhibition by the D2DR agonist 
quinpirole was examined.  A23187-stimulated AC1 activity was inhibited by 54±2% 
with a logIC50 of -8.08±0.13 (Figure 2.3A).  In cells expressing AGS3, modest, 
but significant increases in maximal inhibition (67±4%) and potency (logIC50 = -
8.83±0.19) for D2LDR-mediated inhibition of AC1 activity by quinpirole were 
observed.  AC2 is conditionally stimulated (requiring co-activation of AC2 by Gαs 
or PKC) by Gβγ subunits following the activation of Gi/o-coupled receptors (Tsu 
and Wong, 1996; Yoshimura and Cooper, 1993; Zimmermann and Taussig, 
1996).  To study acute Gβγ subunit signaling, HEK293 cells stably expressing 
AC2 and the D2LDR were incubated with PMA to stimulate AC2, and quinpirole to 
activate the D2LDR (subsequently releasing Gβγ subunits).  Maximal activation of 
the D2LDR by quinpirole resulted in a robust increase in cAMP accumulation 
through conditional activation of AC2 (240±18% of PMA response) with a 
logEC50 of -7.05±0.06 (Figure 2.3B).  AGS3 co-expression did not affect the 
maximal activation of AC2 (250±20% of PMA response), but a significant shift in 




was observed as compared to cells not expressing AGS3.  Though modest, the 
effects of AGS3 on D2LDR-mediated regulation of AC1 or AC2 are consistent with 
enhanced Gβγ subunit modulation of each effector.  Specifically, Gβγ subunits 
inhibit signaling mediated by AC1, but increase AC2 activity, and AGS3 
expression augments the potency of these effects, presumably by binding Gαi 
subunits.  The effects of AGS3 expression on acute D2LDR-mediated AC1 or 
AC2 activity are contrary to other cell-based studies examining the effects of 
AGS3 expression on acute G protein signaling.  For example, AGS3 did not alter 
α2-adrenergic receptor-inhibited AC activity in CHO cells (Sato et al., 2004).  
Perhaps more relevant to our D2DR-AC2 studies is the observation that AGS3 
failed to alter D2SDR-stimulated GIRK channel activity, a Gβγ mediated signaling 
event (Webb et al., 2005).  These findings suggest that AGS3 may display AC-






Figure 2.3 Effect of AGS3 expression on acute regulation of AC isoforms.  A. 
Acute inhibition of A23187 (10 μM)-stimulated cAMP accumulation was 
measured following incubation with quinpirole as indicated in HEK293 cells stably 
expressing AC1 and the D2LDR, or AC1 and the D2LDR together with AGS3-
Venus.  B. Cyclic AMP accumulation was quantified in HEK293 cells stably 
expressing AC2 and the D2LDR with or without AGS3-Venus following acute 
treatment with PMA (1 μM) and increasing concentrations of quinpirole as 
indicated.  Data points represent mean ± S.E.M. of at least three independent 




2.3.3 Desensitization of D2LDR-mediated AC1 and AC2 signaling  
 In addition to studying AC regulation by acute activation of the D2LDR, we 
were also interested in studying desensitization of the D2LDR.  Cells stably 
expressing AC1 and the D2LDR were treated with quinpirole for 2 h in an effort to 
promote functional receptor desensitization.  Following washing, cells were re-
exposed to quinpirole and the subsequent cAMP accumulation was measured.  
Persistent D2LDR activation by quinpirole failed to induce significant 
desensitization of D2LDR modulation of AC1 activity.  Specifically, quinpirole 
treatment maximally inhibited A23187-stimulated AC1 activity by 56±9.1% with a 
logIC50 of -8.0±0.20 following persistent D2LDR activation, as compared to 
maximum inhibition of 59±1.8% and log IC50 of -8.5±0.20 after vehicle 
pretreatment (n=2).  We then examined the effects of AGS3 expression on 
D2LDR-modulated AC1 activity following persistent D2LDR stimulation.  These 
experiments revealed that AGS3-expressing cells pretreated with quinpirole 
displayed a desensitization of D2LDR-modulated AC1 inhibition that was 
manifested as a significant loss of maximal inhibition (60±6%) compared to 
vehicle pretreated cells (84±8%), but without a significant change in potency 
(logIC50 = -8.03±0.39 and -8.64±0.17, respectively) (Figure 2.4).  The AGS3-
promoted desensitization of AC1 inhibition may occur through interactions with 
Gαi subunits that are involved in the inhibition AC1 activity.  However, it has been 
suggested that Gαi-AGS3 complexes can couple with, and be regulated by Gαi-




modulation of downstream Gβγ subunit signaling (Oner et al., 2010).  
Furthermore, an AGS3 consensus peptide disrupted Gβγ subunit activation of 
GIRK channels following repeated stimulation of D2SDRs (Webb et al., 2005).  
Given that Gβγ subunits inhibit AC1 activity (Taussig et al., 1993b), these data 
present the possibility that the desensitization of AC1 inhibition is also associated 







Figure 2.4 The effect of AGS3 expression on functional desensitization of D2LDR-
modulated AC1 activity.  HEK293 cells stably expressing AC1, the D2LDR, and 
AGS3-Venus were treated with quinpirole (1 μM) or vehicle for 2 hrs, followed by 
selective AC1 stimulation with A23187 (10 μM) and activation of the D2LDR with 




  In contrast to AC1, a complete desensitization of D2LDR-mediated 
potentiation of AC2 activation was observed following quinpirole pretreatment in 
D2LDR-AC2 cells.  Specifically, quinpirole pretreatment resulted in 103±11% 
desensitization of D2LDR-mediated potentiation of AC2 activity as compared to 
vehicle pretreatment (Figure 2.5).  These observations suggest potential 
differences in the general mechanisms for desensitization of D2LDR-modulated 
AC1 and AC2 activity.  Such mechanisms presumably reflect the differential 
regulatory properties of AC1 and AC2 that involve G protein modulation 
(Hanoune and Defer, 2001).  Subsequent experiments examined the effects of 
AGS3 on desensitization of D2LDR-potentiated AC2 activity.  Surprisingly, 
expression of AGS3 resulted in significantly less desensitization (46±7%) of 
D2LDR-mediated potentiation of AC2 activity (Figure 2.5).  The specificity of this 
blockade was probed by expressing an AGS3 mutant that does not bind Gαi 
subunits, AGS3-Q/A (Peterson et al., 2002).  AGS3-Q/A failed to significantly 
alter quinpirole-induced desensitization of D2LDR-AC2 signaling (78±3%), 
suggesting that AGS3 expression inhibits desensitization of D2LDR signaling 







Figure 2.5 The effect of AGS3 expression on functional desensitization of D2LDR-
modulated AC2 activity.  HEK293 cells stably expressing AC2 and the D2LDR 
alone, or together with AGS3-Venus or AGS3-Q/A-Venus were treated with 
quinpirole (1 μM) or vehicle for 2 hrs, followed by stimulation with PMA (1 μM) 
and quinpirole (1 μM).  Data represent the mean ± S.E.M. of at least three 
independent experiments.  ** p < 0.01, compared with AC2+D2L condition, one 




2.3.4 Effects of AGS3 expression on heterologous sensitization of AC1 and AC2 
 In addition to desensitization, persistent activation of many Gi/o-coupled 
receptors (e.g., D2 dopamine and μ-opioid) results in enhanced subsequent AC 
activation.  This heterologous sensitization (a.k.a. superactivation) of cAMP 
signaling involves both Gαi/o and Gβγ subunits (Watts and Neve, 2005), but the 
mechanisms of sensitization for AC1 and AC2 appear to differ (Cumbay and 
Watts, 2001).  The functional effects of AGS3 expression on AC sensitization 
following persistent activation of the D2LDR were examined.  For these 
experiments, cells expressing AC1 and the D2LDR were stimulated with the D2DR 
agonist quinpirole for 2 h, followed by selective activation of AC1 by A23187.  
Quinpirole pretreatment resulted in a 235±4% enhancement of A23187-
stimulated AC1 activity compared to the vehicle pretreatment (Figure 2.6A).  
Cells co-expressing AGS3 displayed a reduction in subsequent AC1 stimulation 
(178±12% of vehicle condition) following quinpirole pretreatment, suggesting that 
AGS3 expression attenuates AC1 sensitization by ~40%.   
 The effects of AGS3 expression on the regulation of AC2 following 
persistent D2LDR activation were also explored.  AC2 displayed an enhanced 
responsiveness (182±9% of vehicle condition) to stimulation by PMA following 
quinpirole pretreatment (Figure 2.6B).  The D2LDR-mediated sensitization of AC2 
was nearly eliminated (120±3% of vehicle condition) in AGS3-expressing cells.  
In contrast, AGS3-Q/A did not alter D2LDR-mediated sensitization of AC2 




are involved in the inhibition of AC2 sensitization.  The ability of AGS3 
expression to prevent heterologous sensitization of AC1 and AC2 is similar to 
that observed by expressing the Gβγ subunit scavenger, βARK-CT ((Koch et al., 
1994; Nguyen and Watts, 2005) and see chapter 3 for AC2).  These data add 
support to the hypothesis that AGS3 potentially alters Gβγ subunit signaling 







Figure 2.6 Effect of AGS3 expression on heterologous sensitization of AC 
isoforms.  A. HEK293 cells stably expressing AC1 and D2LDR were stimulated 
with vehicle or quinpirole (1 μM) for 2 hr, washed, and subsequently stimulated 
with A23187 (10 μM) as indicated.  Data represent mean ± S.E.M. of three 
independent experiments.  * p < 0.05, unpaired t-test.  B. HEK293 cells stably 
expressing AC2 and D2LDR in the absence of, or coexpressed with AGS3-Venus 
or AGS3-Q/A-Venus as indicated were pretreated with vehicle or quinpirole (1 
μM) for 2 hr, washed, and subsequently stimulated with PMA (1 μM).  Data 
represent mean ± S.E.M. of at least three independent experiments.  ** p < 0.01, 




 The inhibition of D2LDR-mediated sensitization of AC1 and AC2 by AGS3 
expression is consistent with a report revealing that AGS3 inhibits α2-adrenergic 
receptor-mediated sensitization of AC isoforms expressed in CHO cells 
(predominantly expressing AC6) (Sato et al., 2004; Varga et al., 1998).  In 
contrast, evidence suggests that opioid receptor-induced up-regulation of AGS3 
expression mediates sensitization of AC5 and AC7 in nucleus accumbens/striatal 
neurons (Fan et al., 2009).  These differential effects suggest an isoform-
dependence for sensitization that may reflect complex and unique isoform-
specific mechanisms of AC sensitization involving Gαi, Gβγ, or a combination of 
the two, and subsequently altered downstream signaling.  Alternatively, the 
isoform-specific effects on AC signaling may reflect differences in receptor types, 
cell types, or experimental paradigms.  The differential effects of AGS3 on AC 
sensitization, desensitization, and acute D2LDR-mediated signaling are similar to 
what has been observed for ligands that possess functional selectivity (or 
promote agonist-directed trafficking) (Kenakin, 1995).  Such an observation 
posits that receptor- and effector-modulating signaling molecules introduce an 
additional level of complexity for cell signaling studies.  For example, AGS3 
differentially alters desensitization of D2LDR-mediated modulation of AC1 and 
AC2, while reducing sensitization of both AC isoforms. These complex 
mechanisms for regulation by AGS3 in vitro suggest the opportunity for greater 





2.3.5 Significance of AGS3-regulated AC signaling to drugs of abuse  
 In vivo studies suggest that AGS3 has a “gatekeeper” role for drug-
seeking behavior in response to heroin, cocaine, or ethanol.  For example, 
knocking out AGS3 expression in specific brain regions resulted in a loss of drug-
seeking behavior or cocaine-induced locomotor sensitization (Bowers et al., 2008; 
Bowers et al., 2004; Yao et al., 2005).  Interestingly, AGS3 expression is up-
regulated in the nucleus accumbens core or prefrontal cortex during withdrawal 
periods following prolonged ethanol or cocaine self-administration, respectively 
(Bowers et al., 2008; Bowers et al., 2004).  In conjunction with overwhelming 
evidence that dopamine systems and cAMP signaling pathways are involved in 
drug addiction (Carlezon et al., 2005; McClung and Nestler, 2003; Nestler, 2001), 
our data suggest that AGS3 overexpression during periods of withdrawal may 
change the profile of signaling through specific AC isoforms in response to 
persistent Gi/o-coupled receptor activation.  In addition, recent studies with AC 
knockout mice suggest a role for Ca2+-stimulated ACs (AC1 and AC8) in the 
regulation of cocaine behavioral sensitization (DiRocco et al., 2009).  It will be 
important to study the role of individual AC isoforms in specific brain regions in 
the context of drug-seeking behavior, where AGS3 may be exerting its effects by 
fine-tuning D2LDR-mediated signaling through distinct AC isoforms.    
 Taken as a whole, our data suggest that AGS3 expression alters D2LDR-
mediated regulation of effector proteins in a manner that is effector-specific and 




AGS3 has modest, but potency-enhancing effects on effector modulation in 
response to acute Gi-coupled receptor stimulation.  Expression of AGS3 
promoted desensitization of prolonged D2LDR-mediated signaling through AC1, 
but reduced desensitization of AC2 signaling.  In addition, D2LDR-mediated 
sensitization of AC1 and AC2 signaling was attenuated by AGS3 expression.  It 
is becoming apparent that AGS3 is involved in altering G protein signaling in a 




CHAPTER 3. HETEROLOGOUS SENSITIZATION OF ADENYLYL CYCLASE 2 
IS DEPENDENT ON G PROTEIN BETA-GAMMA SUBUNIT SIGNALING 
3.1 Introduction 
 AC sensitization was first reported in 1975 in the lab of Marshall Nirenberg, 
but an understanding of the mechanisms of AC sensitization remains elusive 
(Watts and Neve, 2005).  However, the signaling pathways underlying AC 
sensitization appear to be overlapping, but distinct for each isoform (Watts and 
Neve, 2005).  The present study focuses on sensitization of adenylyl cyclase 
type 2 (AC2), as AC2 is expressed in brain regions co-expressing D2DRs and 
can be selectively activated in HEK293 cells (Cumbay and Watts, 2001; Visel et 
al., 2006; Weiner et al., 1991).  AC2 is activated by Gαs and protein kinase C 
(PKC) phosphorylation in response to phorbol ester stimulation (e.g. PMA ) and 
Gq-coupled receptor activation (Shen et al., 2012; Yoshimura and Cooper, 1993; 
Zimmermann and Taussig, 1996).  Furthermore, AC2 is also conditionally 
activated by Gβγ subunits in response to Gi/o-coupled receptor signaling 
(Federman et al., 1992; Taussig et al., 1993b).  In response to persistent D2LDR 
activation, AC2 is readily sensitized, but appears to have a unique mechanism of 




PKC-mediated activation, but not Gαs- or forskolin-mediated stimulation 
(Cumbay and Watts, 2001).  The mechanism of AC2 sensitization, however, has 
been largely unexplored.   An understanding of the molecular adaptations that 
underlie D2 dopamine receptor-mediated sensitization of AC2 signaling would 
provide insight into the diverse modulation of cAMP signaling through AC 
isoforms and contribute to our understanding of the pathophysiology and 
potential therapeutic targeting of neurological disorders including drug abuse.   
 Gβγ subunit signaling is necessary for sensitization of AC isoforms 
including AC1 (Nguyen and Watts, 2005), AC5 (AvidorReiss et al., 1996), and 
AC6 (Thomas and Hoffman, 1996), but has been unexplored for D2LDR-mediated 
sensitization of AC2.  We have demonstrated that D2LDR-mediated sensitization 
of AC2 is inhibited by expression of AGS3 and it is hypothesized that AGS3 
expression may lead to disrupted Gβγ signaling in response to persistent Gi/o-
coupled receptor activation (Chapter 2).  Thus, it is possible that sensitization of 
AC2 in response to long-term D2LDR activation proceeds via Gβγ subunit 
signaling.  We directly examined the role of Gβγ subunits in the development of 
D2LDR-mediated sensitization of AC2 with a Gβγ subunit sequestering protein, 
two small molecule Gβγ signaling inhibitors, and a cell permeable peptide 
inhibitor of Gβγ.  We also pharmacologically investigated the roles of several 






3.2 Materials and Methods 
3.2.1 Materials 
 [3H]-cAMP (33 Ci/mmol) was purchased from PerkinElmer Life and 
Analytical Sciences (Boston, MA).  Spiperone, (±)-quinpirole, 3-isobutyl-1-
methylxanthine (IBMX), G418, Dulbecco’s modified Eagle’s medium (DMEM), 
and trichloroacetic acid were purchased from Sigma-Aldrich (St. Louis, MO).  
Phorbol 12-myristate 13-acetate (PMA) was purchased from Tocris Bioscience 
(Ellisville, MO).  Lipofectamine 2000, antibiotic-antimycotic solution, and Zeocin 
were purchased from Invitrogen (Carlsbad, CA).  FetalClone I (FCI) serum, 
bovine calf serum (BCS), Hank’s balanced salt solution (HBSS), and Earle’s 
balanced salt solution (EBSS) were purchased from Hyclone (Logan, UT). 
 
3.2.2 Cell culture and transfection 
 HEK293 cells were grown in DMEM supplemented with 5% FCI, 5% BCS, 
and 1% antibiotic-antimycotic solution and maintained in a humidified incubator 
at 37°C and 5% CO2.  For transient transfections, HEK293 cells were seeded 
into 96-well plates and allowed to grow to 70% confluency.  Transient 
transfection was carried out for 48 h with Lipofectamine 2000 according to the 
manufacturer’s protocol.  The generation, characterization, and maintenance of 





3.2.3 Cyclic AMP accumulation assay 
 Cells were grown to confluency in either 48-well or 96-well plates and 
cAMP assays were performed on ice in assay buffer (EBSS containing 15 mM 
Na+-HEPES, 2% BCS, and 0.02% ascorbic acid).  For acute cAMP accumulation 
experiments, cells were stimulated at 37°C for 15 minutes in the presence of 500 
μM IBMX.  The stimulation buffer was decanted and cells were lysed with ice-
cold 3% trichloroacetic acid.  The plate was stored at 4°C for at least 1 h before 
cAMP quantification.  For persistent receptor activation experiments, cells were 
grown to confluency in 48-well plates and pretreated in assay buffer with either 
vehicle or 1 μM (±)-quinpirole for 2 h at 37°C and 5% CO2.  Cells were washed 
with assay buffer three times (3 minutes each), and subsequent stimulation was 
achieved by selective activation of AC2 (1 μM PMA) in the presence of 500 μM 
IBMX and 1 μM spiperone to block residual agonist binding from the pretreatment.   
 Heterologous sensitization experiments with pharmacological inhibitors 
were carried out in HEK293 cells stably expressing AC2 and the D2LDR.  Cells 
were seeded into 96-well plates and grown to confluency.  Cell growth media 
was decanted and cells were pretreated with pharmacological inhibitors in Hank’s 
balanced salt solution (HBSS), 20 mM HEPES, and 0.1% fatty acid free bovine 
serum albumin for 15 min at 37°C and 5% CO2.  Cells with pharmacological 
inhibitors were then pretreated for an additional 2 h with either vehicle or 100 nM 
(±)-quinpirole.  Subsequent AC2 activation was carried out by stimulating the 




37°C and 5% CO2 for 15 min.  The cells were lysed with 3% trichloroacetic acid 
and stored at 4°C for at least 1 h before cAMP quantification. 
 
3.2.4 Cyclic AMP quantification 
 Cyclic AMP was quantified using a competitive binding assay (Przybyla 
and Watts, 2010).  Duplicate samples of lysate from the cAMP accumulation 
assay were added to reaction tubes, followed sequentially by [3H]-cAMP (~1 nM 
final concentration), and cAMP-binding protein (~100 μg of crude bovine adrenal 
extract) in 500 μL of cAMP binding buffer (100 mM Tris-HCl, 100 mM NaCl, 3 
mM EDTA, pH 7.4).  The assay was carried out at 4°C for 2 h and harvested by 
filtration through Millipore FB 96-well filter plates, and radioactivity was quantified 
on a TopCount NXT scintillation counter (Perkin Elmer).  Cyclic AMP 





 Our initial sensitization experiments employed HEK293 cells that were 
transiently transfected with AC2 and the D2LDR.  Consistent with significant AC2 
expression and function, HEK293 cells co-expressing AC2 and the D2LDR 
displayed a robust increase in cAMP accumulation in response to PMA activation 




vector (0.60±0.06 pmol/well, n = 3).  To observe D2LDR-mediated sensitization of 
AC2, cells were pretreated for 2 h with the D2LDR agonist quinpirole, and 
subsequently stimulated with PMA to activate AC2.  The quinpirole-pretreated 
cells co-expressing AC2 and the D2LDR displayed PMA-stimulated cAMP 
accumulation that was 251±34% of the vehicle pretreatment condition, whereas 
the empty vector transfected cells provided a response that was similar to that of 
vehicle-treated cells (Figure 3.1).  These observations are consistent with our 
previous studies using cells stably expressing AC2, where persistent D2LDR 
activation resulted in a sensitized response to AC2 activation via PKC as 
measured by the enhancement of cAMP accumulation over that of the vehicle 
pretreatment condition (Chapter 2 and (Cumbay and Watts, 2001)).  Studies 
have suggested an important role for Gi/o protein subunits in the development of 
AC sensitization (Watts and Neve, 2005).  The regulatory properties of AC2 offer 
a unique system to dissociate the functional roles of Gαi/o and Gβγ subunits in 
AC sensitization.  Specifically, AC2 is thought to be insensitive to functional 
regulation by Gαi subunits (Tang and Gilman, 1991; Taussig et al., 1994), 
thereby allowing the specific observation of Gβγ subunit-modulated AC2 activity.  
To directly study the role of Gβγ subunits in AC2 sensitization, the membrane-
localized Gβγ subunit-sequestering protein βARKct-CD8 was co-expressed with 
AC2 and the D2LDR in HEK293 cells.  Expression of βARKct-CD8 resulted in a 
blockade of D2LDR-mediated sensitization of AC2 (124±13% of vehicle response), 





Figure 3.1 Effect of the Gβγ subunit sequestering protein on heterologous 
sensitization of AC2.  HEK293 cells were transiently transfected with AC2, the 
D2LDR, and either empty vector or βARKct-CD8.  Cells were pretreated with 
quinpirole or vehicle for 2 h and subsequently stimulated with 1 μM PMA.  Data 
are expressed as a percentage of the vehicle condition for each transfection and 
are the mean ± S.E.M. of three independent experiments.  The raw cAMP values 
for each condition are as follows: AC2+D2L vehicle pretreatment condition = 2.75 
± 0.48 pmol/well; AC2 + D2L quinpirole pretreatment condition = 6.97 ± 1.55 
pmol/well; AC2 + D2L + βARKct-CD8 vehicle pretreatment condition  = 2.73 ± 
0.78 pmol/well; AC2 + D2L + βARKct-CD8 quinpirole pretreatment condition  = 




 The observation that βARKct-CD8 prevented heterologous sensitization 
suggests that the role of Gβγ subunits in AC2 sensitization could be either direct 
or indirect.  In an effort to explore the direct pathway, we tested two small 
molecule Gβγ signaling inhibitors for their ability to modulate sensitization of AC2.  
HEK293 cells stably expressing AC2 and the D2LDR (HEK-AC2/D2L cells) were 
pretreated with increasing concentrations of the agonist quinpirole, followed by 
subsequent AC2 activation by PMA treatment.  As expected, quinpirole 
pretreatment resulted in a concentration-dependent enhanced responsiveness of 
AC2 to activation by PMA (Figure 3.2A).  Initial studies with the small molecule 
inhibitors, M119 and gallein, revealed that the quinpirole-induced enhanced 
response to PMA was not altered by the small molecule Gβγ signaling inhibitors.  
The lack of efficacy of M119 and gallein may represent the reported specificity for 
inhibition of specific Gβγ-effector interfaces (Bonacci et al., 2006). Thus, we 
examined the ability of M119 and gallein to block conditional acute activation of 
AC2 by Gβγ subunits (Federman et al., 1992; Taussig et al., 1993b).  For these 
studies HEK-AC2/D2L cells were treated with PMA (to activate AC2) in the 
presence of quinpirole to activate the D2LDR (allowing for activation of Gαi and 
release of Gβγ subunits) for Gβγ-dependent potentiation of AC2 activity.  The 
results of these studies revealed that the Gβγ signaling inhibitors, M119 and 
gallein, had no effect on either PMA-stimulated or Gβγ-dependent potentiation of 






Figure 3.2 The effect of Gβγ signaling inhibitors on D2LDR-mediated AC2 
signaling.  A. The effect of M119 and gallein (10 μM) on quinpirole-induced 
sensitization was measured in HEK-AC2/D2L cells.  Cells were pretreated with 
increasing concentrations of quinpirole for 2 h in the presence of vehicle, M119, 
or gallein and subsequently stimulated with 1 μM PMA.  Data are representative 
of two independent experiments.  B. The effect of M119 and gallein (10 μM) on 
acute quinpirole-induced potentiation of PMA-stimulated AC2 activity was 





 In an effort to rapidly assess the activity of several small molecules for 
modulation of D2LDR-induced sensitization of AC2, we developed a 96 well 
sensitization assay (with reduced wash and decant steps) for increased 
throughput (Conley et al., in press).  The higher throughput sensitization assay 
provided the ability to efficiently investigate multiple pharmacological modulators 
simultaneously.  The observation that βARKct-CD8 expression inhibits D2LDR-
induced sensitization of AC2 and lack of effect by M119 and gallein suggest the 
hypothesis that AC2 sensitization is mediated by Gβγ subunits, in an indirect 
fashion, by a downstream effector of Gβγ subunits.  Furthermore, previous 
sensitization studies with other adenylyl cyclases have provided evidence that a 
number of kinases may also be involved in the development and expression of 
sensitization of adenylyl cyclase (Chakrabarti et al., 1998; Johnston et al., 2002).   
Thus, several ligands including a peptide Gβγ signaling inhibitor, small molecule 
inhibitors of Gβγ effectors, and several additional kinase inhibitors were tested for 
the ability to inhibit quinpirole-induced sensitization of AC2 in HEK-AC2/D2L cells.  
Specifically, HEK-AC2/D2L cells were pretreated with inhibitors in the presence of 
either vehicle or quinpirole, and subsequently stimulated with PMA to promote 
PKC activation of AC2.  The results of these studies are depicted as a 
percentage of sensitization (i.e., quinpirole induced sensitization = 100%).  
Consistent with the effects of βARKct-CD8, the cell-permeable Gβγ subunit 
sequestering peptide, QEHA-TAT significantly inhibited sensitization in the HEK-
AC2/D2L cells, whereas the small molecule Gβγ subunit inhibitor, gallein, had no 




reported pharmacological kinase inhibitors that target Gβγ effectors that include 
c-JNK, Raf-1, PI3K, or MEK.  Much to our disappointment, there was no 
significant difference observed in the D2LDR-mediated sensitization of AC2 in the 
presence of the Gβγ-modulated kinase inhibitors (Table 3.1).  Additional kinases, 
including those that have been identified as being involved in sensitization of AC 
isoforms (i.e., PKC and PKA) were also examined in the same manner 
(Chakrabarti et al., 1998; Johnston et al., 2002).  As expected, the PKC inhibitor 
bisindolylmaleimide I (BisI) blocked sensitization of AC2 (3.0±1.7% sensitization).  
Inhibitors of PKA (H89) and PI3K/PI4K (phenylarsine oxide, PAO) significantly 
reduced the level of D2LDR-mediated sensitization of AC2 (29±12% and 29±5% 






Table 3.1 Effects of pharmacological inhibitors on D2LDR-mediated sensitization 
of AC2.  Data are expressed as a percent sensitization with the quinpirole-
induced sensitization = 100%.  Data are the mean ± S.E.M. of five independent 
experiments. 
 
Compound Target Mean±S.E.M. 
Control  100 
10 μM Gallein Gβγ 110±24 
30 µM QEHA-TAT Gβγ 62±8.2* 
10 μM SP600125 c-JNK 130±13 
30 μM GW5074 Raf-1 99±12 
300 nM Wortmannin PI3K 95±10 
30 μM PD98059 MEK 90±6.2 
10 μM H89 PKA 29±12 *** 
10 μM PAO PI3K/PI4K 29±5.5 *** 







 G protein subunits are known to be important components of the signaling 
pathways that contribute to the development of heterologous sensitization of 
multiple isoforms of adenylyl cyclase (Watts and Neve, 2005).  Studies with 
pertussis toxin and pertussis-toxin insensitve Gαi/o subunits have indicated 
essential roles for Gαi/o subunit activation in AC sensitization (Watts and Neve, 
1996; Watts et al., 1998), but mounting evidence also suggests that Gβγ subunits 
play an important part in the development of AC sensitization (AvidorReiss et al., 
1996; Nguyen and Watts, 2005; Rhee et al., 2000; Rubenzik et al., 2001).  As 
most ACs are differentially regulated by Gαi/o and Gβγ subunits, the precise 
roles of these subunits in sensitization of cAMP signaling have been difficult to 
examine (Hanoune and Defer, 2001; Patel et al., 2001).  Nevertheless, AC2 
shows only conditional activation by Gβγ subunits and is not directly regulated by 
Gαi/o subunits (Tang and Gilman, 1991; Taussig et al., 1994).  These unique 
regulatory properties of AC2 allow for the selective study of Gβγ subunit signaling 
in sensitization of PKC-stimulated AC2 activity.  The present data suggest that 
similar to other AC isoforms, Gβγ subunits are necessary for the sensitization of 
AC2.  Specifically, the membrane-localized Gβγ subunit sequestering protein 
βARKct-CD8 attenuated D2LDR-mediated sensitization of AC2.  Sensitization of 
AC2 was also reduced using a cell-permeable peptide inhibitor of Gβγ signaling, 
QEHA-TAT.  The peptide sequence corresponds to a Gβγ subunit-binding 




signaling (Chen et al., 1995a).  Our data are in agreement with our previous 
study, where AGS3 blocked D2LDR-mediated sensitization of AC2 (Chapter 2).  
AGS3 is hypothesized to disrupt Gβγ subunit signaling in response to long-term 
or repeated Gi-coupled receptor signaling.  These findings, along with the unique 
properties of AC2 suggest that D2LDR activation leads to a Gβγ-dependent event 
that selectively enhances PKC-mediated activation of AC2. 
 Two small molecule Gβγ subunit signaling inhibitors, M119 and gallein 
were also studied for their effects on D2LDR-mediated sensitization of AC2.  
Surprisingly, neither small molecule (up to 10 μM) altered sensitization of AC2 or 
D2LDR-potentiated AC2 activity (a Gβγ subunit-mediated effect).  The lack of 
activity of these compounds was discouraging, but may be explained by the 
effector specificity profiles displayed by the small molecule inhibitors (Bonacci et 
al., 2006).  The small molecule inhibitors selectively bind to a common region of 
Gβγ, known as the “Gβγ hot spot”, that interacts with Gα subunits and many Gβγ 
effector proteins (Ford et al., 1998; Hamm, 1998; Li et al., 1998; Lin and Smrcka, 
2011).  It is thought that different residues or regions within the hot spot are 
important for binding different effectors (Ford et al., 1998; Li et al., 1998).  It is 
possible that M119 and gallein do not interact with the region of Gβγ that 
mediates acute potentiation of AC2 signaling.  
 Several studies have contributed evidence that suggests AC2 has multiple 
Gβγ subunit binding sites (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006; 
Weitmann et al., 2001).  Specifically, at least five distinct sites have been 




subunits (see Figure 1.6) (Boran et al., 2011; Diel et al., 2008; Diel et al., 2006; 
Weitmann et al., 2001).  It is therefore possible that persistent activation of the 
D2LDR releases Gβγ subunits that directly interact with AC2, allowing a 
conformation that provides an enhanced response to activation by PKC. The 
identification of multiple Gβγ binding sites makes it tempting to speculate that the 
Gβγ sites for sensitization of AC2 may be unique from those involved with 
conditional activation.  
 Gβγ subunits regulate a multitude of downstream effectors (Khan et al., 
2013; Smrcka, 2008).  Therefore, it is possible that Gβγ subunit signaling 
indirectly leads to sensitization of AC2 via modulation of downstream Gβγ 
effectors.  We addressed this possibility by examining the ability of 
pharmacological inhibitors of Gβγ subunit effectors to modulate D2LDR-mediated 
sensitization of AC2 in HEK-AC2/D2L cells.  The concentrations of 
pharmacological inhibitors tested had no significant effect on D2LDR-mediated 
AC2 sensitization.  However, upon treatment of HEK-AC2/D2L cells with H89 or 
PAO, significant inhibition of AC2 sensitization was observed, suggesting roles 
for PKA and PI4K.  Interestingly, subsequent studies with PAO revealed a 
biphasic potentiation of acute AC2 stimulation in response to PMA treatment 
(data not shown) and no effect of additional PI4K inhibitors (LY294002 and Pik93, 
John Paul Spence and Val J. Watts, unpublished results).  These results suggest 
PAO modulation of D2LDR-mediated sensitization of AC2 is complex and perhaps 




PKC mediate sensitization of AC2 in response to persistent D2LDR activation by 
quinpirole. 
 The present study leveraged the unique regulatory properties of AC2 (i.e., 
lack of direct modulation by Gαi/o subunits and selective sensitization to PKC 
activation) to demonstrate that Gβγ subunits are required for AC sensitization.  
However, the mechanism underlying the enhancement of PKC-stimulated AC2 
remains unknown.  Ongoing efforts to identify signaling components that mediate 
AC sensitization include the development of higher throughput cell-based cAMP 
detection methodology to facilitate unbiased approaches such as siRNA library 
screening and small molecule screening (e.g., known kinase inhibitor sets).  





CHAPTER 4. DEVELOPMENT OF A HIGH-THROUGHPUT SCREENING 
PARADIGM FOR THE DISCOVERY OF SMALL MOLECULE 
MODULATORS OF ADENYLYL CYCLASE: IDENTIFICATION OF AN 
ADENYLYL CYCLASE 2 INHIBITOR 
4.1 Introduction 
 Cyclic AMP (cAMP) is a crucial component of signal transduction 
cascades that modulates diverse fundamental biological processes (Hanoune 
and Defer, 2001).  The cellular levels of cAMP are dynamically modulated by two 
families of enzymes.  Specifically, adenylyl cyclases (ACs) synthesize cAMP 
from ATP (Hanoune and Defer, 2001) and phosphodiesterase enzymes degrade 
cAMP (Bender and Beavo, 2006).  The specificity of cAMP signaling is influenced 
by the interplay of signaling molecules that are expressed within a given cell.  For 
example, nine membrane-bound mammalian AC isoforms have been identified 
that have unique profiles of regulation by G protein subunits, protein kinases, and 
Ca2+ (Hanoune and Defer, 2001; Patel et al., 2001).  Specifically, the AC 
isoforms are commonly activated by the stimulatory G protein (Gs), but are 
categorized into four subgroups based on their sequence similarities and 
regulatory properties (Hanoune and Defer, 2001; Patel et al., 2001).  The group I 




 II ACs (AC2, AC4, and AC7) are insensitive to Ca2+, but conditionally activated 
by G protein Gβγ subunits.  The group III ACs (AC5 and AC6) are inhibited by 
free Ca2+, Gαi/o subunits, and phosphorylation by protein kinase A.  AC9, the 
lone member of group IV is distinguished by its relative insensitivity to stimulation 
by forskolin.  
 Insight from knockout and transgenic mouse studies suggest that 
individual AC isoforms contribute to important physiological processes and 
diseases (Sadana and Dessauer, 2009), suggesting that selective AC 
modulators have therapeutic utility for the treatment of conditions involving 
cardiac function, aging, and pain.  As such, the AC5/AC6 inhibitors PMC-6 and 
AraAde have shown efficacy in preventing cardiomyocyte apoptosis (Iwatsubo et 
al., 2004) and a mouse model of heart failure, respectively (Iwatsubo et al., 2012).  
Also, a small molecule AC1 inhibitor, NB001, has been reported to have 
analgesic effects in animal models of neuropathic and inflammatory pain 
(Vadakkan et al., 2006; Wang et al., 2011).  However, a dearth of isoform-
selective small molecule AC modulators has limited the study of AC isoforms as 
therapeutic targets (Pierre et al., 2009; Seifert et al., 2012).  For example, AC2 is 
potentially involved in skeletal muscle physiology, lung diseases, neuroendocrine 
tumors (NETs), and colorectal cancer (Berdeaux and Stewart, 2012; Drozdov et 
al., 2011; Duerr et al., 2008; Yu et al., 2011).  Yet, the pharmacological study of 
AC2 is difficult because most small molecule AC inhibitors preferentially inhibit 
other AC isoforms (Pierre et al., 2009; Seifert et al., 2012).  BODIPY-forskolin 




AC2 activity is hindered because it also partially activates AC1 and AC5 (Erdorf 
et al., 2011; Pinto et al., 2008).  Given the shortcomings of small molecule AC 
modulators and the absence of published reports of AC2 knockout animals, the 
identification of selective AC2 modulators is expected to provide useful chemical 
probes to facilitate the study of AC2.   
 The present report describes the development and execution of a cell-
based screening approach for the discovery of novel small molecule inhibitors of 
AC2.  We screened the NIH clinical collections I and II (727 compounds) for 
small molecules that inhibit cAMP accumulation in response to selective 
activation of AC2.  Compounds identified as active were examined in a series of 
confirmation assays to validate direct AC2 inhibition and define their AC isoform-
selectivity profiles.  Our studies have resulted in the identification of SKF-83566 
as a selective AC2 inhibitor that is expected to be a promising tool to investigate 
the physiological roles of AC2. 
 
 
4.2 Materials and methods 
4.2.1 Materials 
 The NIH clinical collections I and II were purchased from Evotec, Inc 
(South San Francisco, CA).  Oxymetholone, tranilast, amlexanox, duloxetine, and 
indatraline were purchased from Sequoia Research Products (Pangbourne, 




Analytical Sciences (Boston, MA).  A23187, 3-isobutyl-1-methylxanthine (IBMX), 
loratadine, prochlorperazine, maprotiline, thioridazine, G418, Dulbecco’s 
modified Eagle’s medium (DMEM), and trichloroacetic acid (TCA) were 
purchased from Sigma-Aldrich (St. Louis, MO).  Phorbol 12-myristate 13-acetate 
(PMA), forskolin, MDL-12,330A HCl, prostaglandin E2 (PGE2), SQ22,536, and 
(±)-SKF-83566 HBr were purchased from Tocris Bioscience (Ellisville, MO).  2’5’-
dideoxyadenosine was purchased from Santa Cruz Biotechnology (Dallas, TX).  
Lipofectamine 2000, opti-MEM, and antibiotic-antimycotic 100x solution were 
purchased from Life technologies (Grand Island, NY).  FetalClone I serum, 
bovine calf serum, HEPES, and Hank’s balanced salt solution (HBSS) were 
purchased from Hyclone (Logan, UT).  BisindoloylmaleimideI (BisI) was 
purchased from Calbiochem (La Jolla, CA).  The HTRF cAMP and Cellul’ERK 
kits were purchased from Cisbio Bioassays (Bedford, MA). 
 
4.2.2 Stable cell line generation and cell culture conditions 
 HEK293 cells were cultured in DMEM supplemented with 5% bovine calf 
serum, 5% fetal clone I, and 1% antibiotic-antimycotic 100x solution and 
maintained in a humidified incubator at 37°C and 5% CO2.  For generation of a 
clonal stable cell line, HEK293 cells were transfected with pcDNA3.1(+) encoding 
human AC1, AC2, or AC5 using Lipofectamine 2000 according to the 
manufacturer’s protocol.  Stable clones were selected by growth in media 




expression of AC isoforms was confirmed functionally by measuring cAMP 
accumulation to selective pharmacological activation conditions.  For example, 
AC1 was stimulated with 3 µM A23187, AC2 was stimulated with the phorbol 
ester, PMA, and AC5 was activated by 300 nM forskolin. 
 The C2C12 mouse skeletal muscle cell line was purchased from the 
American Type Culture Collection. C2C12 myoblasts were maintained at a low 
confluency in DMEM media containing 10% fetal bovine serum. Myoblasts 
(passages 3-17) were plated in 96-well format at 5x104 cells per well. 
Differentiation into myotubes was induced once the cells reached 90% 
confluency by switching to medium supplemented with 2% horse serum. The 
growth medium was changed every 24 hours. Myotubes were allowed to mature 
for 5 days before being experiments were completed.  
 
4.2.3 Cisbio HTRF cAMP assay 
 The cellular cAMP levels were measured using either the Cisbio HTRF 
cAMP dynamic 2 assay kit or a dynamic 2/HiRange hybrid kit (consisting of 
cAMP-d2 from the dynamic 2 kit and the anti-cAMP cryptate conjugate from the 
HiRange kit).  The cAMP assays were performed on cryopreserved cells that 
were rapidly thawed at 37°C and resuspended in cell suspension buffer (HBSS, 
20 mM HEPES, 0.1% fatty acid free BSA or opti-MEM for HEK-hAC1 cells).  
Cells were centrifuged at 500×g and the supernatant was aspirated.  Cells were 




supernatant was aspirated and cells were seeded into a 384-well plate and 
allowed to incubate at 37°C and 5% CO2 for 2.5 h.  Cells were then treated as 
indicated with ligands diluted in stimulation buffer (HBSS, 20 mM HEPES, 500 
µM IBMX or opti-MEM, 500 µM IBMX for HEK-hAC1 cells) and incubated for 1 h 
at room temperature.  The stimulation was terminated by sequential addition of 
10 μl/well of cAMP-d2 and 10 µl/well of anti-cAMP cryptate conjugate, each 
diluted (1:39) in lysis buffer.  The experiments that used the dynamic 2 kit for 
cAMP detection were performed without IBMX in the stimulation buffer (to 
accommodate the sensitivity for cAMP detection), but with IBMX in the lysis 
buffer (to prevent phosphodiesterase-mediated degradation of cAMP in the 
lysate). Following a 1 h incubation at room temperature, the time-resolved 
fluorescence energy transfer (TR-FRET) was measured with a lag time of 100 μs 
and integration time of 300 μs using a Synergy4 (BioTek) fluorescence plate 
reader (excitation filter: 330/80 nm and emission filters: 620/10 nm and 665/8 
nm).  The resulting cAMP concentrations were calculated in GraphPad Prism by 
applying the 620/665 nm fluorescence ratio values to a standard curve of known 
cAMP concentrations. 
 
4.2.4 Screening conditions 
 Cryopreserved HEK-hAC2 cells were seeded into a 384-well plate at 15 
μl/well using a MultiFlo (Biotek) bulk reagent dispenser.  Following a 2.5 h 




room temperature on the bench for 15 min.  Test compounds (80 nl) were added 
to the cells with a MultiPette-mounted 384-well pin tool and allowed to incubate 
at room temperature for 30 min.  AC2 activity was then stimulated by addition of 
5 µl of PMA (50 nM final concentration) diluted in stimulation buffer with the 
MultiFlo reagent dispenser, followed by incubation at room temperature for 1 h.  
The Cisbio HTRF cAMP dynamic 2 kit was used to quantify the cellular cAMP as 
described above.  Briefly, the cAMP-d2 (containing 500 μM IBMX final volume) 
and anti-cAMP cryptate conjugate working reagents were sequentially added (10 
μl/well each) with a MultiFlo reagent dispenser and incubated at room 
temperature for 1 h.  Test compounds were initially screened in singlet or 
duplicate and all cAMP concentrations were converted to percent inhibition of the 
PMA-stimulated cAMP response. 
 
4.2.5 3H-cAMP assay 
 Cryopreserved HEK-hAC2 cells were thawed and prepared as described 
above.  Cells were seeded at a density of 12,000 cells per well into a 384-well 
plate in cell suspension buffer and incubated for 2.5 h at 37°C and 5% CO2.  
Test compounds were added to the cells with a MultiPette-mounted 384-well pin 
tool and allowed to incubate at room temperature for 30 min.  The AC stimulation 
was carried out at room temperature for 1 h and the reaction was stopped by the 
addition of cold (4°C) TCA to provide a final TCA concentration of 3%.  The 




previously described (Przybyla and Watts, 2010).  C2C12 cell cAMP experiments 
were performed similarly, with the exceptions that the assay was performed in 
96-well format on continuously propagated cells before differentiation into 
myotubes and compounds were delivered by multi-channel pipette for both 
pretreatment and stimulation steps. 
 
4.2.6 ERK1/2 phosphorylation assay 
 HEK-hAC2 cells were seeded into 96-well plates at a density of 25,000 
cells per well in opti-MEM and incubated overnight at 37°C and 5% CO2.  Drug 
treatment was carried out in opti-MEM as follows.  Cells were pretreated with test 
compound (30 µM) at 37°C for 10 min and ERK1/2 phosphorylation was 
stimulated by the addition of PMA (50 nM) and incubation for 10 min at 37°C.  
The resulting ERK1/2 phosphorylation was measured using the Cisbio htrf 
Cellul’ERK assay according to the manufacturer’s protocol (two-plate protocol).  
Briefly, the stimulation buffer was decanted and supplemented lysis buffer was 
added, followed by shaking at 500 rpm at room temperature for 30 min. The anti-
ERK-Eu3+-cryptate and anti-phospho-ERK-d2 antibodies were combined and 
added to a 384-well low-volume plate (PerkinElmer, white, Proxiplate 384 Plus).  
Lysate from the stimulation or positive/negative control lysate was then added on 
top of the HTRF reagents and incubated for 2 h at room temperature.  The TR-






4.3.1 Assay development and screening of the NIH clinical collections I and II 
 The lack of robust inhibitors of AC2 (Pavan et al., 2009; Pierre et al., 2009; 
Seifert et al., 2012) and the absence of published reports on AC2-/- mice suggest 
that the discovery of AC2 inhibitors will provide important research tools.  Thus, 
one initial goal of the present study was to develop an approach to identify and 
validate novel inhibitors of AC2 activity in intact cells.  To achieve this goal, we 
developed and optimized assay parameters for the measurement of intracellular 
cAMP in 384-well format in a semi-automated fashion, a tactic that may 
ultimately allow for large-scale high-throughput screening to identify novel AC2 
inhibitors.   
 HEK293 cells are known to endogenously express multiple AC isoforms 
(Hellevuo et al., 1993; Ludwig and Seuwen, 2002).  Therefore, to specifically 
study AC2 modulation, it is important to identify pharmacological stimulation 
conditions that selectively activate recombinant AC2 when expressed in HEK293 
cells.  We and others have previously reported that the protein kinase C (PKC)-
activating phorbol ester, PMA, selectively stimulates cAMP accumulation in 
HEK293 cells stably expressing recombinant rat AC2 (Cumbay and Watts, 2001; 
Yoshimura and Cooper, 1993).  For this study, HEK293 cells stably expressing 
human AC2 (hAC2) were constructed and screened for cAMP accumulation in 
response to PMA.  It is notable that the basal level of cAMP in the HEK-hAC2 




constitutive activity of AC2, a property that has been previously observed (Pieroni 
et al., 1995; Pinto et al., 2008).  As expected, PMA treatment had no effect on 
cAMP in HEK-wt cells, but provided an ~8 fold enhancement of cAMP in HEK-
hAC2 cells (data not shown and Figure 4.1A).  These results suggest that 
recombinant hAC2 can be selectively activated by PMA in an HEK293 cell 
background. 
 Following the verification of PMA treatment as a strategy for selective 
activation of AC2, potential screening parameters were further explored by 
performing a more in-depth evaluation of the effects of PMA in HEK-hAC2 cells.  
PMA treatment provided a concentration-dependent increase in cAMP with an 
EC50 value of 16±5.0 nM (n = 3) (Figure 4.1A).  We chose to use 50 nM PMA 
(~EC85 concentration) to stimulate AC2 for the study of AC2 inhibitors.  As a 
control for the inhibition of AC2 activity, the PKC inhibitor BisI was used to inhibit 
the phorbol ester-mediated activation of AC2.  Treatment with BisI provided full 
inhibition of PMA-stimulated AC2 activity with an IC50 of 16±1.9 nM (n = 3), 
suggesting that 1 μM BisI is sufficient to completely inhibit AC2 activity stimulated 






Figure 4.1 Optimization of conditions for an intact-cell assay that is capable of 
high-throughput screening for small molecule inhibitors of AC2.  A. 
Concentration-response curve analysis of PMA for stimulation of an AC2-
mediated cAMP response in HEK-hAC2 cells.  Data are the mean±S.E.M. of 
three independent experiments.  Inset: Inhibition of 50 nM PMA-stimulated AC2 
activity with the PKC inhibitor BisI.  Data are the mean±S.E.M. of three 
independent experiments.  B. Evaluation of assay robustness by Z’ analysis (Z’ = 
((AVGmax – 3 * SDmax/√n) – (AVGmin + 3 * SDmin/√n)) / (SDmax/√n)).  Data 




 Ultimately, our approach for the identification of AC inhibitors relies on the 
development of a cell-based assay that is capable of high-throughput screening 
of small molecule libraries.  Therefore, it was important to evaluate the 
robustness of the HEK-hAC2 cell cAMP assay when converted to a semi-
automated format that is amenable to high-throughput screening (see methods).  
Specifically, assay robustness was examined by performing a Z’ analysis for the 
assay parameters developed for screening (Zhang et al., 1999).  The Z’ value 
was calculated using 50 nM PMA as the maximum stimulation control and 1 μM 
BisI as the minimum stimulation control.  Our AC2 screening assay provided a Z’ 
= 0.44 ± 0.02 (n = 3), suggesting that the assay is appropriate for small molecule 
library screening (Figure 4.1B) (NCGC Assay Guidance Manual, 
www.ncbi.nlm.nih.gov/books/NBK53196/). 
 The NIH clinical collections I and II consist of 727 total test compounds 
that have a history of use in human clinical trials (www.nihclinicalcollection.com).  
The collections contain drug-like molecules with documented biological activity 
and safety profile information.  The modest size of the collections, paired with the 
reasons stated above, make the NIH clinical collections a good starting collection 
for early screening efforts in the search for AC2 inhibitors.  The NIH clinical 
collections were screened for the ability of test compounds (25 μM) to inhibit 
PMA-stimulated AC2 activity in HEK-hAC2 cells.  Of the 727 compounds 
screened (the full screening results are reported in the appendix, Table A.1), 10 




accumulation in HEK-hAC2 cells (displaying > 30% inhibition at 25 µM) were 





Table 4.1 Screening of NIH Clinical Collections I and II for inhibition of AC2 
activity.  The NIH Clinical Collections I and II (25 µM) were screened for inhibition 
of PMA-stimulated (50 nM) cAMP accumulation in HEK-hAC2 cells using the 
Cisbio HTRF cAMP dynamic 2 detection methodology.  The data represent the 
average percent inhibition of the PMA-stimulated cAMP response from duplicate 





















4.3.2 Confirmation and validation of activity 
 Confirmation studies were carried out using freshly prepared powders that 
were purchased from commercial sources. The initial confirmation of active small 
molecules used a single concentration (30 µM) of the test compounds for the 
inhibition of AC2 activity.  HEK-hAC2 cells were incubated with 50 nM PMA to 
selectively activate AC2 in the presence of test compound and the resulting 
cAMP accumulation was measured with the Cisbio HTRF cAMP dynamic 2 kit 
(identical to the assay format used for small molecule library screen).  All test 
compounds provided inhibition of AC2 activity at 30 μM, confirming the activity 





Table 4.2 Confirmation of the inhibitory activity of test compounds identified in the 
screen of NIH Clinical Collections I and II.  Active compounds (30 µM) were 
tested for inhibition of PMA-stimulated cAMP in HEK-hAC2 cells using either the 
Cisbio HTRF cAMP dynamic 2 technology or a [3H]-cAMP competition method 
for detection of cAMP.  Data are reported as the mean±S.E.M. of the percent 









SKF-83566 95±1.6 94±2.8 
Tranilast 76±2.9 79±5.3 
Loratadine 61±0.5 71±8.1 
Thioridazine 36±5.7 ND 
Duloxetine 39±3.8 ND 
Amlexanox 45±5.7 ND 
Indatraline 60±2.0 53±5.5 
Oxymetholone 58±1.9 58±2.9 
Prochlorperazine 41±8.3 ND 
Maprotiline 26±1.8 ND 






 The screening assay and initial confirmation of active compounds rely on 
TR-FRET for the detection of cAMP (see materials and methods).  It is possible 
that the active compounds have inherent fluorescence that can be measured in 
the same wavelengths as those utilized for cAMP detection, thereby skewing the 
measured fluorescence and affecting the resulting estimation of the cAMP 
concentration (Degorce et al., 2009).  Thus, we assessed the ability of the best 
compounds (i.e., those that provided at least 50% inhibition in the confirmation 
assay) to inhibit AC2 activity in a non-fluorescence-based assay.  The active 
compounds SKF-83566, oxymetholone, tranilast, indatraline, and loratadine were 
tested for their ability to inhibit PMA-stimulated cAMP accumulation in a 3H-
cAMP competitive binding assay.  All of the compounds tested retained the ability 
to inhibit PMA-stimulated cAMP accumulation in HEK-hAC2 cells, indicating bona 
fide reduction of cAMP, rather than interference with the fluorescence detection 
methodology (Table 4.2).  Furthermore, the extent of inhibition of PMA-stimulated 
AC2 activity by the test compounds in the 3H-cAMP assay was nearly identical to 
that observed in the TR-FRET-based cAMP detection method.  
 Our screening strategy utilized PMA to selectively stimulate AC2 via 
phosphorylation mediated by PKC (Jacobowitz and Iyengar, 1994).  Thus, it is 
possible that the compounds identified as active may exert their cAMP-
attenuating effects through inhibition of PKC rather than directly inhibiting AC2.  
PMA-mediated PKC activation is known to stimulate ERK1/2 phosphorylation in 
HEK293 cells (DellaRocca et al., 1997), allowing for a simple counter-screen to 




phosphorylation in response to PKC activation in HEK-hAC2 cells in the absence 
and presence of the active compounds (Figure 4.2B).  As expected, PMA 
treatment resulted in a significant enhancement of ERK1/2 phosphorylation 
(5.7±0.2 fold over basal) that was inhibited completely by the PKC inhibitor, BisI.  
In contrast, SKF-83566, oxymetholone, tranilast, and loratadine did not 
significantly alter the PMA-mediated ERK1/2 phosphorylation in HEK-hAC2 cells, 
suggesting that these compounds do not inhibit PKC.  Indatraline, however, 
inhibited the PMA-mediated ERK1/2 phosphorylation by ~80%. 
 The lack of inhibition of PKC-dependent ERK1/2 phosphorylation by SKF-
83566, oxymetholone, tranilast, and loratadine is consistent with a direct 
inhibition of AC2 activity by these drugs.  To further test this supposition, we 
examined the ability of SKF-83566, oxymetholone, tranilast, and loratadine to 
inhibit AC2 activity stimulated via other mechanisms. AC2 is also stimulated in a 
PKC-independent manner by Gαs in response to activation of Gs-coupled 
receptors and directly via the small molecule AC activator, forskolin.  
Prostaglandin E2 (PGE2) is known to bind and activate the Gs-coupled EP2/4 
prostanoid receptors that are endogenously expressed in HEK293 cells (Bogard 
et al., 2012; Willoughby et al., 2007).  As expected, PGE2 treatment resulted in a 
concentration-dependent increase in cAMP accumulation in HEK-hAC2 cells 
(EC50: 160±78 nM, n = 3).  To examine the effects of inhibitors on Gαs-stimulated 
AC2 activity, the identified active compounds were then tested for the inhibition of 
300 nM PGE2-stimulated cAMP in HEK-hAC2 cells (Figure 4.2C).  Oxymetholone, 




cAMP in HEK-hAC2 cells.  Next, they were similarly tested for their ability to 
inhibit the cAMP generated in response to direct AC stimulation by forskolin 
(Figure 4.2D).  Oxymetholone, SKF-83566, tranilast, and loratadine significantly 
inhibited forskolin-stimulated cAMP accumulation in HEK-hAC2 cells.  These 
data are in agreement with the effects of the test compounds on PKC-mediated 
ERK1/2 phosphorylation.  Specifically, indatraline and BisI inhibited PKC-
mediated ERK1/2 phosphorylation, but not Gαs- or forskolin-stimulated cAMP in 
HEK-hAC2 cells.  Taken together, these observations suggest that inhibition of 
PMA-stimulated cAMP by indatraline in HEK-hAC2 cells is due to inhibition of 
PKC.  More importantly, our data indicate that SKF-83566, oxymetholone, 
tranilast, and loratadine inhibit multiple modes of AC2 stimulation (i.e., PKC-, 







Figure 4.2 Counter-screening for validation of active compounds as AC2 
inhibitors.  A.  Schematic for PKC-dependent and PKC-independent activation of 
AC2.  B. The effects of test compounds (30 µM) on PMA-stimulated ERK1/2 
phosphorylation were measured in HEK-hAC2 cells.  Data are mean±S.E.M. of 
three independent experiments.  ***, p < 0.001 (one sample t-test compared to 
100).  C. The effects of test compounds (30 µM) on 300 nM PGE2-stimulated 
cAMP accumulation and D. 3µM forskolin-stimulated cAMP accumulation was 
measured in HEK-hAC2 cells.  Data are mean±S.E.M. of three independent 
experiments. ** p < 0.01, compared to vehicle condtion, one-way analysis of 




4.3.3 AC isoform selectivity profiles 
 The selectivity profiles of the active compounds for inhibition of AC 
isoforms was explored using intact cell cAMP assays.  The ability of compounds 
to modulate cAMP levels in HEK-hAC2 cells was compared to that of HEK-hAC1 
and HEK-hAC5 cells, as well as HEK-wt cells (Figure 4.3).  AC1 and AC5 were 
chosen as representative ACs from group I and group III ACs, respectively.  AC1 
activity was selectively activated by the calcium ionophore A23187 (3 µM) and 
AC5 was stimulated by 300 nM forskolin in HEK293 cells stably expressing each 
isoform (data not shown).  Test compounds (30 µM) were evaluated for the ability 
to modulate selective activation of AC1 and AC5 activity in HEK293 cells.  None 
of the test compounds inhibited AC1 activity, however, loratadine significantly 
potentiated A23187-stimulated cAMP by ~150%.  Studies with HEK-hAC5 cells 
revealed that loratadine and tranilast strongly inhibited forskolin-stimulated cAMP 
in HEK-hAC5 cells, while SKF-83566 had more modest activity (~35% inhibition).  
Tranilast and loratadine also significantly inhibited forskolin-stimulated AC activity 
in HEK-wt cells, whereas SKF-83566 had no significant effect.  Oxymetholone 
modestly, but significantly inhibited PMA-stimulated cAMP in HEK-hAC2 cells, 
but had no effect on the AC responses in HEK-hAC1, -hAC5, or –wt cells.  These 
results suggest that the active compounds show distinct patterns of cAMP 






Figure 4.3 AC isoform-selectivity profile of test compounds in intact-cell studies.  
AC isoform selectivity was assessed by testing the ability of test compounds (30 
µM) to modulate A. 3µM A23187-stimulated cAMP in HEK-hAC1 cells, B. 50 nM 
PMA-stimulated cAMP in HEK-hAC2 cells, C. 300 nM forskolin-stimulated cAMP 
in HEK-hAC5 cells, and D. 3 µM forskolin-stimulated cAMP in HEK-wt cells.  * p 
< 0.05, ** p < 0.01, compared to vehicle condition, one-way analysis of variance 




 The direct modulation of AC isoforms was explored using a cell free, 
reconstituted system to directly assess the effects of test compounds on AC 
activity (Conley et al., under review).  Specifically, the effects of the test 
compounds have been studied in AC activity assays that were performed using 
membranes from Sf9 insect cells expressing recombinant AC1, AC2, or AC5.  As 
expected, SKF-83566 significantly inhibited forskolin-stimulated AC2 activity (> 
40%), suggesting a direct mode of inhibition (mechanistic studies suggest 
noncompetitive inhibition with respect to ATP).  SKF-83566 was inactive against 
AC1 or AC5.  A similar pattern of AC isoform selectivity was observed with 
tranilast (See figure 4.4 for chemical structures of SKF-83566 and tranilast).  In 
contrast to SKF-83566 and tranilast, a commercially available AC inhibitor, 
NKY80, showed marked inhibition of AC1 and AC5, but only modest inhibition of 
AC2 activity.  These studies identified SKF-83566 as the most favorable 
compound to carry into further studies, as it provided the most robust AC2 
inhibition, while having no effect on forskolin-stimulated cAMP levels in HEK-wt 











 The AC isoform-selectivity of SKF-83566 was further characterized by 
performing a concentration-response analysis for inhibition of cAMP in HEK-
hAC2 and HEK-hAC5 cells.  SKF-83566 fully inhibited PMA-stimulated cAMP in 
HEK-hAC2 cells with an IC50 value of 10±1.4 µM and maximum inhibition of 
104±2% (Figure 4.5A).  Additionally, the potency and efficacy values of SKF-
83566 for inhibition of 3 µM forskolin stimulation (IC50: 19±3.3 µM and maximum 
inhibition: 113±2%, n = 3) and 300 nM PGE2 stimulation (IC50: 21±4.5 µM and 
maximum inhibition: 117±2%, n = 3) in HEK-hAC2 cells were similar to those 
observed for inhibition of the PMA response in HEK-hAC2 cells.  The robust 
inhibition below basal levels presumably reflects inhibition of the constitutive AC2 
activity.  As anticipated from the single point studies, SKF-83566 only partially 
inhibited forskolin-stimulated cAMP in HEK-hAC5 cells (< 40%) at a 
concentration of 130 µM. We consistently observed less inhibition of AC5 at 400 
µM suggesting a biphasic response (Figure 4.5A).  Nonetheless, these results 






Figure 4.5 Concentration-response analysis of SKF-83566 for inhibition of cAMP.  
A. Dose-response curves of SKF-83566 for inhibition of PMA-stimulated (50 nM) 
cAMP in HEK-hAC2 cells and forskolin-stimulated (300 nM) cAMP in HEK-hAC5 
cells.  B. Dose-response curves of SKF-83566, MDL-12,330A, SQ22,536, and 
2’5’-dideoxyadenosine (2’5’ddAd) for inhibition of PMA-stimulated (50 nM) cAMP 
in HEK-hAC2 cells.  The SKF-83566 data in panels A and B are from the same 
experiments, as these studies were performed simultaneously.  Data are 
expressed as a percentage of the stimulation response and are reported as the 




 The ability of SKF-83566 to inhibit PMA-stimulated AC2 activity was 
directly compared to several known AC inhibitors (i.e., SQ22,536, MDL-12,330A, 
and 2’5’-dideoxyadenosine; Figure 4.5B).  Efficacy comparisons revealed marked 
differences between SKF-83566 (> 100% inhibition) and the known inhibitors (i.e., 
SQ22,536, 29±3%; MDL-12,330A, 33±4%; and 2’5’-dideoxyadenosine, 38±3%) 
each at a concentration of 400 µM.  These results demonstrate that SKF-83566 
displays superior potency and efficacy for inhibition of AC2 activity when directly 
compared to SQ22,536, MDL12,330A, and 2’5’-dideoxyadenosine in HEK-hAC2 
cells. 
 
4.3.4 SKF-83566 as a chemical probe for AC2 function 
 The most potent and selective AC2 inhibitor (SKF-83566) was examined 
in cell models where AC2 is natively expressed (along with other AC isoforms), 
allowing confirmation of its activity in a more physiological context and evaluation 
of its use as a tool to probe AC2 function.  AC2 is reported to be abundantly 
expressed in skeletal muscle tissues (Ludwig and Seuwen, 2002; Suzuki et al., 
1998; Torgan and Kraus, 1996).  Therefore, the ability of SKF-83566 to inhibit 
forskolin-stimulated cAMP accumulation was studied in differentiated mouse 
C2C12 skeletal muscle myotubes (Figure 4.6).  As expected, SKF-83566 
inhibited forskolin-stimulated cAMP with an IC50 value of 15±6.5 µM and 
maximum inhibition of 69±8.8%, consistent with SKF-83566 inhibiting 





Figure 4.6 SKF-83566 as a chemical probe for native AC2 activity.  The effect of 
SKF-83566 on forskolin-stimulated (30 µM) cAMP was measured in mouse 
C2C12 skeletal muscle cells that were differentiated into myotubes.  Data are 




 Human bronchial smooth muscle cells express AC2, AC4, and AC6 
(Bogard et al., 2012) and recent studies suggest that forskolin-stimulated 
interleukin-6 (IL-6) expression in hBSMCs is selectively mediated by AC2 
(Bogard and Ostrom, 2013).  Therefore, the effect of SKF-83566 on forskolin-
stimulated IL-6 mRNA expression was measured in hBMSCs using quantitative 
RT-PCR (Conley et al., under review).  SKF-83566 treatment reduced the 
forskolin-stimulated IL-6 mRNA to 38±11% of the vehicle treated cells.  These 
results indicate that SKF-83566 inhibited the AC2-mediated upregulation of IL-6 
mRNA expression in hBSMCs, suggesting that SKF-83566 may be a useful tool 




 Several studies have implicated AC isoforms in physiological functions 
and disease states, leading to the hypothesis that ACs are potentially novel 
therapeutic targets (Pierre et al., 2009; Sadana and Dessauer, 2009).  However, 
further research is required to validate AC isoforms as therapeutic targets and 
advancements have been limited due to the current paucity of small molecule 
modulators that are potent and AC-isoform selective.  The need for additional 
small molecule tools to assess the in vivo activity of AC isoforms is further 
reinforced in the case of AC2, where there is both a lack of selective small 




studies for AC2.  Therefore, we developed an HTS-compatible intact-cell small 
molecule screening approach and subsequent validation paradigm for the 
discovery of AC2 inhibitors. 
 The present study used the HTRF cAMP detection technology from Cisbio 
to develop a robust and scalable HTS assay.  The development of an intact-cell 
assay for small molecule AC modulators was designed to reduce cell-
permeability issues that have plagued the utility of several small molecule AC 
modulators (Seifert et al., 2012).  However, the intact-cell screening format 
presents several challenges that are associated with apparent reductions in the 
cAMP signal that are independent of direct AC inhibition, including fluorescence 
detection artifacts, cell death/toxicity, and indirect modes of cAMP reduction that 
require subsequent validation experiments.  The effectiveness of the validation 
experiments to identify PKC inhibitors was evident in the case of indatraline, as it 
was found to inhibit PMA-stimulated ERK1/2 phosphorylation, but unable to 
modulate PKC-independent stimulation of cAMP in HEK-hAC2 cells.  The 
complementary cAMP studies in wild type and stably transfected HEK293 cells 
validated that the compounds selectively inhibit the exogenously expressed AC 
isoform.  For example, SKF-83566 appeared to have activity for inhibition of 
cAMP in HEK-hAC2 and HEK-hAC5 cells, but no activity for the inhibition of 
cAMP in the HEK293 cell background.  Conversely, the inhibition observed by 
tranilast and loratadine was more difficult to interpret because each of these 
compounds strongly inhibited the forskolin-stimulated cAMP accumulation in the 




exogenously-expressed ACs.  Therefore, tranilast and loratadine appeared to 
have effects on multiple AC isoforms, including endogenous ACs expressed in 
HEK293 cells.  For example, our in vitro studies suggested direct modulation of 
AC2 by tranilast, but indirect modulation of AC1 and AC5.  The identification of 
SKF-83566 as a selective and direct AC2 inhibitor demonstrated the utility of the 
screening approach and the complementary validation experiments.  The 
success of this initial study combined with additional optimization for increased 
assay robustness offers promise for future screening efforts of larger and more 
diverse chemical libraries.   
 The identification of SKF-83566 as a selective AC2 inhibitor represents 
another key contribution of the present report.  SKF-83566 was originally 
reported as an antagonist at D1 dopamine and 5HT2 receptors (Berkowitz et al., 
1984; Ohlstein and Berkowitz, 1985).  Nevertheless, the differences in potency 
between the receptor antagonism (Berkowitz et al., 1984; Ohlstein and Berkowitz, 
1985) and AC2 inhibition by SKF-83566 (i.e., 0.5-30 nM for dopamine/serotonin 
receptor antagonism versus ~10 µM for AC2 inhibition), together with our control 
validation assays, suggested that we were observing AC2 inhibition in HEK-
hAC2 cells.  Interestingly, a recent study suggests that D1/D5 dopamine 
receptors are closely linked to AC by ligand similarity (Lin et al., 2013), perhaps 
suggesting that receptor antagonism and AC2 inhibition may have overlapping 
chemical requirements.  Future studies with SKF-83566 should be focused on 
enhancing its pharmacological properties including its specificity for AC and 




therefore, pharmacological studies of the resolved enantiomers is expected to 
provide enhanced potency for inhibition of AC2.  Additionally, classic structure-
activity relationship studies would also be useful to identify chemical moieties and 
functional groups that are important for AC2 inhibition and enhance the specificity 
and isoform-selectivity for AC2. 
 Despite the potential drawbacks associated with its receptor antagonism, 
SKF-83566 remains an important addition to the repertoire of AC modulators.  
For example, SKF-83566 displayed unmatched potency and efficacy for inhibition 
of AC2 when directly compared to several commonly used AC inhibitors (i.e. 
NKY80, MDL-12,330A, SQ22,536, and 2’5’-dideoxyadenosine).  SKF-83566 also 
selectively inhibited AC2 (vs other AC isoforms), perhaps offering advantages 
over the diterpene analog, BODIPY-forskolin, that non-selectively modulates AC 
isoforms with a bidirectional modulation profile (i.e., inhibition of AC2 and partial 
activation of AC1 and AC5) (Erdorf et al., 2011; Pinto et al., 2008).  The 
bidirectional modulation makes it difficult to use BODIPY-forskolin as a chemical 
probe in systems where multiple AC isoforms are expressed.  In contrast, our 
studies with C2C12 mouse skeletal muscle cells and hBSMCs demonstrated the 
applicability of SKF-83566 as a tool to assess native AC function in a 
physiological context, suggesting the possibility for its use as an in vivo probe.   
 The identification of additional selective AC2 modulators is expected to 
contribute to the understanding of the physiological roles of AC2.  There is 
currently little direct evidence that suggests AC2 as a therapeutic target, but this 




AC2.  Despite these limitations, AC2 has been associated with several diseases, 
offering a wealth of opportunities for the use of SKF-83566 as a chemical probe 
for AC2 function.  For example, a potential role for AC2-mediated signaling in 
skeletal muscle physiology is suggested by the abundant expression of AC2 in 
adult skeletal muscle (Ludwig and Seuwen, 2002; Suzuki et al., 1998; Torgan 
and Kraus, 1996) and that increased cAMP signaling is implicated in several 
aspects of muscle physiology including hypertrophy, muscle repair, regeneration, 
and functional adaptation (Berdeaux and Stewart, 2012).  However, the 
contribution of individual AC isoforms is not well-understood in these 
physiological processes (Berdeaux and Stewart, 2012), suggesting that SKF-
83566 can be used as a chemical tool to study the contribution of AC2-mediated 
cAMP signaling to muscle physiology and skeletal muscle pathologies including 
Duchenne’s muscular dystrophy and muscle atrophy associated with cancer, 
ageing, and AIDS.  
 Recent studies also suggest a role for AC2 in the airway, as AC2 
mediates IL-6 expression in hBSMCs (Bogard and Ostrom, 2013).  Consistent 
with this observation, it observed that SKF-83566 was able to inhibit a forskolin-
stimulated IL-6 response in hBSMCs (Conley et al., under review).  Interestingly, 
increased IL-6 expression has been detected in asthma patients (Neveu et al., 
2010) and IL-6 is thought to play an active role in the pathogenesis of lung 
diseases such as asthma and chronic obstructive pulmonary disease (Neveu et 
al., 2010; Rincon and Irvin, 2012).  Taken together, it’s possible that AC2 is 




Thus, SKF-83566 can be utilized to determine if AC2 mediates the increased IL-6 
levels in lung diseases, and if this event contributes to pathogenesis. 
 AC2 also appears to be involved in neuroendocrine tumors (NETs), as 
ADCY2 expression is upregulated in a “malignant cluster” of pancreatic NETs 
(Duerr et al., 2008) and identified as a component of an upregulated 
cAMP/protein kinase A/CREB pathway in small intestinal NETs (Drozdov et al., 
2011).  Further in vitro expression and pharmacological analysis suggested that 
AC2 may be a functional mediator for upregulation of CREB-regulated transcripts 
that are associated with proliferation in small intestinal NETs (Drozdov et al., 
2011).  It is also noteworthy that ADCY2 expression is inversely correlated with 
survival in colorectal cancer patients (Yu et al., 2011).  The studies described 
above suggest that AC2 has a potential role in the progression of NETs and 
colorectal cancer, but it is unclear if the enhanced AC2 expression is pathological, 
protective, or merely a marker of these disease states.  SKF-83566 could be 
used as a chemical probe to test the functional role of AC2 catalytic activity in 
these pathophysiological states, and in the case of a causal relationship, suggest 
therapeutic utility for targeting AC2. 
 In conclusion, the present report describes the development and 
implementation of an HTS-capable intact-cell screening assay and subsequent 
validation strategy to identify small molecule inhibitors of AC2.  This initial 
screening effort identified SKF-83566 as a selective AC2 inhibitor with superior 
pharmacological properties for selective modulation of AC2 when directly 




CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
 This work addressed various aspects of AC2 modulation within the 
framework of three main research aims: 1.) To test the hypothesis that AGS3 
expression influences D2LDR-mediated cAMP signaling mediated via AC1 and 
AC2.  2.)  To test the hypothesis that D2LDR-mediated heterologous sensitization 
of AC2 is Gβγ subunit-dependent.  3.)  To develop and implement a high-
throughput screening paradigm for the discovery of small molecule modulators of 
AC2.  The conclusions of this work and its implications for future research are 
discussed below. 
 Activator of G protein signaling 3 was first identified in a yeast-based 
screen for receptor-independent activation of G protein signaling and in vitro 
biochemical studies revealed that AGS3 binds Gαi subunits in the GDP-bound 
state and serves as a guanine nucleotide dissociation inhibitor (De Vries et al., 
2000; Takesono et al., 1999).  Such biochemical studies suggested the 
hypothesis that stabilization of Gαi-GDP by AGS3 prevents the inactivating re-
association/rearrangement of the G protein heterotrimer, thus resulting in 
sustained Gβγ subunit signaling.  In addition to the biochemical function of AGS3, 




responses associated with drugs of abuse and have demonstrated that AGS3 
expression is up-regulated in the nucleus accumbens core or prefrontal cortex 
during withdrawal periods following prolonged ethanol or cocaine self-
administration, respectively (Bowers et al., 2008; Bowers et al., 2004).  Taken 
together, the biochemical and in vivo studies suggest that AGS3 may contribute 
to molecular changes associated with drugs of abuse by affecting G protein-
mediated AC/cAMP signaling.  Consistent with this hypothesis, others have 
demonstrated that AGS3 expression results in attenuated α2-adrenergic 
receptor-induced heterologous sensitization of AC in CHO cells (Sato et al., 
2004).  However, AC isoforms display distinct patterns modulation by G protein 
subunits, suggesting that AGS3 may differentially modulate G protein signaling 
through AC isoforms.  Given the evidence that AGS3, cAMP signaling pathways, 
and dopamine systems are each involved in drug addiction (Carlezon et al., 2005; 
McClung and Nestler, 2003; Nestler, 2001), we studied the effects of AGS3 
expression on D2LDR-mediated signaling mediated by individual AC isoforms in 
HEK293 cells.  
 We examined the ability of AGS3 to modulate recombinant AC1 or AC2 
signaling in HEK293 cells following both acute and prolonged activation of the 
D2LDR.  AGS3 expression modestly enhanced the potency of acute quinpirole-
induced D2LDR modulation of AC1 or AC2 activity.  Prolonged quinpirole 
activation of the D2LDR was altered by AGS3 in a manner that promoted 
desensitization of D2LDR-mediated inhibition of AC1, whereas desensitization of 




reduced D2LDR-mediated sensitization of AC1 and AC2 in HEK293 cells.  These 
data suggest that AGS3 is involved in altering G protein-mediated cAMP 
signaling in a complex fashion that is both effector-specific and dependent on the 
duration of receptor activation. 
 The effects of AGS3 on D2LDR-mediated sensitization of AC1 and AC2 
are consistent with a mechanism where AGS3 disrupts Gβγ subunit signaling 
associated with persistent Gi-coupled receptor modulation.  Several lines of 
evidence converge to suggest that AGS3 influences Gβγ-mediated effector 
signaling.  For example, our results are consistent with a previous study that 
demonstrated the ability of an AGS3 consensus peptide to disrupt signaling 
mediated by a different Gβγ subunit effector (G protein inwardly rectifying 
potassium channels) following repeated activation of the D2SDR (Webb et al., 
2005).  Furthermore, Gβγ subunit sequestering by expression of βARKct 
inhibited D2LDR-mediated sensitization of both AC1 (Nguyen and Watts, 2005) 
and AC2 (Chapter 3), suggesting that Gβγ subunit signaling is necessary for 
D2LDR-mediated sensitization of these isoforms.  Interestingly, a recent study 
that utilized bioluminescence resonance energy transfer demonstrated that 
AGS3 is able to functionally couple with and dissociate from Gi-coupled 
receptors in an agonist-dependent manner (Oner et al., 2010).  Taken together, 
these studies suggest the possibility that AGS3 competes with Gβγ subunits for 
binding with Gαi-GDP, thus selectively blocking Gβγ subunit signaling in an 
indirect manner via Gαi-AGS3 coupling to receptor.  Adding further complexity, 




duration of receptor activation because AGS3 alters persistent receptor activation, 
but only displays modest or no significant effects for signaling in response to 
acute receptor activation. 
 Our subsequent studies from chapter 3 directly examined the Gβγ subunit-
dependence of D2LDR-mediated sensitization of AC2 and are therefore relevant 
to the observed effects of AGS3.  The regulatory properties of AC2 provide a 
means to differentiate the contribution of Gα and Gβγ subunits to sensitization.  
Specifically, AC2 is conditionally activated by Gβγ subunits and is not directly 
regulated by Gαi/o subunits (Tang and Gilman, 1991; Taussig et al., 1993b; 
Taussig et al., 1994).  These unique regulatory properties of AC2 allowed for the 
selective study of Gβγ subunit signaling in sensitization of PKC-stimulated AC2 
activity.  The observations from chapter 3 suggest that similar to other AC 
isoforms, Gβγ subunits are necessary for the sensitization of AC2.  Specifically, 
the membrane-localized Gβγ subunit sequestering protein βARKct-CD8 and the 
cell-permeable peptide inhibitor of Gβγ signaling, QEHA-TAT both attenuated 
D2LDR-mediated sensitization of AC2.  The Gβγ subunit-dependence of D2LDR-
mediated sensitization of AC2 is in agreement with our observations from chapter 
2, where AGS3 blocked D2LDR-mediated sensitization of AC2, further 
contributing to the emerging hypothesis that AGS3 alters Gβγ subunit signaling 
following persistent Gi-coupled receptor activation.     
 Future studies of the molecular effects of AGS3 expression on receptor-
mediated Gβγ subunit expression and translocation/localization may shed light 




mediated by AC1 and AC2.  The localization and translocation of Gβγ subunits 
have been studied by fluorescence microscopy upon expression of recombinant 
fluorescently-labeled G protein subunits (Digby et al., 2008), suggesting that the 
influence of AGS3 on D2LDR-mediated Gβγ subunit localization can be explicitly 
studied and in a temporal fashion.  The effects of AGS3 on the localization of 
specific Gβ and Gγ subunit dimer combinations can be similarly studied by 
bimolecular fluorescence complementation (Digby et al., 2006; Digby et al., 2008; 
Mervine et al., 2006; Yost et al., 2007).  This technology relies on the use of a 
fluorescent protein that is split into two non-fluorescent fragments.   One of the 
fragments can be fused to Gβ and the complementary fragment can be fused to 
Gγ, and upon interaction of the tagged Gβ and Gγ subunits, the full fluorescent 
protein reconstitutes, providing fluorescence.  In summary, our data and the 
observations of others suggest that AGS3 may alter Gβγ subunit signaling in 
response to persistent Gi-coupled receptor activation.  Future studies that utilize 
fluorescently labeled Gβγ subunits may facilitate the direct examination of the 
effects of AGS3 on the temporal and spatial localization of Gβγ subunits, perhaps 
providing insight into the mechanistic details of their effects on AC isoform 
signaling. 
 It is clear that Gβγ subunit signaling is necessary for D2LDR-mediated 
sensitization of AC2 in HEK293 cells.  Gβγ subunits directly interact with AC2 in 
several areas and modulate its catalytic activity in a conditional fashion (Boran et 
al., 2011; Diel et al., 2008; Diel et al., 2006; Tang and Gilman, 1991; Taussig et 




also directly modulate several downstream effectors including PLCβ2, KIR3.1 
potassium channels, and voltage-gated Ca2+ channels (Khan et al., 2013; 
Smrcka, 2008), suggesting that development of sensitization may occur by either 
direct Gβγ modulation of AC2 or via an indirect Gβγ signaling pathway.  Though 
the pharmacological investigation of downstream Gβγ subunit effectors in 
chapter 3 did not identify effectors involved in sensitization, several observations 
support the hypothesis that the development of D2LDR-mediated sensitization of 
AC2 occurs through indirect Gβγ signaling pathways, rather than Gβγ directly 
modulating AC2.  Specifically, D2LDR-mediated sensitization of AC1 is Gβγ 
subunit-dependent (Nguyen and Watts, 2005), but is inhibited by Gβγ subunits 
(Taussig et al., 1993b; Taussig et al., 1994).  Furthermore, several intermediate 
signaling components have been implicated in the development of AC 
sensitization (Johnston et al., 2002; Varga et al., 2002; Varga et al., 2003; Watts 
and Neve, 2005).  We also observed a complete loss of subsequent D2LDR-
mediated potentiation of PKC activation of AC2 following long-term D2LDR 
activation (Chapter 2).  Though D2LDR activation acutely stimulates AC2 
conditionally via Gβγ subunits, this observation suggests a loss of Gβγ subunit 
activation of AC2 following long term D2LDR stimulation.  Nonetheless, the 
hypothesis that AC2 sensitization is facilitated by direct Gβγ subunit binding to 
AC2 can be directly tested.  Similar to the Gβγ localization studies proposed 
above, fluorescently labeled Gβγ subunits can be monitored by fluorescence 
microscopy following prolonged D2LDR activation.  Furthermore, Rluc-tagged 




fluorescently-tagged proteins with Rluc-AC2 (Baragli et al., 2008; Dupre et al., 
2007; Petrin et al., 2011; Rebois et al., 2012).  These available research tools 
suggest that BRET studies of fluorescently-tagged Gβγ subunits and Rluc-AC2 
following prolonged D2LDR activation can be used to test the hypothesis that 
D2LDR-mediated sensitization of AC2 occurs by direct modulation of AC2 by Gβγ 
subunits.  
 The observations in chapter 3 provided evidence for Gβγ subunits as 
mediators of AC2 sensitization, but a comprehensive mechanism remains 
unsolved.  However, several possible mechanisms can be proposed for the 
development of the enhanced PKC-mediated stimulation of AC2 following long-
term D2LDR activation.  Previous studies suggest that AC2 shows an activator-
selective pattern of heterologous sensitization (Cumbay and Watts, 2001).  
Specifically, persistent D2LDR activation enhances AC2 cAMP responses to 
phorbol ester activation of PKC, but not in response to forskolin or the Gs-
coupled β-adrenergic receptor agonist, isoproterenol (Cumbay and Watts, 2001).  
These data clearly implicate PKC in AC2 sensitization.  It is possible that long-
term D2LDR activation results in enhanced PKC expression in HEK293 cells, 
leading to enhanced responses to phorbol ester-mediated AC2 activation.  PKC 
expression profiling by western blotting for PKC isoforms in HEK293 cells can be 
performed following prolonged quinpirole treatment and compared to the 
expression levels of a vehicle treatment.  PKCα (Zimmermann and Taussig, 1996) 
and PKCδ (Nguyen and Watts, 2006) are implicated in the acute activation of 




remains to be reported.  A combination of approaches that include siRNA, PKC 
isoform overexpression, and isoform-selective PKC peptide inhibitors can be 
used to determine the specific PKC isoforms that are involved in both acute and 
subsequent activation of AC2 following persistent D2LDR activation.  It is also 
possible that long-term D2LDR activation altered the levels of PKC that are in 
close proximity to AC2.  The latter possibility could be mediated by two anchoring 
proteins (i.e., RACK1 and AKAP79) that are endogenously expressed in HEK293 
cells (Bauman et al., 2006; Liu et al., 2007).  For example, the PKC anchoring 
protein RACK1 functions to target PKC to its substrates (Schechtman and 
Mochly-Rosen, 2001).  Furthermore, RACK1 is known to directly bind Gβγ 
subunits and influence Gβγ-mediated signaling (Chen et al., 2008; Chen et al., 
2005; Chen et al., 2004).  Alternatively, AKAP79 directly interacts with AC2 
(Efendiev et al., 2010) and is also known to scaffold PKA and PKC (Welch et al., 
2010), but Gβγ subunit-modulation of this protein has not been reported (based 
on my knowledge).  Future research should be focused on the potential role of 
these proteins in the development of D2LDR-mediated sensitization of AC2. 
 Molecular studies of heterologous sensitization have largely focused on 
the roles G proteins (e.g., Gαi/o, Gβγ, and Gαs subunits), proteins that modulate 
G protein signaling (e.g., RGS and AGS proteins), and protein kinases that are 
well-known to be downstream of G proteins.  The precise mechanisms of AC 
sensitization are not well understood, even after nearly four decades of research.  
We propose that unbiased approaches can be utilized to identify novel 




sensitization.  Such unbiased approaches include siRNA library screening or 
small molecule screening of known pharmacological modulators (e.g., kinase 
inhibitor collections).  The cell-based cAMP detection methodology that our 
laboratory has utilized to study sensitization, however, was generally unsuitable 
for siRNA library or small molecule screening endeavors.  Therefore, steps were 
taken to reduce the number of wash and decant steps, miniaturize the cAMP 
quantification assay, and identify an assay workflow that is amenable to 
automation to facilitate the development an assay format that is amenable to the 
unbiased strategies for the study of sensitization (Conley et al., in press).  As part 
of the initial validation of the high-throughput screening capable cAMP assay and 
workflow, the implementation of this technology to screen for small molecule 
inhibitors of AC2 was reported in chapter 4.  The cell-based high-throughput 
screening paradigm that we developed can likely be readily adjusted to measure 
small molecule modulation of heterologous sensitization.  Furthermore, the assay 
format has since been modified to accommodate screening of an siRNA library 
against the kinome for inhibition of Gi-coupled receptor-mediated sensitization of 
AC isoforms (Conley et al., in press).  It is expected that these unbiased 
approaches will provide new mechanistic information regarding the adaptive 
heterologous sensitization response. 
 The development of an HTS-capable cell-based assay to measure the 
modulation of AC activity was initially designed to address assay format 
requirements for the unbiased approaches to study heterologous sensitization as 




of an assay format for an siRNA library screen for the modulation of heterologous 
sensitization of AC, we first developed and implemented a screening assay for 
small molecule modulators of acute AC activity.  This strategy allowed for the 
initial development of a relatively simpler assay, while providing the opportunity 
to assess the robustness of the cAMP detection technology and the miniaturized 
assay platform for its HTS-amenable attributes.  Furthermore, the lack of potent 
and selective small molecule AC modulators presented an opportunity to address 
a well-known research need in the AC field, while providing proof-of-concept for 
the HTS-amenable cAMP assay.  Specifically, AC isoforms are implicated in 
several physiological processes and disease states (Pierre et al., 2009; Sadana 
and Dessauer, 2009), but advancements in the therapeutic targeting of AC 
isoforms have been limited by the lack of potent and isoform-selective small 
molecule modulators (Pavan et al., 2009; Pierre et al., 2009; Seifert et al., 2012).  
The discovery of AC isoform-selective small molecules is expected to facilitate 
the validation of AC isoforms as therapeutic targets and augment the study of AC 
isoform function in vivo.  Identification of chemical probes for AC2 is particularly 
important because there are no published genetic deletion studies and few small 
molecule modulators.  Chapter 4 demonstrates the development and 
implementation of an intact-cell small molecule screening approach and 
subsequent validation paradigm for the discovery of AC2 inhibitors.  The NIH 
clinical collections I and II were screened for inhibitors of AC2 activity, using 
PMA-stimulated cAMP accumulation as a functional readout.  Active compounds 




orthogonal and counter screening assays. The screening effort identified SKF-
83566 as a selective AC2 inhibitor with superior pharmacological properties for 
selective modulation of AC2 when compared to currently available AC inhibitors.  
Furthermore, the utility of SKF-83566 as a small molecule probe to study the 
function of endogenous ACs was demonstrated in C2C12 mouse skeletal muscle 
cells. 
 Future studies should be aimed at understanding the molecular basis of 
AC2 inhibition by SKF-83566.  A combination of biochemical, molecular modeling, 
and mutagenesis studies have typically been employed to understand the 
mechanisms of small molecule modulation of AC.  Biochemical studies of 
enzyme kinetics using cell membranes that overexpress AC2 suggest that SKF-
83566 is noncompetitive with respect to ATP (Conley et al., under review), but its 
relationship to other activators, such as forskolin, or Gαs (Dessauer, 2002; 
Dessauer and Gilman, 1997; Dessauer et al., 1999; Iwatsubo et al., 2004; Onda 
et al., 2001) can also be studied.  There is also a precedent for molecular 
modeling based on the crystal structures of the catalytic C1 and C2 domains 
(Pinto et al., 2008; Tesmer et al., 1997; Zhang et al., 1997).  Similar molecular 
modeling analyses are underway for SKF-83566 docking to AC to predict the 
specific site of interaction.  Subsequent to molecular modeling studies, mutation 
of residues that are predicted to be crucial for binding can be performed to 
experimentally validate the model.  The complementary approaches described 
above may provide useful insight into the mechanism of AC2 modulation by SKF-




 SKF-83566 is an important new chemical probe for AC2, but it also 
displays antagonist activity against D1 dopamine and 5HT2 serotonin receptors 
(Berkowitz et al., 1984; Ohlstein and Berkowitz, 1985).  Future efforts should be 
focused toward strategies to enhance the pharmacological properties of SKF-
83566 to increase the specificity for AC and enhance the potency and selectivity 
for inhibition of AC2.  First, our study utilized SKF-83566 as a racemic mixture, 
warranting additional pharmacological studies to determine which enantiomer is 
more active for inhibition of AC2.  Interestingly, a recent study suggests that 
D1/D5 dopamine receptors are closely linked to AC by ligand similarity (Lin et al., 
2013), perhaps suggesting that receptor antagonism and AC2 inhibition will 
share the same active enantiomer (i.e, (+)-SKF-83566) (Berkowitz et al., 1984; 
Ohlstein and Berkowitz, 1985).  Furthermore, (+)-SCH-23390 (a structural 
analogue of SKF-83566) significantly inhibited PMA-stimulated AC2 activity in 
HEK-hAC2 cells, suggesting that (+)-SKF-83566 is the active enantiomer for 
inhibition of AC2 (Table A.2 and Figure A.1).  The enantiomer studies are 
expected to at least provide enhanced potency for inhibition of AC2.  Additionally, 
classic structure-activity relationship studies would also be useful to identify 
chemical moieties and functional groups that are important for AC2 inhibition and 
enhance the specificity and isoform-selectivity for AC2.  A modest structure-
activity study is reported in Table A.2 and Figure A.1 of the appendix. 
 Our results from chapter 4 demonstrate the utility of the screening 
approach and suggest that the series of complementary post-screening 




the success of the initial pilot screen of a 727 compound collection (NIH clinical 
collections I and II) suggests that the screening and validation paradigm is 
sufficiently robust to accommodate future screening of larger and more diverse 
chemical libraries to identify additional novel small molecule AC2 inhibitors.  
Consistent with this prediction, a screen of the Spectrum Collection (2,320 
compounds) for inhibitors of AC2 activity has been performed and the results and 
initial confirmation of activity is reported in the appendix (Table A.3 and Table 
A.4).  Furthermore, the assay format that was developed to study cAMP levels in 
HEK-hAC2 cells is expected to be readily adapted for other AC isoforms, 
including AC1 and AC5.  Specifically, parameters such as pharmacological 
stimulation conditions and cell number should be optimized for each specific 
target, but the overall semi-automated workflow and cAMP detection technology 
is expected to support these studies without modification.  Identification of new 
small molecule modulators of AC1 and AC5 are expected to contribute to our 
understanding of these isoforms in physiological processes including pain 
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 A high-throughput screening approach for the discovery of small molecule 
inhibitors of AC2 was described in chapter 4.  Specifically, the NIH clinical 
collections I and II were screened for the ability of compounds (25 μM) to inhibit 
50 nM PMA-stimulated AC2 activity in HEK-hAC2 cells.  The complete screening 




Table A.1 Screening of NIH Clinical Collections I and II for inhibition of AC2 
activity.  The NIH Clinical Collections I and II (25 µM) were screened for inhibition 
of PMA-stimulated (50 nM) cAMP accumulation in HEK-hAC2 cells using the 
Cisbio HTRF cAMP dynamic 2 detection methodology.  The data represent the 
average percent inhibition of the PMA-stimulated cAMP response from duplicate 
plates. 
Compound Name % Inhibition 
(-)-Cotinine -14.29 
(+)-3-HYDROXY-N-METHYLMORPHINAN D-TARTRATE 23.30 
(+)-CIS-DILTIAZEM HYDROCHLORIDE -60.31 
(+/-)-Epinephrine hydrochloride -123.98 
(+/-)-NOREPINEPHRINE HYDROCHLORIDE -71.99 
(Â±)-Vesamicol hydrochloride -5.49 
1-(2-Methyl-5-nitro-imidazol-1-yl)-propan-2-ol -41.71 
1,1-DIMETHYL-4-PHENYLPIPERAZINIUM IODIDE -12.35 
1,3,5(10)-ESTRATRIEN-3-OL-17-ONE SULPHATE, SODIUM SALT -34.06 
10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl- [CAS] 35.21 
17-BETA-ESTRADIOL 17-VALERATE -427.70 
19-Norethindrone -79.01 
19-NORETHINDRONE ACETATE -162.15 
1-BENZYLIMIDAZOLE 23.73 
1H-Cyclopenta[b]quinolin-9-amine, 2,3,5,6,7,8-hexahydro-, 
monohydrochloride- [CAS] -1.71 
1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS] -14.30 
1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)- 
[CAS] -43.54 
1H-Indole-2-propanoic acid, 1-[(4-chlorophenyl)methyl]-3-[(1,1-
dimethylethyl)thio]-Alpha,Alpha-dimethyl-5-(1-methylethyl)- [CAS] -866.27 






2H-Indol-2-one, 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)- [CAS] -95.83 













Table A.1 Continued. 
4-Thiazolidinecarboxylic acid, 2-oxo-, (R)- [CAS] -28.68 












1-piperidinyl]acetyl]-5,11-dihydro- [CAS] 6.14 
7-NITROINDAZOLE -49.80 
8-Azaspiro[4.5]decane-7,9-dione, 8-[2-[[(2,3-dihydro-1,4-benzodioxin-2-
yl)methyl]amino]ethyl]-, monomethanesulfonate [CAS] -28.35 
8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-
benzo[5,6]cyclohepta[1,2-b]pyridine 13.56 
9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE 11.92 
ACARBOSE -10.38 
ACEBUTOLOL HYDROCHLORIDE -25.27 





Adenine 9-beta;-D-arabinofuranoside -9.90 










AM 404 -283.12 
AM-251 5.15 
AMCINONIDE -1.11 
AMFEBUTAMONE HCl -12.60 
Aminoglutethimide -38.97 





Table A.1 Continued. 
AMIODARONE HYDROCHLORIDE -370.47 
Amisulpride -19.13 
AMLEXANOX 41.47 
AMLODIPINE BASE 24.13 
AMOXAPINE -16.78 
AMOXICILLIN CRYSTALLINE -60.10 
Ampicillin Sodium -64.53 
AMPIROXICAM -39.71 
Anafranil -68.51 









ATOMOXETINE HCl 1.54 








Beclomethasone dipropionate -20.74 
BENACTYZINE HYDROCHLORIDE -48.45 
BENAZEPRIL HCl -4.13 
Bendrofluazide -24.41 
BENIDIPINE HCl -194.19 
BENPROPERINE PHOSPHATE -8.36 
Bentyl -89.31 
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, monosodium salt 
[CAS] -2.76 






methylethyl)-, (R)- [CAS] 
-19.11 
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Buflomedil HCl -6.25 
BUMETANIDE -1.04 

















CEFATRIZINE PROPYLENE GLYCOL -28.72 
CEFAZOLIN SODIUM SALT -44.82 
CEFDINIR 10.10 
CEFIXIME TRIHYDRATE -6.49 
CEFOTAXIME SODIUM SALT -28.23 
CEFOXITIN SODIUM SALT -58.42 
CEFPODOXIME PROXETIL -42.62 
Cefuroxime 9.32 
Celecoxib 16.11 
Cephalexin monohydrate -47.87 






Table A.1 Continued. 
CETRAXATE HCl -19.18 
CGS 12066B -235.66 















citalopram hydrobromide -51.02 
CLARITHROMYCIN 0.08 
Clobenpropit -37.96 










CORTISONE ACETATE -39.61 
Cromolyn Sodium 0.10 
CYPROHEPTADINE -26.41 
Cytoxan -21.75 
d-3-Methoxy-N-methylmorphinan hydrobromide -21.95 
DACTINOMYCIN -28.81 
DANAZOL -351.79 
Dantrolene sodium salt -16.00 
Dapsone -5.46 
DAUNORUBICIN HYDROCHLORIDE -18.55 
D-CYCLOSERINE -10.81 
D-CYCLOSERINE -42.47 
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DEXBROMPHENIRAMINE MALEATE -27.93 




DICHLOROACETIC ACID -55.71 












DOLASETRON MESYLATE -29.16 
Donepezil -26.59 
DOXAPRAM HYDROCHLORIDE -14.91 
Doxazosin -92.28 
Doxepin -51.07 
DOXEPIN HYDROCHLORIDE -26.94 
DOXORUBICIN HYDROCHLORIDE 33.53 
DOXYCYCLINE 37.36 
Doxylamine succinate salt -27.08 
DROPERIDOL -39.13 
Duloxetine 16.04 




Econazole Nitrate -301.82 
EDROPHONIUM CHLORIDE 46.54 
EFAVIRENZ -44.75 





Table A.1 Continued. 
ENALAPRILAT 22.39 
ENROFLOXACIN -26.16 
Epigallocatechin gallate -13.06 
EPIRUBICIN HYDROCHLORIDE 18.31 
Eryped 4.37 
ESCITALOPRAM OXALATE -33.09 
ESMOLOL HYDROCHLORIDE -9.35 
ESOMEPRAZOLE Mg -70.39 
Eszopiclone -48.05 
















FENOLDOPAM MESYLATE -22.47 
FENPIVERINIUM BROMIDE 5.18 
FINASTERIDE -22.29 








FLUOCINOLONE ACETONIDE 12.99 
FLUOCINOLONE ACETONIDE 21-ACETATE -35.57 
Fluorometholone -76.25 
Fluperlapine -9.92 








Table A.1 Continued. 
FLUTICASONE PROPIONATE 29.83 
fluvastatin -44.95 
Fluvoxamine 16.65 
Folic acid -22.44 
FORMOTEROL FUMARATE DIHYDRATE -88.12 
FTORAFUR -27.87 
FUROSEMIDE -11.34 









ester [CAS] -7.71 
Glycopyrrolate 8.42 
Glycopyrrolate -29.69 
GOSERELIN ACETATE 2.29 
GR 89696 17.49 
GRANISETRON HCl -16.86 
Griseofulvin -83.55 
Guanidine, N-cyano-N'-(1,1-dimethylpropyl)-N''-3-pyridinyl- [CAS] 9.58 







HUPERZINE A 17.45 
Hydrochlorothiazide -54.49 
HYDROCORTISONE -39.84 





IDARUBICIN HCl -58.20 
IDEBENONE -328.07 
Ifenprodil 16.10 














IPRATROPIUM BROMIDE MONOHYDRATE -53.51 
IPRIFLAVONE -31.76 
IRBESARTAN -25.62 
IRINOTECAN HCl )trihydrate) -32.70 






ITAVASTATIN Ca -53.39 





Ketorolac tromethamine -73.56 
KETOTIFEN FUMARATE -15.38 
KITASAMYCIN -38.50 
L-694,247 -3.82 














pteridinyl)methyl]methylamino]benzoyl]- [CAS] 10.82 
LIDOCAINE -21.96 





Table A.1 Continued. 
LINEZOLID -10.12 
LOBELINE HYDROCHLORIDE -13.53 
LOFEPRAMINE -179.59 
LOFEXIDINE HCl 0.30 




L-Ornithine, N5-[imino(methylamino)methyl]-[CAS] 15.83 
LOSARTAN Potassium -9.59 
LOTEPREDNOL ETABONATE -6.30 
Lovastatin -153.47 
Loxapine succinate -21.33 
LOXOPROFEN SODIUM 1.74 
L-THYROXINE -9.99 
LY 171883 13.22 






Medroxyprogesterone 17-acetate -58.25 
Mefenamic Acid -141.11 
Mefloquine hydrochloride 31.17 
MEGESTROL ACETATE -52.62 
Meloxicam -22.67 
MEMANTINE HYDROCHLORIDE 3.22 
Memantine hydrochloride -62.34 
MEPIRIZOLE -33.25 





























MICONAZOLE NITRATE -1049.78 
Micropenin 1.62 













MONTELUKAST Na -35.55 
MOSAPRIDE CITRATE -35.42 
MOXIFLOXACIN HCl 22.06 








Nalidixic Acid -16.93 
NALOXONE HYDROCHLORIDE -48.66 
NALTREXONE HYDROCHLORIDE -7.68 
Naltrindole -16.75 
nandrolone -1195.60 
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Nicotinic Acid -68.84 
NIFEDIPINE -241.22 


















OLIGOMYCIN C -25.65 
OLMESARTAN MEDOXOMIL 17.80 
OLOPATADINE HCl -4.64 
OMEPRAZOLE -74.37 
Ondansetron -44.81 





OXICONAZOLE NITRATE -471.14 
Oxiranecarboxylic acid, 2-[6-(4-chlorophenoxy)hexyl]-, ethyl ester- [CAS] -119.90 
OXYBUTYNIN CHLORIDE 7.90 
Oxymetholone 37.00 
OXYPHENONIUM BROMIDE -0.88 
Oxytetracycline hydrochloride -32.15 
ozagrel, monohydrochloride -12.71 









PANTOPRAZOLE SODIUM SALT 4.43 





PD 81723 -101.66 
PEFLOXACIN MESYLATE 2.49 
Pemoline -26.94 
PENCICLOVIR -9.46 
Penicillin V -29.64 
Pentoxifylline -6.30 
PERGOLIDE MESYLATE -34.66 












Picrotin - Picrotoxinin -7.74 
PIDOTIMOD -25.49 
PILOCARPINE HYDROCHLORIDE -24.04 
Pinacidil monohydrate -37.17 
PINDOLOL 6.77 
PIOGLITAZONE HCl -37.91 







PRAMIPEXOLE HCl -10.50 
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Prazosin -74.72 
Prednisolone -71.01 
PREDNISOLONE ACETATE -58.18 
Prednisone -59.54 
PRILOCAINE HYDROCHLORIDE -56.61 


















PYRIDINE-2-ALDOXIME METHOCHLORIDE 16.69 
Pyrimethamine 4.91 
QUETIAPINE HEMIFUMARATE -55.53 
Quinapril  hydrochloride -59.85 
Quinidine hydrochloride monohydrate -43.57 






Ranitidine hydrochloride -7.39 
Ranolazine dihydrochloride -15.06 
Reichsteins substanceÂ S -24.58 
REPAGLINIDE 24.07 
Resveratrol -80.06 





















ROPIVACAINE HCl 14.31 
ROSIGLITAZONE HCl -29.74 
ROSIGLITAZONE MALEATE -21.83 
ROXATIDINE ACETATE HCl -23.89 
RU 24969 -100.81 
RUFLOXACIN HCl 16.34 
RUTIN -7.79 
Rythmol -24.02 
S(-)-Timolol maleate -11.27 
SALBUTAMOL SULFATE -57.70 
Salmeterol -66.58 
SAQUINAVIR MESYLATE 0.63 






SIBUTRAMINE HCl -48.81 
Simvastatin -282.50 
SKF 83566 85.21 
Sonazine -10.09 
Sotalol hydrochloride -14.64 
SPECTINOMYCIN DIHYDROCHLORIDE PENTAHYDRATE -80.03 
Spironolactone -89.91 






























TERBINAFINE HCl -1025.30 











THIORIDAZINE HYDROCHLORIDE 58.40 
THIOTHIXENE 16.34 
TIAGABINE HCl -36.11 
TIBOLONE -131.53 
TICLOPIDINE HCl -242.87 
TINIDAZOLE -19.86 





TOLTERODINE TARTRATE -27.08 
TOPIRAMATE -19.99 
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TOREMIFENE CITRATE -16.54 
TOSUFLOXACIN TOSYLATE -41.06 
Tramadol -25.90 
TRANILAST 68.77 
TRAZODONE HYDROCHLORIDE -4.12 
TREMULACIN -315.25 





TRIMEBUTINE MALEATE -97.99 
Trimethoprim -0.16 
TRIPELENNAMINE HYDROCHLORIDE -34.08 
Tripfluoperazine Hydrochloride 28.64 
TRIPTOLIDE -5.67 
TROPICAMIDE -60.08 




URAPIDIL HYDROCHLORIDE -26.34 
Urecholine -9.34 
URSODEOXYCHOLIC ACID -49.48 
VALACICLOVIR HYDROCHLORIDE -20.27 
VALDECOXIB -42.76 
Valproic Acid -98.54 
VALSARTAN -40.09 
VARDENAFIL CITRATE 16.37 
VECURONIUM BROMIDE -25.16 
VENLAFAXINE HCl -36.29 
VINCRISTINE SULFATE -49.39 
VINDESINE SULFATE -61.35 
VINORELBINE BITATRATE -45.00 
Viramune -11.00 
Vistaril Pamoate 17.41 
VORICONAZOLE -11.99 
WARFARIN SODIUM -12.62 
Westcort -49.55 




















 The NIH clinical collections I and II contain drug-like molecules with 
documented biological activity and a history of use in human clinical trials.  These 
properties create a bias for biological activity that is non-specific with regard to 
AC2 inhibition.  For example, SKF-83566 was validated as a direct small 
molecule AC2 inhibitor, but is also known to be a dopamine and serotonin 
receptor antagonist (see discussion in chapter 4).  Therefore, it is desirable to 
identify chemical moieties and functional groups that confer specificity and/or 
potency for inhibition of AC2.  As such, a modest structure-activity relationship 
study was designed by testing analogues of four compounds (SKF-83566, 
tranilast, loratadine, and oxymetholone, see Figure A.1 for chemical structures) 
that were identified and validated as modulators of AC2 activity (3671-5745, 
1683-6987, 8005-4220, 4100-1558, and N050-006 were purchased from 
ChemDiv, San Diego, CA).  All compounds were tested for the ability to modulate 
cAMP accumulation in response to activation of AC isoforms in HEK-hAC2 
(activation by 50 nM PMA, 3 μM forskolin, and 300 nM PGE2), HEK-hAC1 
(activation by 3 μM A23187), HEK-hAC5 (activation by 300 nM forskolin), and 
HEK-wt cells (activation by 3 μM forskolin) as described in chapter 4 (Table A.2).  
These experiments represent an initial small-scale structure-activity relationship 
study for the compounds that inhibit AC2 activity, while simultaneously counter-





    
Figure A.1 Chemical structures of active compounds and their analogues. 
 
 
 Table A.2 AC isoform-selectivity profiles of test compounds in intact-cell studies.  AC isoform selectivity was assessed 
by testing the ability of test compounds (30 µM) to modulate cAMP responses in HEK-hAC2 cells, HEK-hAC1 cells, 
HEK-hAC5 cells, and HEK-wt cells.  Data are reported as a percent of the vehicle treatment condition and represent 
the Mean ± S.E.M. of three independent experiments.  * p < 0.05, ** p < 0.01,*** p < 0.001 compared to vehicle 
condition, one sample t-test compared to 100. 
 
 
AC2 AC1 AC5 WT 
 
50 nM 






FSK 3 µM FSK 
 
Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
SKF-83566 HBr 16±0.66*** 36±3.3** 20±2.6** 100±8.1 61±2.7** 85±3.0* 
(+)-SCH23390 HCl 54±1.1*** 74±1.7** 68±3.6* 120±6.6 74±5.7* 100±14 
Nor-S-(-)-SCH 23388 HCl 77±7.9 71±4.1* 82±9.2 81±10 98±5.3 93±8.8 
SKF81297 HBr 86±8.2 130±9.3 100±20 84±16 200±2.4*** 260±8.4** 
SKF82958 HBr 81±16 94±10 82±9 80±12 120±4.1 210±0.74*** 
SCH39166 HBr 98±11 100±1.5 110±8.9 ND ND 110±14 
6264-0080 310±36* 360±25** 360±75 33±4.4** 330±33* 240±19* 
3671-5745 110±18 150±9.7* 130±6.4* 130±15 92±2.2 110±3.5 
Oxymetholone 67±11 56±24 32±1.6*** 75±9.7 100±9.7 84±11 
N050-0006 89±12 110±5.7 110±7.6 100±15 99±2.9 100±4.4 
Tranilast 33±5.0** 32±3.7** 55±2.8** 96±5.4 31±0.31*** 60±6.4* 
1683-6987 98±4.8 92±2.8 110±16 94±5.9 110±2.2* 130±5.6* 
8005-4220 81±12 88±4.7 83±8.2 96±7.3 90±7.2 91±1.4* 
4100-1558 88±7.9 110±1.8* 160±14 75±5.9 110±5.0 110±6.5 
Loratadine 50±6.8* 21±1.3*** 46±2.3** 120±7.8 16±0.80*** 51±3.2** 





 The development and initial success of a robust cell-based HTS assay for 
inhibitors of AC2 (see chapter 4) prompted further screening.  In an effort to 
identify novel and diverse small molecule inhibitors of AC2, the Spectrum 
Collection (MicroSource Discovery Systems Inc.) was screened for inhibition of 
PMA-stimulated cAMP in HEK-hAC2 cells as described in chapter 4.  The 
Spectrum Collection is a diverse chemical collection that contains 2,320 
compounds (60% drugs, 25% natural products, and 15% other bioactive 
molecules) and provided the opportunity to extend the screening efforts initiated 
by screening the NIH clinical collections I and II.  The complete results from the 
screening of the Spectrum Collection compounds (20 μM) for inhibition of 50 nM 






Table A.3 Screening of the Spectrum Collection for inhibition of AC2 activity.  The 
Spectrum Collection (20 µM) was screened for inhibition of PMA-stimulated (50 
nM) cAMP accumulation in HEK-hAC2 cells using the Cisbio HTRF cAMP 
dynamic 2 detection methodology.  The data represent the percent inhibition of 
the PMA-stimulated cAMP response in singlet. 
 
Compound Name % Inhibition 










12a-HYDROXY-9-DEMETHYLMUNDUSERONE-8-CARBOXYLIC ACID -1.59 
13-METHYL-4,4-BISNOR-8,11,13-PODOCARPATRIEN-3-ONE -89.76 
14-METHOXY-4,4-BISNOR-8,11,13-PODOCARPATRIEN-3-ONE -104.77 
18alpha-GLYCYRRHETINIC ACID -10.67 
18-AMINOABIETA-8,11,13-TRIENE SULFATE -21.67 
1-HYDROXY-3,6,7-TRIMETHOXY-2,8-DIPRENYLXANTHONE 12.42 
1-MONOPALMITIN 21.46 
1-PHENYLBIGUANIDE HYDROCHLORIDE 1.78 
1R,2S-PHENYLPROPYLAMINE -37.14 
2,2'-AZO-bis-2-AMINOPROPANE 5.68 







2,3-DIMERCAPTOSUCCINIC ACID -92.54 
2,4-DICHLOROPHENOXYACETIC ACID 19.65 








Table A.3 Continued. 
2',4'-DIHYDROXYCHALCONE -121.12 
2',4-DIHYDROXYCHALCONE -121.33 









2-AMINOGUANIDINE HEMISULFATE 1.26 
2-BENZOYL-5-METHOXYBENZOQUINONE -42.64 
2-HYDROXY-3,4-DIMETHOXYBENZOIC ACID -11.99 
2-HYDROXY-5 (6)EPOXY-TETRAHYDROCARYOPHYLLENE -12.54 
2-MERCAPTOBENZOTHIAZOLE -138.94 




2-METHYL GRAMINE -45.27 
2-METHYL-4-(PIPERIDIN-1-YLCARBOXY)-5-
ISOPROPYLPHENYLTRIMETHYLAMMONIUM CHLORIDE 19.65 
2-METHYL-5,7,8-TRIMETHOXYISOFLAVONE 29.32 
2-METHYLENE-5-(2,5-DIOXOTETRAHYDROFURAN-3-YL)-6-OXO--

































3-DEOXO-3beta-HYDROXYMEXICANOLIDE 16-ENOL ETHER -13.90 
3-DEOXY-3beta-HYDROXYANGOLENSIC ACID METHYL ESTER -0.07 
3-DESHYDROXYSAPPANOL TRIMETHYL ETHER -36.43 
3H-1,2-DITHIOLE-3-THIONE -56.41 
3-HYDROXY-3',4'-DIMETHOXYFLAVONE -20.12 
3-HYDROXY-4-(SUCCIN-2-YL)-CARYOLANE delta-LACTONE -13.55 
3-HYDROXYFLAVONE -37.15 
3-HYDROXYTYRAMINE -12.69 
3-ISOBUTYL-1-METHYLXANTHINE (IBMX) -25.40 
3-METHOXYCATECHOL -46.70 
3-METHYLORSELLINIC ACID 1.78 
3-METHYLXANTHINE 6.78 
3-NOR-3-OXOPANASINSAN-6-OL 4.61 
3-OXOURSAN (28-13)OLIDE -64.00 
4-(3-BUTOXY-4-METHOXYBENZYL)IMIDAZOLIDIN-2-ONE -171.13 



























5-AMINOPENTANOIC ACID HYDROCHLORIDE -11.53 
5-CHLOROINDOLE-2-CARBOXYLIC ACID -2.24 






6,7-DICHLORO-3-HYDROXY-2-QUINOXALINECARBOXYLIC ACID 24.66 
6alpha-METHYLPREDNISOLONE ACETATE -12.77 
6-AMINONICOTINAMIDE -2.19 























8beta-HYDROXYCARAPIN, 3,8-HEMIACETAL -36.95 
8-CYCLOPENTYLTHEOPHYLLINE -12.07 
8-HYDROXYCARAPINIC ACID -1.19 
ABACAVIR SULFATE -13.47 
ABAMECTIN (avermectin B1a shown) -46.12 
ABIENOL -307.12 
ABIETIC ACID -140.80 
ACACETIN DIACETATE 3.52 
ACADESINE 0.52 
ACAMPROSATE CALCIUM 10.25 
ACARBOSE -21.61 
ACEBUTOLOL HYDROCHLORIDE -12.92 







ACEPROMAZINE MALEATE 41.78 







ACETOHYDROXAMIC ACID 17.87 
ACETOPHENAZINE MALEATE 7.80 
ACETOSYRINGONE -26.37 
ACETRIAZOIC ACID 14.96 







Table A.3 Continued. 





ACEXAMIC ACID -25.66 
ACIPIMOX 5.78 
ACONITIC ACID 0.74 
ACONITINE -0.62 






ADENOSINE PHOSPHATE -35.03 
ADIPHENINE HYDROCHLORIDE -30.87 
ADONITOL -13.78 
ADRENOLONE HYDROCHLORIDE -35.34 
AESCULIN 31.99 
AGARIC ACID 5.80 
AGELASINE (stereochemistry of diterpene unknown) -21.88 







ALCLOMETAZONE DIPROPIONATE 1.24 
ALENDRONATE SODIUM -25.22 
ALEURETIC ACID 25.65 
ALEXIDINE HYDROCHLORIDE -17.11 
ALFLUZOSIN 7.19 
ALGESTONE ACETOPHENIDE -116.80 













alpha-CYANO-3-HYDROXYCINNAMIC ACID -12.69 
alpha-CYANO-4-HYDROXYCINNAMIC ACID -22.14 
alpha-DIHYDROGEDUNOL -44.72 




alpha-TOCHOPHERYL ACETATE -9.96 
alpha-TOXICAROL (dl) -84.54 






ALVERINE CITRATE -12.25 
AMANTADINE HYDROCHLORIDE -29.46 
AMBROXOL HYDROCHLORIDE 18.10 
AMCINONIDE 5.86 
AMIFOSTINE -28.05 
AMIKACIN SULFATE -20.17 
AMILORIDE HYDROCHLORIDE 5.53 
AMINACRINE -20.42 
AMINOBENZTROPINE -7.07 
AMINOCAPROIC ACID -7.59 
AMINOCYCLOPROPANECARBOXYLIC ACID -3.20 
AMINOETHOXYDIPHENYLBORANE -245.61 
AMINOETHYLISOTHIOUREA DIHYDROBROMIDE -2.24 
AMINOGLUTETHIMIDE -4.43 
AMINOHIPPURIC ACID -14.06 
AMINOHYDROXYBUTYRIC ACID -11.85 






Table A.3 Continued. 
AMINOPENTAMIDE SULFATE -11.35 
AMINOPTERIN 12.62 
AMINOPYRINE 9.78 
AMINOSALICYLATE SODIUM -13.99 
AMINOTHIAZOLE 23.05 




AMITRIPTYLINE HYDROCHLORIDE -8.22 
AMLODIPINE BESYLATE 56.23 
AMMONIUM LACTATE -7.86 
AMODIAQUINE DIHYDROCHLORIDE -23.71 
AMOXAPINE 7.07 
AMOXICILLIN 13.90 
AMPHOTERICIN B -8.29 




AMPYZINE SULFATE 9.37 
AMSACRINE -20.19 
AMYGDALIN -0.92 
ANABASAMINE HYDROCHLORIDE -10.67 
ANABASINE HYDROCHLORIDE -0.85 
ANAGRELIDE HYDROCHLORIDE -78.00 
ANASTROZOLE 2.40 
ANCITABINE HYDROCHLORIDE -12.50 
ANDROSTA-1,4-DIEN-3,17-DIONE -60.76 
ANDROSTERONE -196.30 
ANDROSTERONE ACETATE -371.76 
ANEBROMPHENIRAMINE MALEATE 20.61 
ANETHOLE -45.28 
ANGOLENSIN (R) -64.73 








Table A.3 Continued. 
ANISODAMINE HYDROBROMIDE 6.34 
ANISOMYCIN -24.59 





ANTIMYCIN A (A1 shown) -185.07 
ANTIPYRINE 12.11 
APHYLLIC ACID -42.44 
APIGENIN -17.04 
APIGENIN DIMETHYL ETHER -25.04 
APIIN -22.50 
APIOLE -174.46 





ARCAINE SULFATE 0.67 
ARECOLINE HYDROBROMIDE 8.04 
ARGININE HYDROCHLORIDE -24.91 
ARIPIPRAZOLE -225.19 
ARSANILIC ACID -16.53 






ARTHONIOIC ACID -123.25 
ASARYLALDEHYDE 2.59 
ASCORBIC ACID 40.72 
ASCORBYL PALMITATE 22.67 
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ASTAXANTHIN -26.21 
ASTEMIZOLE 43.15 
ASTRAGALOSIDE IV -21.84 
ATENOLOL -5.65 
ATOMOXETINE HYDROCHLORIDE -13.55 
ATORVASTATIN CALCIUM -8.22 
ATOVAQUONE 5.03 
ATRACURIUM BESYLATE 4.08 
ATRANORIN -110.98 
ATROPINE SULFATE -19.17 
AURAPTENE -6.43 
AURIN TRICARBOXYLIC ACID -5.26 
AUROTHIOGLUCOSE -11.94 





AVOCADYNE ACETATE 25.46 
AVOCADYNOFURAN -3.41 
AVOCATIN A 50.49 





AZATADINE MALEATE -19.21 
AZATHIOPRINE -27.69 
AZELAIC ACID 22.19 
AZELASTINE HYDROCHLORIDE 13.97 
AZITHROMYCIN -0.08 
AZLOCILLIN SODIUM -23.14 
AZOBENZENE -61.67 
AZTREONAM 23.85 
BACAMPICILLIN HYDROCHLORIDE -16.95 











BALSALAZIDE DISODIUM 17.38 
BAMBUTEROL HYDROCHLORIDE 1.31 
BARBITAL -20.14 
BATYL ALCOHOL 0.13 
BECLAMIDE -1.14 
BECLOMETHASONE DIPROPIONATE -36.00 
BEKANAMYCIN SULFATE 10.76 
BEMOTRIZINOL -6.10 
BENAZEPRIL HYDROCHLORIDE 26.21 
BENDROFLUMETHIAZIDE 24.53 
BENFLUOREX HYDROCHLORIDE -19.43 
BENFOTIAMINE 11.77 
BENOXINATE HYDROCHLORIDE 3.39 
BENSERAZIDE HYDROCHLORIDE -41.68 
BENURESTAT 12.69 
BENZALKONIUM CHLORIDE -6.49 
BENZANTHRONE -1067.13 
BENZBROMARONE -115.15 
BENZETHONIUM CHLORIDE -43.26 
BENZO[a]PYRENE -108.23 
BENZOCAINE 21.47 
BENZOIC ACID -23.04 
BENZONATATE -37.01 
BENZOXIQUINE 3.07 
BENZOYL PEROXIDE -17.87 
BENZOYLPAS 5.74 
BENZTHIAZIDE 7.15 
BENZYDAMINE HYDROCHLORIDE -14.24 
BENZYL ALCOHOL -24.54 
BENZYL BENZOATE -16.03 
BENZYL ISOTHIOCYANATE -22.37 
BEPHENIUM HYDROXYNAPTHOATE 13.33 
BEPRIDIL HYDROCHLORIDE -46.09 






Table A.3 Continued. 
BERBERINE CHLORIDE 2.95 
BERGAPTEN -32.78 
BERGENIN 7.56 
beta-AMYRIN ACETATE 6.85 
beta-CAROTENE -111.70 
beta-CARYOPHYLLENE ALCOHOL -6.45 
beta-ESCIN 41.97 
BETAHISTINE HYDROCHLORIDE -14.46 
BETAINE HYDROCHLORIDE -10.27 
BETAMETHASONE -20.63 
BETAMETHASONE 17,21-DIPROPIONATE 13.86 
BETAMETHASONE ACETATE -1.80 
BETAMETHASONE SODIUM PHOSPHATE 7.35 






BETAXALOL HYDROCHLORIDE 7.13 
BETAZOLE HYDROCHLORIDE 5.83 
BETHANECHOL CHLORIDE -7.67 
BETULIN 17.44 
BETULINIC ACID -148.36 
BEZAFIBRATE 1.04 
BICALUTAMIDE -40.83 
BICUCULLINE (+) -12.12 
BICUCULLINE(-) METHIODIDE -35.95 
BIFONAZOLE -58.83 
BILIRUBIN -68.13 












Table A.3 Continued. 
BISOPROLOL FUMARATE 10.60 
BISPHENOL A -58.69 
BISSALICYL FUMARATE 1.75 
BITHIONATE SODIUM -139.66 
BITOSCANATE 11.25 
BIXIN -23.21 
BLASTICIDIN S 19.37 
BLEOMYCIN (bleomycin B2 shown) -0.11 
BOLDINE 10.19 
BORNEOL -1.14 
BORNYL ACETATE -28.15 
















BUFLOMEDIL HYDROCHLORIDE 7.20 
BUMETANIDE 17.98 
BUPIVACAINE HYDROCHLORIDE -27.00 
BUPROPION -25.84 












Table A.3 Continued. 
BUTYLATED HYDROXYTOLUENE -450.16 
CACODYLIC ACID -39.64 
CADAVERINE TARTRATE 13.03 
CADIN-4-EN-10-OL -29.23 
CAFESTOL 11.76 
CAFESTOL ACETATE -12.20 
CAFFEIC ACID -1.19 
CAFFEINE 13.32 
CALCEIN 24.19 
CALCIUM GLUCEPTATE 13.61 
CAMPHOR (1R) 21.52 
CAMPTOTHECIN -12.33 




CANRENOIC ACID, POTASSIUM SALT 18.36 
CANRENONE -34.75 
CANTHARIDIN -13.98 
CANTHAXANTHIN (euglenanone) -7.31 
CAPECITABINE -5.88 
CAPOBENIC ACID -6.49 












CARBENICILLIN DISODIUM 11.39 
CARBENOXOLONE SODIUM -15.48 






Table A.3 Continued. 
CARBIDOPA -48.43 
CARBINOXAMINE MALEATE -9.72 
CARBOPLATIN -27.67 
CARISOPRODOL -17.63 
CARMINIC ACID 17.85 
CARMOFUR 12.06 
CARMUSTINE -76.58 
CARNITINE (dl) HYDROCHLORIDE 8.23 




CARTEOLOL HYDROCHLORIDE 10.14 
CARVEDILOL -75.51 
CARVEDILOL PHOSPHATE -177.70 
CARYLOPHYLLENE OXIDE -53.97 
CARYOPHYLLENE [t(-)] -188.99 
CARZENIDE 7.68 
CASANTHRANOL [cascaroside A shown] -69.10 
CATECHIN PENTAACETATE -139.68 








CEFAMANDOLE NAFATE -13.64 
CEFAMANDOLE SODIUM 1.14 
CEFAZOLIN SODIUM 18.91 
CEFDINIR -1.32 
CEFDITORIN PIVOXIL -48.78 
CEFEPIME HYDROCHLORIDE 5.72 
CEFMENOXIME HYDROCHLORIDE -13.20 
CEFMETAZOLE SODIUM -2.44 






Table A.3 Continued. 
CEFOPERAZONE -2.69 
CEFORANIDE -4.36 
CEFOTAXIME SODIUM -14.87 
CEFOTETAN 17.04 
CEFOXITIN SODIUM -18.35 
CEFPIRAMIDE -5.52 
CEFPODOXIME PROXETIL -22.23 
CEFPROZIL 3.96 
CEFSULODIN SODIUM -9.96 
CEFTAZIDIME 3.26 
CEFTIBUTEN -3.20 
CEFTIOFUR HYDROCHLORIDE -7.64 
CEFTRIAXONE SODIUM TRIHYDRATE -0.28 
CEFUROXIME AXETIL 9.24 
CEFUROXIME SODIUM -5.01 
CELASTROL -307.12 
CELECOXIB 16.46 
CELLOBIOSE (D[+]) 12.87 
CEPHALEXIN 21.42 
CEPHALOSPORIN C SODIUM 18.15 
CEPHALOTHIN SODIUM -1.73 
CEPHAPIRIN SODIUM 18.42 
CEPHARANTHINE -3.38 
CEPHRADINE 6.90 
CETIRIZINE HYDROCHLORIDE 2.30 
CETRIMONIUM BROMIDE 29.30 
CETYLPYRIDINIUM CHLORIDE -8.92 
CHAULMOOGRIC ACID -23.21 
CHENODIOL -13.88 






CHLORAMPHENICOL PALMITATE 5.59 






Table A.3 Continued. 
CHLORANIL 81.80 
CHLORCYCLIZINE HYDROCHLORIDE -26.97 
CHLORHEXIDINE HYDROCHLORIDE -67.47 
CHLORINDIONE 6.83 
CHLORMADINONE ACETATE -1.87 
CHLORMEZANONE 5.90 
CHLOROCRESOL -49.66 
CHLOROGUANIDE HYDROCHLORIDE -0.32 
CHLOROPHYLLIDE Cu COMPLEX Na SALT 70.63 
CHLOROPYRAMINE HYDROCHLORIDE -3.88 




CHLORPHENIRAMINE (S) MALEATE -6.70 
CHLORPROMAZINE 25.27 
CHLORPROPAMIDE -7.29 
CHLORPROTHIXENE HYDROCHLORIDE 50.50 
CHLORPYRIFOS -232.94 
CHLORQUINALDOL 19.54 
CHLORTETRACYCLINE HYDROCHLORIDE -27.53 
CHLORTHALIDONE -31.98 
CHLORZOXAZONE -25.02 







CHOLESTERYL ACETATE -15.00 
CHOLIC ACID -33.87 
CHOLIC ACID, METHYL ESTER -60.12 
CHOLINE CHLORIDE -4.51 
CHROMOCARB -10.99 
CHRYSANTHEMIC ACID -23.61 
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CHRYSANTHEMYL ALCOHOL -21.70 
CHRYSAROBIN -535.96 
CHRYSIN -69.57 
CHRYSIN DIMETHYL ETHER -54.22 
CHRYSOPHANOL -300.27 
CHUKRASIN METHYL ETHER -25.67 
CIANIDANOL -12.01 




















CLAVULANATE LITHIUM -4.61 
CLEMASTINE FUMARATE 12.35 
CLEMIZOLE HYDROCHLORIDE -14.62 
CLENBUTEROL HYDROCHLORIDE -27.86 
CLIDINIUM BROMIDE 2.73 
CLIMBAZOLE 11.60 
CLINAFOXACIN HYDROCHLORIDE 9.25 
CLINDAMYCIN HYDROCHLORIDE 7.25 
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CLOFIBRIC ACID -6.87 
CLOFILIUM TOSYLATE -1.32 
CLOFOCTOL -439.91 
CLOMIPHENE CITRATE 1.75 
CLOMIPRAMINE HYDROCHLORIDE -58.86 
CLONAZEPAM -13.66 
CLONIDINE HYDROCHLORIDE -33.09 
CLOPERASTINE HYDROCHLORIDE -1.76 
CLOPIDOGREL SULFATE 1.77 
CLOPIDOL -11.58 




CLOVANEDIOL DIACETATE -62.30 




COLESEVALAM HYDROCHLORIDE (high mol wt copolymer @10mg/ml) -11.24 
COLFORSIN -3268.26 
COLISTIMETHATE SODIUM 34.85 
COLISTIN SULFATE -35.98 
CONESSINE 12.20 
CONVALLATOXIN -10.67 
CORALYNE CHLORIDE 6.85 
CORTISONE -28.25 
CORTISONE ACETATE -33.50 
CORYNANTHINE -18.21 




















CYCLAMIC ACID 9.58 
CYCLANDELATE -81.68 
CYCLIZINE -2.93 




CYCLOPENTOLATE HYDROCHLORIDE -26.56 
CYCLOPHOSPHAMIDE -3.93 





CYPROHEPTADINE HYDROCHLORIDE -22.21 
CYPROTERONE -1.28 
CYPROTERONE ACETATE 6.58 
CYROMAZINE -0.72 
CYSTAMINE DIHYDROCHLORIDE -16.96 
CYSTEAMINE HYDROCHLORIDE 3.84 
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DACTINOMYCIN -25.95 
DALBERGIONE 12.50 
DALBERGIONE, 4-METHOXY-4'-HYDROXY- -30.25 
DANAZOL -30.48 
DANTHRON -250.19 
DANTROLENE SODIUM 19.91 
DAPSONE 2.92 
DARIFENACIN HYDROBROMIDE -38.06 
DASATINIB  -12.94 
DAUNORUBICIN 10.88 
DEACETOXY(7)-7-OXOKHIVORINIC ACID -4.39 
DEACETOXY-7-OXOGEDUNIN -92.69 
DEACETYLGEDUNIN -23.26 
DEBRISOQUIN SULFATE -27.48 
DECAHYDROGAMBOGIC ACID -445.84 
DECAMETHONIUM BROMIDE -23.75 
DECOQUINATE -24.58 
DEFERIPRONE -28.25 
DEFEROXAMINE MESYLATE 8.60 
DEGUELIN(-) -92.20 
DEHYDROABIETAMIDE -48.61 
DEHYDROACETIC ACID 25.15 
DEHYDROCHOLATE SODIUM -6.11 




DEMECLOCYCLINE HYDROCHLORIDE -8.93 
DEMETHYLNOBILETIN -150.16 
DENATONIUM BENZOATE -9.12 
DEOXYADENOSINE 68.04 
DEOXYANDIROBIN -10.99 
DEOXYCHOLIC ACID -4.59 
DEOXYGEDUNIN -50.92 
DEOXYKHIVORIN -8.72 
DEOXYSAPPANONE B 7,3'-DIMETHYL ETHER -116.45 
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DEOXYSAPPANONE B 7,4'-DIMETHYL ETHER -128.48 
DEOXYSAPPANONE B TRIMETHYL ETHER -113.13 




DESACETYL (7)KHIVORINIC ACID, METHYL ESTER -7.23 
DESACETYLCOLFORSIN -689.41 
DESIPRAMINE HYDROCHLORIDE 1.54 
DESLORATADINE HYDROCHLORIDE -72.14 
DESLORATIDINE 35.35 
DESONIDE -9.95 
DESOXYCORTICOSTERONE ACETATE -17.81 
DESOXYMETASONE -2.50 
DESOXYPEGANINE HYDROCHLORIDE -5.26 
DESVENLAFAXINE SUCCINATE -41.55 
DEXAMETHASONE 33.87 
DEXAMETHASONE ACETATE 12.64 
DEXAMETHASONE SODIUM PHOSPHATE -1.16 




DEXPROPRANOLOL HYDROCHLORIDE 23.31 
DIACERIN -10.83 
DIACETAMATE -45.41 
DIALLYL SULFIDE -19.50 






DIBUCAINE HYDROCHLORIDE -25.02 
DIBUTYL PHTHALATE -46.34 
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DICLAZURIL -10.33 
DICLOFENAC SODIUM -37.83 




DICYCLOMINE HYDROCHLORIDE -2.08 
DIDEACETYL (1,3)-7-DESACETOXY-7-OXO-DEOXYKHIVORINIC ACID 8.34 
DIENESTROL -24.92 
DIETHYLCARBAMAZINE CITRATE -4.73 
DIETHYLSTILBESTROL 7.25 
DIETHYLTOLUAMIDE -1.25 
DIFFRACTAIC ACID -20.97 
DIFLORASONE DIACETATE 31.48 
DIFLOXACIN HYDROCHLORIDE -6.58 
DIFLUBENZURON 4.03 
DIFLUNISAL -43.34 






DIHYDROCELASTRYL DIACETATE -84.14 
DIHYDROERGOTAMINE MESYLATE -24.92 
DIHYDROFISSINOLIDE -45.93 
DIHYDROFOLIC ACID -16.00 
DIHYDROGAMBOGIC ACID -179.43 
DIHYDROGEDUNIC ACID, METHYL ESTER -28.41 
DIHYDROGEDUNIN -23.26 
DIHYDROJASMONIC ACID 109.86 




DIHYDROSTREPTOMYCIN SULFATE -8.78 
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DILAZEP DIHYDROCHLORIDE -14.95 
DILOXANIDE FUROATE -34.18 




DIMETHYL 4,4-o-PHENYLENE-BIS (3-THIOPHANATE) -60.23 
DIMETHYL FUMARATE -155.37 
DIMETHYLCAFFEIC ACID -4.09 







DIPERODON HYDROCHLORIDE -9.35 
DIPHENHYDRAMINE HYDROCHLORIDE -34.31 







DISOPYRAMIDE PHOSPHATE -3.22 
DISULFIRAM -673.59 
DJENKOLIC ACID 3.40 
D-LACTITOL MONOHYDRATE -6.94 
d-LIMONENE 5.90 
DOBUTAMINE HYDROCHLORIDE 4.80 
DOCETAXEL -27.18 
DOCOSANOL 12.46 
DOCUSATE SODIUM 7.07 
DOMPERIDONE -68.51 
DONEPEZIL HYDROCHLORIDE -20.72 
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DORAMECTIN -83.97 
DOXAPRAM HYDROCHLORIDE -11.94 
DOXAZOSIN MESYLATE -63.71 




DOXYCYCLINE HYDROCHLORIDE 38.93 
DOXYLAMINE SUCCINATE -4.51 
D-PHENYLALANINE -37.92 
DROFENINE HYDROCHLORIDE -15.03 
DROPERIDOL -32.38 
DROSPIRENONE -20.41 
DUARTIN (-) -66.38 
DUARTIN, DIMETHYL ETHER -68.02 
DULOXETINE HYDROCHLORIDE -58.70 
DUTASTERIDE -31.22 




ECAMSULE TRIETHANOLAMINE 12.01 
ECONAZOLE NITRATE -79.20 
EDARAVONE -42.09 
EDETATE DISODIUM -11.09 
EDITOL -35.88 
EDOXUDINE 37.66 
EDROPHONIUM CHLORIDE 40.41 
EFAROXAN HYDROCHLORIDE -29.22 
EFLOXATE -208.19 
ELAIDYLPHOSPHOCHOLINE 50.01 
ELETRIPTAN HYDROBROMIDE 3.39 

















EPHEDRINE (1R,2S) HYDROCHLORIDE -6.61 
EPI(13)TORULOSOL -53.79 
EPIAFZELECHIN (2R,3R)(-) -26.27 
EPIAFZELECHIN TRIMETHYL ETHER 2.88 
EPIANDROSTERONE -114.16 
EPICATECHIN -3.00 
EPICATECHIN MONOGALLATE -12.77 
EPICATECHIN PENTAACETATE -10.19 
EPIESTRIOL 12.06 
EPIGALLOCATECHIN -6.04 
EPIGALLOCATECHIN 3,5-DIGALLATE 14.49 
EPIGALLOCATECHIN-3-MONOGALLATE -47.93 
EPINEPHRINE BITARTRATE -59.39 
EPIRUBICIN HYDROCHLORIDE -18.88 
EPITESTOSTERONE 0.13 
EPOXYGEDUNIN -66.42 




ERGONOVINE MALEATE 23.45 
ERGOSTEROL -51.70 
ERGOSTEROL ACETATE -46.59 
ERGOTAMINE TARTRATE -6.68 
ERYTHROMYCIN -3.90 
ERYTHROMYCIN ESTOLATE -15.95 
ERYTHROMYCIN ETHYLSUCCINATE 15.39 
ERYTHROSE -0.58 
ERYTHROSINE SODIUM 109.92 







Table A.3 Continued. 
ESCULIN MONOHYDRATE 30.74 
ESEROLINE FUMARATE -132.98 
ESOMEPRAZOLE POTASSIUM 22.98 
ESTRADIOL -33.29 
ESTRADIOL ACETATE -64.70 
.ESTRADIOL BENZOATE -164.11 
ESTRADIOL CYPIONATE -192.32 
ESTRADIOL DIACETATE -112.34 
ESTRADIOL DIPROPIONATE -133.79 
ESTRADIOL METHYL ETHER -21.80 
ESTRADIOL VALERATE -155.41 




ESTRONE ACETATE -390.03 
ESTRONE BENZOATE -117.50 
ESTROPIPATE 3.91 
ETHACRIDINE LACTATE 44.59 
ETHACRYNIC ACID -164.34 
ETHAMBUTOL HYDROCHLORIDE -14.13 
ETHAMIVAN -0.49 
ETHANOLAMINE OLEATE -22.51 
ETHAVERINE HYDROCHLORIDE -82.34 








ETHYL PARABEN -49.92 
ETHYNODIOL DIACETATE -456.27 
ETICLOPRIDE HYDROCHLORIDE 17.01 















EUPHOL ACETATE -27.09 










FAST GREEN FCF 109.86 







FENDILINE HYDROCHLORIDE -43.69 
FENOFIBRATE -300.63 
FENOFIBRIC ACID 0.88 
FENOLDIPAM MESYLATE 1.18 
FENOPROFEN -0.99 
FENOTEROL HYDROBROMIDE -22.43 
FENSPIRIDE HYDROCHLORIDE 8.31 
FENTHION -85.97 
FERULIC ACID 13.85 







Table A.3 Continued. 
FINASTERIDE 5.00 











FLUDARABINE PHOSPHATE 24.58 
FLUDROCORTISONE ACETATE 18.83 




FLUMETHAZONE PIVALATE 9.14 
FLUNARIZINE HYDROCHLORIDE -123.66 
FLUNISOLIDE -15.57 
FLUNIXIN MEGLUMINE 15.37 
FLUNIXIN MEGLUMINE 12.34 



















Table A.3 Continued. 
FLUVASTATIN -45.40 
FLUVOXAMINE MALEATE -0.90 
FOLIC ACID -17.81 
FOMEPIZOLE -9.73 
FOMEPIZOLE HYDROCHLORIDE 15.83 
FORMESTANE -179.59 
FORMONONETIN 16.59 
FOSCARNET SODIUM 13.42 
FOSFOMYCIN CALCIUM -8.52 
FOSFOSAL 5.48 









FUSARIC ACID -22.58 
FUSIDIC ACID 29.23 
GABAPENTIN -6.83 
GABOXADOL HYDROCHLORIDE 5.40 
GADOTERIDOL 15.82 
GALANGIN -21.14 
GALANGIN TRIMETHYL ETHER -24.52 
GALANTAMINE -0.84 
GALLAMINE TRIETHIODIDE -18.43 
GALLIC ACID -5.38 
GAMBOGIC ACID -12.66 
gamma-AMINOBUTYRIC ACID -30.99 
GANCICLOVIR -16.91 
GANGALEOIDIN -97.80 













GEMIFLOXACIN MESYLATE 30.71 
GENETICIN -2.99 
GENISTEIN -121.96 
GENTAMICIN SULFATE -13.47 
GENTIAN VIOLET 110.02 
GIBBERELLIC ACID -9.32 
GINKGOLIDE A -9.92 
GITOXIGENIN -19.34 








GLUCOSAMINE HYDROCHLORIDE -3.36 
GLUCOSAMINIC ACID -7.00 
GLUTAMINE (D) -9.28 
GLUTAMINE (L) 28.35 
GLUTATHIONE -3.66 
GLYBURIDE -27.23 
GLYCOCHOLIC ACID -0.53 
GLYCOPYRROLATE 10.92 















Table A.3 Continued. 
GUAIOL(-) -90.01 
GUANABENZ ACETATE 12.00 
GUANADREL SULFATE 8.56 
GUANETHIDINE MONOSULFATE -31.58 
GUANFACINE HYDROCHLORIDE -23.67 
GUANIDINE HYDROCHLORIDE -1.83 
HAEMATOMMIC ACID -19.34 
HAEMATOMMIC ACID, ETHYL ESTER -179.06 
HAEMATOPORPHYRIN 87.76 
HAEMATOXYLIN 11.48 
HAEMATOXYLIN PENTAACETATE -53.17 
HALAZONE -12.73 




HARMALOL HYDROCHLORIDE 41.13 
HARMANE -37.78 
HARMINE -29.14 
HARMOL HYDROCHLORIDE -7.60 
HARPAGOSIDE 2.40 
HECOGENIN -14.21 
HECOGENIN ACETATE -49.92 





HEMICHOLINIUM BROMIDE -12.23 
HEPTAMINOL HYDROCHLORIDE -30.69 
HESPERETIN -9.62 
HESPERIDIN -37.84 
HETACILLIN POTASSIUM 25.08 
HETEROPEUCENIN, METHYL ETHER -117.74 
HEXACHLOROPHENE -140.70 







Table A.3 Continued. 
HEXESTROL -90.33 
HEXETIDINE -81.36 
HEXYLENE GLYCOL 3.01 
HEXYLRESORCINOL -20.50 
HIERACIN -10.67 
HISTAMINE DIHYDROCHLORIDE -20.24 
HOMATROPINE HYDROBROMIDE 19.04 
HOMATROPINE METHYLBROMIDE 14.96 
HOMIDIUM BROMIDE 100.44 
HOMOPTEROCARPIN -254.80 
HOMOSALATE -244.45 
HUMULENE (alpha) -98.88 
HUPERZINE A -2.19 
HYCANTHONE 34.41 
HYDRALAZINE HYDROCHLORIDE 28.39 
HYDRASTINE (1R, 9S) -15.80 
HYDRASTININE HYDROCHLORIDE 18.62 
HYDROCHLOROTHIAZIDE 27.36 
HYDROCORTISONE -18.26 
HYDROCORTISONE ACETATE 15.44 
HYDROCORTISONE BUTYRATE 8.59 
HYDROCORTISONE HEMISUCCINATE -9.23 
HYDROCORTISONE PHOSPHATE TRIETHYLAMINE -4.08 
HYDROCORTISONE VALERATE -8.45 
HYDROFLUMETHIAZIDE -26.17 
HYDROLYSIS PRODUCT OF BUSSEIN 7.59 
HYDROQUINIDINE 12.40 
HYDROQUININE HYDROBROMIDE HYDRATE 3.20 
HYDROQUINONE -23.42 
HYDROXYAMPHETAMINE HYDROBROMIDE -2.47 
HYDROXYCHLOROQUINE SULFATE 8.75 
HYDROXYPROGESTERONE -9.68 
HYDROXYPROGESTERONE CAPROATE -203.26 
HYDROXYTOLUIC ACID 9.78 
HYDROXYUREA 3.18 







Table A.3 Continued. 
HYMECROMONE METHYL ETHER -131.59 
HYOSCYAMINE 7.01 
HYPOXANTHINE -1.78 
IBANDRONATE SODIUM 0.33 
IBUPROFEN -6.26 
ICARIIN 3.86 






IMIDAZOL-4-YLACETIC ACID SODIUM SALT -14.96 
IMIPENEM 8.23 












IOPANIC ACID -18.54 
IOTHALAMIC ACID -18.61 
IOVERSOL 17.51 
IOXILAN 1.73 
IPRATROPIUM BROMIDE -15.81 
IPRIFLAVONE -13.23 










Table A.3 Continued. 
IRIGENIN TRIMETHYL ETHER -18.01 
IRIGENIN, 7-BENZYL ETHER -83.12 
IRIGENIN, DIBENZYL ETHER -29.04 
IRIGENOL -54.16 
IRIGINOL HEXAACEATATE -6.05 
IRINOTECAN HYDROCHLORIDE 23.40 





ISOETHARINE MESYLATE -108.48 







ISOPROPAMIDE IODIDE 10.64 
ISOPROTERENOL HYDROCHLORIDE -20.94 
ISOROTENONE -71.23 
ISOSAFROLE -28.02 
ISOSORBIDE DINITRATE 30.36 
ISOSORBIDE MONONITRATE -14.39 




ISOXSUPRINE HYDROCHLORIDE -34.31 
ISRADIPINE -51.71 
ITOPRIDE  HYDROCHLORIDE 0.24 
ITRACONAZOLE -114.11 
IVERMECTIN -151.99 








Table A.3 Continued. 
KAINIC ACID 3.28 
KANAMYCIN A SULFATE 36.98 
KARANJIN 7.64 
KASUGAMYCIN HYDROCHLORIDE 14.29 
KAWAIN 27.60 
KETANSERIN TARTRATE -6.71 
KETOCONAZOLE -241.68 
KETOPROFEN -13.29 
KETOROLAC TROMETHAMINE 0.65 










LABETALOL HYDROCHLORIDE -4.26 
LACCAIC ACID A 7.53 





LANATOSIDE C -31.92 
LANOSTEROL -44.71 
LANOSTEROL ACETATE -85.79 
LANSOPRAZOLE -68.21 
LAPPACONITINE -14.14 
LARIXINIC ACID -30.44 
LARIXOL -82.35 
LARIXOL ACETATE -125.41 
LATHOSTEROL -6.26 







Table A.3 Continued. 




LEUCOVORIN CALCIUM -10.22 
LEVALBUTEROL HYDROCHLORIDE -14.95 
LEVAMISOLE HYDROCHLORIDE -18.37 
LEVCYCLOSERINE -6.98 
LEVOBUNOLOL HYDROCHLORIDE -21.02 
LEVOCARNITINE 7.57 
LEVOCARNITINE PROPIONATE HYDROCHLORIDE 5.20 








LEVULINIC ACID,  3-BENZYLIDENYL- -7.15 




LINCOMYCIN HYDROCHLORIDE -4.29 
LINDANE -3.14 
LIOTHYRONINE 2.87 
LIOTHYRONINE (L- isomer) SODIUM 0.18 
LIPOAMIDE -24.27 
LISINOPRIL 21.21 
LITHIUM CITRATE 24.58 
LITHOCHOLIC ACID -89.59 
L-LEUCYL-L-ALANINE 16.25 
LOBARIC ACID -1.18 
LOBELINE HYDROCHLORIDE -7.17 
LOBENDAZOLE -45.05 






Table A.3 Continued. 
LOMEFLOXACIN HYDROCHLORIDE -37.74 
LOMERIZINE HYDROCHLORIDE -255.69 
LOMUSTINE -41.80 
LONIDAMINE -24.45 
LOPERAMIDE HYDROCHLORIDE 30.36 
LORATADINE 38.17 




LOXAPINE SUCCINATE -2.15 
L-PHENYLALANINOL -18.64 
LUNARINE -22.90 
LUPANINE PERCHLORATE 11.09 
LUPANYL ACID HYDROCHLORIDE -18.30 
LUPEOL 6.30 
LUPININE 3.10 
MADECASSIC ACID -6.57 
MAFENIDE HYDROCHLORIDE -44.13 
MALATHION -476.24 




MANGOSTIN TRIMETHYL ETHER -45.49 
MANNITOL -3.72 
MAPROTILINE HYDROCHLORIDE 5.83 
MEBENDAZOLE 0.62 
MEBEVERINE HYDROCHLORIDE 40.75 
MEBHYDROLIN NAPHTHALENESULFONATE -39.97 
MECAMYLAMINE HYDROCHLORIDE 21.30 
MECHLORETHAMINE -23.75 
MECLIZINE HYDROCHLORIDE -472.39 
MECLOCYCLINE SULFOSALICYLATE 19.17 
MECLOFENAMATE SODIUM -53.54 
MECLOFENOXATE HYDROCHLORIDE -0.03 
MECYSTEINE HYDROCHLORIDE -15.61 






Table A.3 Continued. 
MEDRYSONE -54.33 
MEFENAMIC ACID -104.16 
MEFEXAMIDE 4.94 
MEFLOQUINE 53.47 




MELENGESTROL ACETATE -110.87 
MELEZITOSE 9.79 
MELIBIOSE -19.24 
MELOXICAM SODIUM -11.27 
MELPERONE HYDROCHLORIDE -23.27 
MELPHALAN -19.17 




MENTHYL BENZOATE -1200.51 
MEPARTRICIN -66.68 
MEPENZOLATE BROMIDE -41.62 
MEPHENESIN 8.44 
MEPHENTERMINE SULFATE -8.14 
MEPIROXOL -2.46 
MEPIVACAINE HYDROCHLORIDE -22.30 








MESORIDAZINE BESYLATE 2.80 
MESTRANOL -30.72 
METACETAMOL 4.89 






Table A.3 Continued. 
METAMECONINE -23.12 
METAMPICILLIN SODIUM -11.38 
METAPROTERENOL -1.43 
METARAMINOL BITARTRATE -4.90 
METAXALONE -41.43 
METERGOLINE -256.18 
METFORMIN HYDROCHLORIDE -9.80 
METHACHOLINE CHLORIDE -24.46 
METHACYCLINE HYDROCHLORIDE 10.21 
METHAPYRILENE HYDROCHLORIDE 2.22 
METHAZOLAMIDE -11.04 
METHENAMINE 1.06 
METHICILLIN SODIUM 23.03 
METHIMAZOLE 13.78 
METHIONINE SULFOXIMINE (L) -6.34 
METHOCARBAMOL -8.77 
METHOPRENE (S) -758.04 
METHOTREXATE(+/-) 23.75 
METHOXAMINE HYDROCHLORIDE 15.54 
METHOXSALEN -74.98 
METHOXYAMINE HYDROCHLORIDE -0.38 
METHOXYVONE -140.43 
METHSCOPOLAMINE BROMIDE 33.82 
METHSUXIMIDE -26.05 
METHYCLOTHIAZIDE -6.98 
METHYL 7-DESHYDROXYPYROGALLIN-4-CARBOXYLATE -75.60 
METHYL DEOXYCHOLATE -157.39 
METHYL ORSELLINATE -22.37 
METHYL ROBUSTONE -87.88 
METHYLATROPINE NITRATE -1.45 
METHYLBENZETHONIUM CHLORIDE -55.73 
METHYLDOPA -24.06 
METHYLDOPATE HYDROCHLORIDE 5.92 
METHYLENE BLUE 109.92 
METHYLERGONOVINE MALEATE 34.97 







Table A.3 Continued. 
METHYLPREDNISOLONE SODIUM SUCCINATE 9.31 
METHYLTHIOURACIL -15.30 
METHYLXANTHOXYLIN -72.09 
METHYSERGIDE MALEATE -11.51 
METICRANE 0.17 
METITEPINE MALEATE 46.44 
METOCLOPRAMIDE HYDROCHLORIDE -1.81 
METOLAZONE 25.13 
METOPROLOL TARTRATE -14.90 
METRONIDAZOLE -31.68 
METYRAPONE 2.50 




MEXILETINE HYDROCHLORIDE -11.20 
MIANSERIN HYDROCHLORIDE 14.01 
MICONAZOLE NITRATE -197.94 
MIDODRINE HYDROCHLORIDE 23.55 
MIFEPRISTONE -106.01 
MIGLITOL 8.77 




MINAPRINE HYDROCHLORIDE 11.90 




MITOXANTRONE HYDROCHLORIDE 97.53 
MOCLOBEMIDE -5.01 
MODAFINIL -2.86 
MODALINE SULFATE -57.43 
MOGUISTEINE -19.08 







Table A.3 Continued. 
MONENSIN SODIUM (monensin A is shown) -84.16 
MONOBENZONE -86.14 
MONOCROTALINE -1.45 
MONTELUKAST SODIUM 8.11 
MORANTEL CITRATE 34.75 
MORIN 0.91 
MOROXYDINE HYDROCHLORIDE 25.64 
MOXALACTAM DISODIUM 3.97 
MOXIDECTIN -131.04 
MOXIFLOXACIN HYDROCHLORIDE 48.63 
MOXISYLYTE HYDROCHORIDE -7.47 
MUCIC ACID -12.97 
MUNDOSERONE -131.36 
MUNDULONE -117.53 
MUNDULONE ACETATE -291.40 
MUPIROCIN 11.17 
MUUROLLADIE-3-ONE 16.43 
MYCOPHENOLATE MOFETIL -14.40 
MYCOPHENOLIC ACID 0.02 
MYOSMINE -35.34 
N- (9-FLUORENYLMETHOXYCARBONYL)-L-LEUCINE -75.94 
N,N-HEXAMETHYLENEAMILORIDE -13.84 
NABUMETONE -4.83 
N-ACETYLMURAMIC ACID -6.11 





NAFCILLIN SODIUM 12.97 
NAFRONYL OXALATE 16.04 
NAFTIFINE HYDROCHLORIDE -63.86 
NAFTOPIDIL -39.21 
NALBUPHINE HYDROCHLORIDE 8.53 
NALIDIXIC ACID 7.37 
NALOXONE HYDROCHLORIDE -4.61 






Table A.3 Continued. 







NEFAZODONE HYDROCHLORIDE -55.26 
NEFOPAM -7.51 
NELARABIN 0.70 
NEOMYCIN SULFATE -6.70 
NEOSTIGMINE BROMIDE 3.84 
NEROL -49.31 
NEROLIDOL -12.09 









NICOTINE BITARTRATE -23.06 
NICOTINYL ALCOHOL TARTRATE -29.41 
NIFEDIPINE -125.76 
NIFENAZONE -8.94 

























N-METHYL (-)EPHEDRINE [1R,2S] -3.64 
N-METHYLANTHRANILIC ACID 24.37 
N-METHYLBENZYLAMINE HYDROCHLORIDE 3.33 




NOMIFENSINE MALEATE 2.88 











NORSTICTIC ACID 18.31 
NORSTICTIC ACID PENTAACETATE -184.67 
NORTRIPTYLINE 7.73 
NOSCAPINE HYDROCHLORIDE -19.20 
NOVOBIOCIN SODIUM -2.40 
N-PHENYLANTHRANILIC ACID -33.90 














OCTOPAMINE HYDROCHLORIDE 21.70 
OFLOXACIN 37.31 
OLEANDOMYCIN PHOSPHATE 8.47 
OLEANOIC ACID -30.95 
OLEANOLIC ACID ACETATE -66.81 
OLIGOMYCIN (A shown) -105.05 
OLMESARTAN 16.99 








OROTIC ACID -15.03 
ORPHENADRINE CITRATE 3.05 
ORSELLINIC ACID -0.78 
ORSELLINIC ACID, ETHYL ESTER -64.14 
OSAJIN -526.77 
OSELTAMIVIR PHOSPHATE 24.61 
OUABAIN -11.67 
o-VERATRALDEHYDE -76.02 
OXACILLIN SODIUM -7.35 
OXALIPLATIN 5.85 












Table A.3 Continued. 
OXIBENDAZOLE 6.35 
OXICONAZOLE NITRATE -187.67 
OXIDOPAMINE HYDROCHLORIDE -9.98 
OXIGLUTATIONE DISODIUM SALT 13.68 
OXOLAMINE CITRATE -81.85 




OXYBUTYNIN CHLORIDE -12.42 
OXYMETAZOLINE HYDROCHLORIDE 8.29 
OXYPHENBUTAZONE -171.53 
OXYPHENCYCLIMINE HYDROCHLORIDE -11.24 
OXYPHENONIUM BROMIDE -7.47 
OXYQUINOLINE SULFATE -28.80 
OXYTETRACYCLINE 3.89 
OXYTHIAMINE CHLORIDE HYDROCHLORIDE -11.15 






PALMATINE CHLORIDE 31.18 
PANCURONIUM BROMIDE 14.30 
PANGAMIC ACID SODIUM -5.70 
PANTETHINE -14.86 
PANTHENOL (dl) -7.04 
PANTOPRAZOLE -11.99 
PANTOTHENIC ACID(d) Na salt -19.44 
PAPAVERINE HYDROCHLORIDE -73.90 
PARACHLOROPHENOL -11.74 
PARAMETHADIONE 23.82 
PARAROSANILINE PAMOATE -79.76 
PARAXANTHINE -38.05 
PARGYLINE HYDROCHLORIDE 19.63 






Table A.3 Continued. 
PAROXETINE HYDROCHLORIDE 44.58 
PASINIAZID 1.45 
PATULIN -342.17 
PAZUFLOXACIN MESYLATE -27.09 
p-CHLOROPHENYLALANINE 17.71 
PECTOLINARIN -40.94 
PEFLOXACINE MESYLATE 15.01 
PELLETIERINE HYDROCHLORIDE -27.74 
PEMPIDINE TARTRATE -33.40 




PENICILLIN G POTASSIUM -29.00 
PENICILLIN V POTASSIUM 8.29 
PENTACHLOROPHENOL -872.61 
PENTAGASTRIN -4.22 
PENTAMIDINE ISETHIONATE -20.93 
PENTETIC ACID 25.54 




PERGOLIDE MESYLATE -21.16 
PERHEXILINE MALEATE 28.96 
PERICIAZINE -2.39 
PERILLIC ACID (-) -21.83 
PERILLYL ALCOHOL -94.09 














Table A.3 Continued. 
PHENACETIN -33.29 
PHENACYLAMINE HYDROCHLORIDE -24.50 
PHENAZOPYRIDINE HYDROCHLORIDE -10.03 
PHENELZINE SULFATE 3.71 
PHENETHYL CAFFEATE (CAPE) -137.03 
PHENFORMIN HYDROCHLORIDE 8.17 
PHENINDIONE 2.40 




PHENOXYBENZAMINE HYDROCHLORIDE -324.11 
PHENSUCCIMIDE -5.96 
PHENTERMINE -28.55 
PHENTOLAMINE HYDROCHLORIDE -0.05 
PHENYL AMINOSALICYLATE 18.80 
PHENYLBUTAZONE -1.95 
PHENYLBUTYRATE SODIUM  -19.51 
PHENYLEPHRINE HYDROCHLORIDE -24.92 
PHENYLETHYL ALCOHOL 15.98 
PHENYLMERCURIC ACETATE 101.37 
PHENYLPROPANOLAMINE HYDROCHLORIDE 3.32 




















Table A.3 Continued. 
PIDOTIMOD -18.73 
PILOCARPINE NITRATE -10.38 
PIMAGEDINE HYDROCHLORIDE -7.49 





PIOGLITAZONE HYDROCHLORIDE -25.59 
PIPAMPERONE 27.69 
PIPEMIDIC ACID -3.73 
PIPENZOLATE BROMIDE -1.62 
PIPERACETAZINE 32.62 
PIPERACILLIN SODIUM 4.76 
PIPERAZINE -14.30 
PIPERIC ACID 5.62 
PIPERIDOLATE HYDROCHLORIDE 16.41 
PIPERINE 6.20 
PIPERONYL BUTOXIDE -7.37 





PIRENZEPINE HYDROCHLORIDE 4.84 
PIRIBEDIL HYDROCHLORIDE -4.73 
PIROCTONE OLAMINE -54.55 
PIROMIDIC ACID 1.91 
PIROXICAM 3.81 
PISCIDIC ACID -4.43 
PIZOTYLINE MALATE 3.52 
PLUMBAGIN -23.88 
PODOFILOX -7.28 
PODOPHYLLIN ACETATE -83.68 
PODOTOTARIN -13.20 







Table A.3 Continued. 
POTASSIUM p-AMINOBENZOATE -21.37 
PRALIDOXIME CHLORIDE 29.77 
PRALIDOXIME MESYLATE 11.52 
PRAMIPEXOLE DIHYDROCHLORIDE 14.42 
PRAMOXINE HYDROCHLORIDE -1.39 
PRANOPROFEN 0.85 
PRASTERONE -17.36 
PRASTERONE ACETATE -107.41 
PRASUGREL -19.55 
PRAVASTATIN SODIUM 8.69 
PRAZIQUANTEL -2.57 
PRAZOSIN HYDROCHLORIDE -2.15 
PREDNICARBATE -21.54 
PREDNISOLONE 6.08 
PREDNISOLONE ACETATE -23.41 
PREDNISOLONE HEMISUCCINATE -6.56 
PREDNISOLONE SODIUM PHOSPHATE 16.46 
PREDNISONE -8.70 
PREGABALIN 1.18 
PREGNENOLONE SUCCINATE 7.57 
PRENYLETIN 14.18 
PRIDINOL METHANESULFONATE 13.74 
PRILOCAINE HYDROCHLORIDE -5.04 




PROADIFEN HYDROCHLORIDE -9.73 
PROBENECID -36.27 
PROBUCOL 22.18 
PROCAINAMIDE HYDROCHLORIDE 2.54 
PROCAINE HYDROCHLORIDE -3.50 
PROCARBAZINE HYDROCHLORIDE -1.60 
PROCHLORPERAZINE EDISYLATE 31.52 
PROCYCLIDINE HYDROCHLORIDE -15.13 







Table A.3 Continued. 
PROGLUMIDE -23.71 
PROMAZINE HYDROCHLORIDE 28.74 
PROMETHAZINE HYDROCHLORIDE -27.00 
PRONETALOL HYDROCHLORIDE -18.38 
PROPAFENONE HYDROCHLORIDE 13.15 
PROPANTHELINE BROMIDE -50.68 





PROPOXYCAINE HYDROCHLORIDE -10.51 





PROTOPORPHYRIN IX 55.79 
PROTOVERATRINE A 1.31 




PSEUDOEPHEDRINE HYDROCHLORIDE -9.68 
PTAEROXYLIN -225.22 
PUERARIN 13.05 
PUROMYCIN HYDROCHLORIDE -7.27 
PURPURIN -122.18 
PURPUROGALLIN -49.43 
PURPUROGALLIN-4-CARBOXYLIC ACID -28.05 
PUTRESCINE DIHYDROCHLORIDE -15.12 
PYRANTEL PAMOATE 24.39 
PYRAZINAMIDE -3.07 
PYRETHRINS -447.81 
PYRIDOSTIGMINE BROMIDE 7.48 
PYRIDOXINE -1.32 






Table A.3 Continued. 
PYRIMETHAMINE 31.31 
PYRITHIONE ZINC 69.94 
PYRITHYLDIONE 4.39 
PYRITINOL -14.86 
PYROCATECHUIC ACID 2.63 
PYROGALLIN -345.99 
PYRONARIDINE TETRAPHOSPHATE 24.19 
PYRROMYCIN -207.03 




QUERCETIN 5,7,3',4'-TETRAMETHYL ETHER -57.93 
QUERCITRIN -4.04 
QUETIAPINE 12.75 
QUINACRINE HYDROCHLORIDE 50.63 
QUINALIZARIN 9.84 




QUINIC ACID -3.88 
QUINIDINE GLUCONATE -0.46 
QUININE ETHYL CARBONATE -32.47 
QUININE SULFATE -5.53 
QUINOLINIC ACID -8.72 
QUINPIROLE HYDROCHLORIDE -16.82 
QUIPAZINE MALEATE 5.50 
RABEPRAZOLE SODIUM -2.93 
RACEPHEDRINE HYDROCHLORIDE -2.16 
RACTOPAMINE HYDROCHLORIDE -18.52 
RALOXIFENE HYDROCHLORIDE -8.44 
RAMIFENAZONE 10.31 
RAMIPRIL 1.53 








Table A.3 Continued. 
RASAGILINE -20.07 





RESORCINOL MONOACETATE 1.77 
RESVERATROL -4.68 
RESVERATROL 4'-METHYL ETHER -33.46 
RETINOL -70.56 
RETINYL ACETATE -182.40 
RETINYL PALMITATE -23.76 
RETUSIN 3.61 
RETUSIN 7-METHYL ETHER -7.47 
RHETSININE -16.10 
RHIZOCARPIC ACID -30.07 
RHODINYL ACETATE -194.45 




RIBOFLAVIN 5-PHOSPHATE SODIUM -94.57 




RIMANTADINE HYDROCHLORIDE 15.34 
RISEDRONATE SODIUM -0.83 
RISPERIDONE -36.06 
RITANSERIN -15.04 
RITODRINE HYDROCHLORIDE -16.57 
RITONAVIR 1.31 
RIVASTIGMINE TARTRATE 95.31 
RIZATRIPTAN BENZOATE 2.55 
ROBUSTIC ACID 75.72 











ROPINIROLE HYDROCHLORIDE 3.45 
ROSIGLITAZONE MALEATE 10.08 
ROSMARINIC ACID 7.41 
ROSOLIC ACID -57.04 
ROSUVASTATIN CALCIUM -27.38 
ROTENONE -45.82 
ROTENONIC ACID, METHYL ETHER -138.44 
ROXARSONE -18.60 
ROXATIDINE ACETATE HYDROCHLORIDE -21.81 
ROXITHROMYCIN 1.04 










SALINOMYCIN, SODIUM -152.61 




SALSOLINOL HYDROBROMIDE -4.64 
SALVINORIN A -105.89 
SANGUINARIUM SULFATE -38.43 
SANTONIN -30.35 
SAPPANONE A DIMETHYL ETHER -113.75 









Table A.3 Continued. 





SELEGILINE HYDROCHLORIDE -34.14 
SEMUSTINE -108.88 
SENNOSIDE A 1.40 
SENNOSIDE B -20.10 
SERATRODAST -99.16 
SEROTONIN HYDROCHLORIDE 2.01 
SERTRALINE HYDROCHLORIDE 6.11 
SHIKIMIC ACID -8.07 
SIBUTRAMINE HYDROCHLORIDE -44.14 
SILDENAFIL CITRATE -0.55 
SILIBININ -245.16 
SIMVASTATIN -128.76 
SINAPIC ACID 25.53 




S-ISOCORYDINE (+) 2.65 
SISOMICIN SULFATE -32.18 
SITAGLIPTIN -51.49 
SITOSTERYL ACETATE -12.12 
SKATOLE -83.28 
SMILAGENIN -60.25 
SMILAGENIN ACETATE -16.36 
SNAP (S-NITROSO-N-ACETYLPENICILLAMINE) 9.61 
SODIUM FLUOROACETATE -43.62 
SODIUM MONOFLUOROPHOSPHATE 5.21 
SODIUM NITROPRUSSIDE -0.83 
SODIUM OXYBATE -0.48 
SODIUM PHENYLACETATE -68.10 
SODIUM PHENYLBUTYRATE 13.28 






Table A.3 Continued. 
SODIUM TETRADECYL SULFATE -6.12 
SODIUM THIOGLYCOLATE 27.91 
SOLANESOL -115.03 
SOLANESYL ACETATE -28.68 
SOLASODINE 0.52 
SOLIDAGENONE -94.47 
SOLIFENACIN SUCCINATE -37.43 
SORBITOL -18.61 
SOTALOL HYDROCHLORIDE -1.25 
SPAGLUMIC ACID 20.33 
SPARFLOXACIN 0.28 
SPARTEINE SULFATE -2.02 
SPECTINOMYCIN HYDROCHLORIDE 9.80 








STICTIC ACID 6.65 
STIGMASTA-4,22-DIEN-3-ONE -16.94 
STIGMASTEROL -18.30 
STREPTOMYCIN SULFATE -11.59 
STREPTOZOSIN -1.87 
STROPHANTHIDIN -20.97 
STROPHANTHIDINIC ACID LACTONE ACETATE 6.98 
STRYCHNINE 10.88 
STRYCHNINE METHIODIDE 15.79 
SUCCINYLSULFATHIAZOLE 5.13 









































SUMATRIPTAN SUCCINATE -14.25 
SUPROFEN 10.52 
SURAMIN HEXASODIUM 12.07 
SUXIBUZONE -5.75 
SYMCLOSENE -6.03 
SYRINGIC ACID -22.72 







Table A.3 Continued. 
TADALAFIL 16.25 
TAMOXIFEN CITRATE -52.87 
TANDUTINIB -9.88 
TANGERITIN -38.20 
TANNIC ACID 43.89 
TANSHINONE IIA -218.61 
TANSHINONE IIA SULFONATE SODIUM -49.88 
TAPENTADOL HYDROCHLORIDE 0.01 
TAURINE -15.62 
TAZOBACTAM 6.96 
TEGASEROD MALEATE 28.44 
TEICOPLANIN [A(2-1) shown] -17.53 









TERAZOSIN HYDROCHLORIDE -0.69 
TERBINAFINE HYDROCHLORIDE -1117.66 
TERBUTALINE HEMISULFATE 4.13 
TERCONAZOLE -60.28 
TERFENADINE 17.60 
TERPENE HYDRATE 12.12 
TESTOSTERONE -53.81 
TESTOSTERONE PROPIONATE -167.68 
TETRACAINE HYDROCHLORIDE 7.37 
TETRACHLOROISOPHTHALONITRILE 38.66 
TETRACYCLINE HYDROCHLORIDE 29.71 
TETRAHYDROGAMBOGIC ACID -155.12 
TETRAHYDROSAPPANONE A TRIMETHYL ETHER -48.52 
TETRAHYDROZOLINE HYDROCHLORIDE -8.03 


















THIAMYLAL SODIUM 14.75 
THIMEROSAL 75.93 




THIOPENTAL SODIUM 1.27 





THONZONIUM BROMIDE 33.87 
THONZYLAMINE HYDROCHLORIDE 1.04 
THYMOPENTIN -31.48 
THYMOQUINONE 104.76 
TIAPRIDE HYDROCHLORIDE 21.34 
TIBOLONE -67.78 
TICARCILLIN DISODIUM -34.80 
TICLOPIDINE HYDROCHLORIDE -33.35 
TIGOGENIN -0.25 
TILARGININE HYDROCHLORIDE -12.82 
TILETAMINE HYDROCHLORIDE 14.75 
TILMICOSIN 3.13 
TILORONE 7.93 














TOCAINIDE HYDROCHLORIDE -37.18 
TODRALAZINE HYDROCHLORIDE 5.59 
TOLAZAMIDE -9.24 
TOLAZOLINE HYDROCHLORIDE -19.29 
TOLBUTAMIDE 30.92 
TOLFENAMIC ACID -212.92 
TOLMETIN SODIUM 6.84 
TOLNAFTATE -49.79 
TOLONIUM CHLORIDE 110.45 
TOLPERISONE HYDROCHLORIDE 9.07 
TOLTRAZURIL -25.31 
TOMATIDINE HYDROCHLORIDE -28.77 
TOMATINE 102.87 
TOPIRAMATE 3.41 
TOPOTECAN HYDROCHLORIDE 60.75 
TOREMIPHENE CITRATE -44.59 
TOTAROL -862.37 
TOTAROL ACETATE -826.37 
TOTAROL-19-CARBOXYLIC ACID, METHYL ESTER -755.34 
TRACAZOLATE -91.43 
TRAMADOL HYDROCHLORIDE 4.34 
TRAMIPROSATE 3.11 
TRANDOLAPRIL 12.84 
TRANEXAMIC ACID -14.25 
TRANILAST 54.21 
TRANYLCYPROMINE SULFATE 5.58 
TRAVOPROST -17.24 









Table A.3 Continued. 
TRIAMCINOLONE -19.98 
TRIAMCINOLONE ACETONIDE 14.80 




TRICHLORMETHINE HYDROCHLORIDE -18.90 
TRICLABENDAZOLE -40.18 
TRICLOSAN -461.75 
TRIENTINE HYDROCHLORIDE -7.01 
TRIFLUOPERAZINE HYDROCHLORIDE -15.55 
TRIFLUPROMAZINE HYDROCHLORIDE 22.31 
TRIFLURIDINE -0.28 
TRIGONELLINE 18.26 
TRIHEXYPHENIDYL HYDROCHLORIDE 12.87 
TRILOSTANE -108.87 
TRIMEBUTINE MALEATE -62.49 
TRIMEDLURE -112.71 
TRIMEPRAZINE TARTRATE -13.39 
TRIMETAZIDINE DIHYDROCHLORIDE -9.75 
TRIMETHADIONE 3.91 
TRIMETHOBENZAMIDE HYDROCHLORIDE -30.30 
TRIMETHOPRIM 15.17 
TRIMETHYLCOLCHICINIC ACID 6.17 
TRIMETOZINE 6.72 
TRIMIPRAMINE MALEATE -23.58 
TRIOXSALEN -75.94 
TRIPELENNAMINE CITRATE -5.38 
TRIPROLIDINE HYDROCHLORIDE 11.29 
TRIPTOPHENOLIDE -109.10 
TRISODIUM ETHYLENEDIAMINE TETRACETATE 20.22 
TROCLOSENE POTASSIUM -5.52 
TROLOX -9.17 
TROPICAMIDE -23.32 








Table A.3 Continued. 
TRYPTOPHAN 7.37 
TUAMINOHEPTANE SULFATE 5.64 
TUBOCURARINE CHLORIDE 15.01 
TULOBUTEROL HYDROCHLORIDE -5.97 






UNDECYLENIC ACID -15.54 
URACIL 3.14 




URIDINE TRIPHOSPHATE TRISODIUM -24.68 
URSINOIC ACID 3.61 
URSOCHOLANIC ACID -149.90 
URSODIOL -4.00 
USNIC ACID -32.33 
UTILIN -35.60 
VALACYCLOVIR HYDROCHLORIDE 16.30 
VALERYL SALYCILATE -46.14 
VALGANCICLOVIR HYDROCHLORIDE 11.73 
VALINOMYCIN -225.04 
VALPROATE SODIUM 13.92 
VALSARTAN -19.71 
VANCOMYCIN HYDROCHLORIDE 12.52 
VARDENAFIL HYDROCHLORIDE -15.73 
VECURONIUM BROMIDE 4.67 
VENLAFAXINE HYDROCHLORIDE 12.69 
VERAPAMIL HYDROCHLORIDE -4.96 
VERATRIC ACID 5.05 
VERATRINE SULFATE 8.90 







Table A.3 Continued. 
VINBLASTINE SULFATE -32.74 
VINCRISTINE SULFATE -21.89 
VINORELBINE -71.32 
VINPOCETINE -2.93 









XANTHURENIC ACID 1.43 
XANTHYLETIN -82.39 
XYLAZINE -0.47 
XYLOCARPUS A -31.38 
XYLOMETAZOLINE HYDROCHLORIDE -28.90 
XYLOSE 12.29 
YOHIMBIC ACID HYDRATE -6.79 




ZIDOVUDINE [AZT] -5.33 
ZILEUTON -51.13 
ZINC UNDECYLENATE -14.47 
ZIPRASIDONE MESYLATE -291.85 
ZOLMITRIPTAN 18.79 









 Several compounds that were identified in the small molecule screen of 
the Spectrum Collection (6944-0074 and G856-6223 are structural analogues of 
robustic acid and were purchased from ChemDiv, San Diego, CA) for inhibitors of 
AC2 activity in HEK-hAC2 cells were further characterized for the ability to 
modulate cAMP accumulation in response to activation of AC isoforms in HEK-
hAC2 (activation by 50 nM PMA, 3 μM forskolin, and 300 nM PGE2), HEK-hAC1 
(activation by 3 μM A23187), HEK-hAC5 (activation by 300 nM forskolin), and 




 Table A.4 AC isoform-selectivity profiles of test compounds in intact-cell studies.  AC isoform selectivity was assessed 
by testing the ability of test compounds (30 µM) to modulate cAMP responses in HEK-hAC2 cells, HEK-hAC1 cells, 
HEK-hAC5 cells, and HEK-wt cells.  Data are reported as a percent of the vehicle treatment condition and represent 
the Mean ± S.E.M. of three independent experiments.  * p < 0.05, ** p < 0.01,*** p < 0.001 compared to vehicle 
condition, one sample t-test compared to 100. 
 
 
AC2 AC1 AC5 WT 
 
50 nM 






FSK 3 µM FSK 
 
Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM Mean±SEM 
Amlodipine Besylate 66±13 90±3.0 75±2.8* 140±14 110±4.8 110±15 
Nifedipine 180±22 160±8.3* 260±14** 110±16 130±11 150±11* 
Nicardipine HCl 270±48 110±9.0 230±28* 150±24 110±2.0* 120±13 
6944-0074 220±27* 100±8.7 210±13* 130±9.5 120±6.3 170±11* 
G856-6223 200±51 110±3.9 170±10* 120±8.2 110±11 160±7.4* 
Fluphenazine diHCl 78±12 180±18 93±7.5 62±5.0* 84±6.4 99±5.2 
Methiothepin Maleate 69±11 220±2.0*** 76±8.1 45±1.8** 96±7.0 120±8.1 
Perphenazine 65±6.1* 170±13* 81±8.5 59±5.6* 93±2.3 110±4.9 
(-)-Riboflavin 88±24 64±27 86±29 76±8.3 150±40 260±50 
Deoxyadenosine 64±4.2* 93±7.1 100±5.1 94±6.3 94±4.1 85±5.2 
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